

SUN PHARMACEUTICAL INDUSTRIES LTD.



NURTURING SPECIALTY GROWTH

ABRIDGED ANNUAL REPORT 2017-18

Reaching People. Touching Lives.





Nurturing Specialty Growth

Given the shifting dynamics of the global pharmaceutical market, progressive investments in innovative specialty products show the way forward for us.

At Sun Pharma, we have identified specialty as an additional growth engine; and a means to move up the pharmaceutical value chain through development and global commercialisation of branded patented products. We have invested significant resources in this initiative in the past; and will continue to invest in building the business further in the coming years.

We are meticulously nurturing the specialty business; and have built a portfolio of about 10 specialty products, of which five are already in the market, two more likely to be commercialised in the next few quarters; and two more awaiting USFDA approval.

The current financial year is likely to be a very important year in this journey with the potential launch of key specialty products in the US market. We are reinforcing our global specialty business with focused investments and strategies; and in the long-term, we expect the contribution of specialty products to increase substantially in our overall business.









Contents

02	06	53
Key Performance Indicators	Management Discussion and Analysis	Consolidated Financial Statements
03	24	87
Ten-Year Financial Highlights	Board's Report	Notice
04	30	
Managing Director's Letter	Standalone Financial Statements	



The cover design of this year's annual report focuses on the theme of 'Nurturing Specialty Growth'. The visual treatment to help convey this sentiment has been developed around the idea of connectivity, direction, the sum of parts, particles, and science being the cornerstone of any development and future growth.

Key Performance Indicators (Consolidated)



* During FY11, each equity share of ₹5 was split into five equity shares of ₹1 each.

* During FY14, the Company issued bonus shares in the ratio of one equity share of ₹1 for every share held.

* During FY16, the Company's equity shares have increased to 2,407 Million due to the merger of erstwhile Ranbaxy Laboratories Ltd. (RLL) with the Company, wherein 0.80 equity share of ₹1 each of the Company have been allotted to the shareholders of RLL for every 1 share of ₹5 each held by them.

The Company has adopted Ind-AS accounting standards with effect from 01 April, 2015. Hence, FY16 onwards, the financials are reported as per Ind-AS and are not strictly comparable with previous years. For FY15, the balance sheet items are as per Ind-AS.

Ten-Year Financial Highlights (Consolidated)

(₹ in Million)										
Particular	FY09	FY10	FY11	FY12	FY13	FY14	FY15	FY16	FY17	FY18
Operating Performance										
Revenue from Operations	43,751	38,086	57,279	80,195	112,999	160,804	273,920	284,870	315,784	264,895
Total Income	44,808	42,123	60,827	84,910	116,880	166,326	279,397	291,453	322,016	273,282
Net Profit for the year (after minority interest)	18,780	13,470	18,161	26,567	29,831	31,415	45,394	45,457	69,644	21,616
R&D Expenditure	3,320	2,242	3,313	4,449	7,042	10,418	19,550	23,025	23,138	22,489
a) Capital	222	159	236	362	427	556	1,178	783	1,679	1,819
b) Revenue (Excluding Depreciation)	3,098	2,083	3,077	4,088	6,616	9,862	18,373	22,242	21,459	20,669
c) % of Turnover	8.0%	6.0%	6.0%	5.6%	6.3%	6.5%	7.2%	8.3%	7.6%	8.6%
Financial Position										
Equity Share Capital	1,036	1,036	1,036	1,036	1,036	2,071	2,071	2,407	2,399	2,399
Reserve and Surplus	69,414	77,254	93,798	121,322	148,862	183,178	278,009	327,418	363,997	378,606
Property, Plant & Equipment and other Intangible assets (at cost/ deemed cost)	21,476	23,340	45,473	54,269	75,763	86,505	143,616	187,212	217,315	238,073
Carrying value of Property, Plant & Equipment and other Intangible assets	14,625	15,328	25,214	29,295	45,145	49,827	96,848	124,130	149,404	157,111
Investments	18,595	31,664	26,557	22,129	24,116	27,860	35,028	18,299	11,919	71,429
Net Current Assets	35,485	28,542	58,622	76,749	86,618	126,969	135,488	167,973	150,666	117,716
Stock Information										
Number of Shares (Million)	207	207	1,036	1,036	1,036	2,071	2,071	2,407	2,399	2,399
Adjusted Earning per Share (post exceptional items) (In ₹)*	7.8	5.6	7.5	11.0	12.4	13.1	18.9	18.9	29.0	9.0
Earnings per Share-Basic (In ₹)*	87.8	65.2	17.5	25.7	28.8	15.2	18.9	18.9	29.0	9.0
Earning per Share-Diluted (In ₹)*	87.8	65.2	17.5	25.7	28.8	15.2	18.9	18.9	29.0	9.0

* During the FY11, each equity share of ₹5 was split into five equity shares of ₹1 each.

* During the FY14, the Company issued bonus shares in the ratio of one equity share of ₹1 for every share held.

* During the FY16, the Company's equity shares have increased to 2,407 Million due to the merger of erstwhile Ranbaxy Laboratories Ltd. (RLL) with the Company, wherein 0.80 equity share of ₹1 each of the Company have been allotted to the shareholders of RLL for every 1 share of ₹5 each held by them.

The Company has adopted Ind-AS accounting standards with effect from 01 April, 2015. Hence, FY16 onwards, the financials are reported as per Ind-AS and are not strictly comparable with previous years. For FY15, balance sheet items are as per Ind-AS.

Managing Director's Letter



Dear Shareholders,

The global pharmaceutical industry offers significant opportunities to service the healthcare needs of a growing and ageing global population. The industry has witnessed major investments in developing innovative medicines like monoclonal anti-bodies, immunotherapy drugs and gene therapies. Many of these medicines have seen significant success as they are serving the unmet medical needs of patients, resulting in improved medical outcomes and thus changing the lives of patients. However, pricing in key markets like the US has come under severe pressure in the last two years. The industry will have to adapt to this changed scenario, although it also offers significant learning opportunities.

These changing dynamics are also likely to have an impact on competition since return ratios on investments in the US generics business are coming down and not every generics company will be able to remain economically viable at the current rate of price erosion. As a result, companies will have to optimise their future R&D investments.

The US generics market has been an important driver of growth and profitability for Indian pharmaceutical companies between 2005-15. However, now with the changed dynamics, the importance of other markets has increased. It has also become imperative for companies to identify new engines of growth and invest more in innovation. It is in this context, that Sun Pharma has been investing in building its global specialty business since the last few years. Through this initiative we are trying to gradually move up in the pharmaceutical value chain.

The other key focus area for us will be cost control and product rationalisation, with these efforts spread across R&D projects, manufacturing footprint and other areas. These steps will ensure that we continue to earn reasonable returns on our investments.

Highlights of FY18

As guided at the start of the fiscal, FY18 was a tough year. While we witnessed a decline in our financial performance for the year, the challenges also offer us an opportunity to improve our processes and hence emerge as a much stronger company. Our FY18 revenues degrew by 14% to ₹261 Billion mainly due to decline in our US sales. We have recorded steady growth in all other markets except the US.

Operational Performance

Revenues in the US declined 34% to US\$ 1.36 Billion due to higher base of FY17 wherein we had the benefit of 180-day exclusivity on generic Imatinib. Our subsidiary Taro recorded 25% decline in overall revenues for the year. This decline was mainly driven by more intense competition among manufacturers, new entrants to the market, buying consortium pressures, and a higher ANDA approval rate from the USFDA.

We recorded a 4% growth in our India formulations business. Overall growth for the domestic market was impacted by the temporary disruption in the trade channel due to the implementation of the Goods & Services Tax (GST) during the year. Adjusted for this impact, our India revenues have grown by about 9%.

We grew by 11% in emerging markets for the year. This growth was broad-based across various markets. Our sales in the Rest of World (RoW) markets grew by 20% for the year.

R&D

R&D is the backbone of our business and a key determinant of our future growth and profitability. Our efforts to move up the pharmaceutical value chain mandate that we keep investing in R&D. Our R&D investments for the year were ₹22 Billion, targeted mainly at developing complex generics and specialty products. We continue to be disciplined in identifying future R&D projects for the generics market while simultaneously investing in developing a global specialty portfolio. We are also investing in enhancing our product pipeline for emerging markets and other non-US developed markets.

Nurturing specialty growth

Our journey of building a global specialty business commenced a few years ago, and over the years, we have nurtured this evolving business through increased focus and investments. We have allocated significant resources in building the specialty business.

Our specialty initiatives are directed at achieving two main objectives – to build an additional engine of future growth and secondly to move up the pharmaceutical value chain through development and commercialisation of branded patented products. While we intend to target the global market with our specialty products, developed markets are likely to be key contributors to this strategy.

Our specialty portfolio targets Dermatology, Ophthalmic, Oncology and CNS segments. We are developing our specialty products pipeline with a focus on improving patient outcomes either by addressing unmet medical needs or by enhancing patient convenience through differentiated dosage forms.

Over the past two years, we have also focused on establishing the requisite front-end capabilities for our specialty business. This involves setting up a relevant sales force (for promoting these products to doctors), establishing the required regulatory and market access teams, along with support staff.

Commercialisation of key specialty products

FY18 was a busy year for our specialty business and we crossed many important milestones. We filed two of our important products – Ilumya (Tildrakizumab) and OTX-101 with the USFDA and also received final

approval for Ilumya in the US. We also focused on building the relevant front-end presence in the US for marketing and promoting our specialty products. Some of the key highlights for the year were:

- The USFDA approved our Biologics Licence Application (BLA) for Ilumya in March 2018. Ilumya is an IL-23p19 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis in the US. Launch preparations for Ilumya are ongoing for a potential commercialisation in the US in FY19. Ilumya was also filed with the European Medicines Agency (EMA) in March 2017. EMA's approval for Ilumya is awaited.
- Our New Drug Application (NDA) for OTX-101 was accepted by USFDA in December 2017. This is an important product for Sun Pharma's specialty ophthalmology portfolio. We are awaiting final approval for this product from the USFDA.
- Post the close of the year, we announced USFDA approval for Yonsa® (abiraterone acetate), a novel formulation in combination with methylprednisolone, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Sun Pharma had acquired Yonsa® from Churchill Pharmaceuticals LLC. Churchill is eligible to receive upfront and sales-linked milestone payments, and royalties on sales from Sun Pharma. Yonsa® in combination with methylprednisolone was filed as a New Drug Application (NDA) under the 505(b)(2) regulatory pathway and will be promoted as a branded specialty product in the US. Sun Pharma has already commercialised Yonsa® in the US market.
- We also received approval from the USFDA for a new label for Odomzo® (sonidegib), an oral hedgehog inhibitor to treat patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. The new label incorporates long-term data from the 30-month analysis of BOLT trial, in which Odomzo® continued to show sustained durable tumour response of 26 months with no new safety concerns.
- We have recently initiated investments in the development of two new indications for Ilumya, viz., psoriatic arthritis and ankylosing spondylitis. Although the clinical trials for these new indications will require large front-ended investments, a successful outcome of the trials will significantly expand the addressable market for Ilumya globally.
- The clearance of the Halol facility by the USFDA paves the way for potential approvals for Elepsia XR (Levetiracetam Extended Release tablets) and Xelpros (Latanoprost BAK-free eye drops). These specialty products were in-licensed from Sun Pharma Advanced Research Company Ltd. (SPARC).

Ranbaxy synergies

FY18 was the most important year in terms of accrual of the synergy benefits from the Ranbaxy acquisition. The targeted synergy benefits for FY18 was US\$ 300 Million and we are happy to have achieved this important milestone. As indicated before, we have utilised these synergy benefits to fund our evolving global specialty business.

Global cGMP compliance

Worldwide, pharmaceutical regulatory agencies are focusing on improving the quality of products approved by them. This has mandated adherence to very stringent cGMP standards by pharmaceutical manufacturers with a need to focus on 24x7 compliance status. Ability to successfully adhere to these cGMP standards has become a key determinant of future for the pharmaceutical industry.

During the year, Sun Pharma made significant progress towards 24x7 cGMP compliance. Many of our facilities underwent successful audits by multiple regulatory agencies, including the USFDA. At the same time, remediation work continued at some of the facilities, which had been impacted by cGMP deviations.

Our Halol facility, which was impacted by cGMP deviations in FY15, underwent a re-inspection by the USFDA in February 2018. On completion of the re-inspection, the USFDA issued three observations for the facility. Subsequently in June 2018, the USFDA issued the establishment inspection report (EIR) for the facility, thus clearing the facility. With this clearance, new approvals from this facility for the US market are likely to start coming through gradually.

Restructuring and rationalisation

Given the tough pricing conditions in the US generics market, we continue to make efforts towards optimising our costs. It mandates an unwavering focus on cost control across the organisation. We are trying to achieve better results with lower resources as we try to make the organisation more efficient.

Our efforts in this direction will cover multiple operational aspects. The focus will be on optimising our manufacturing footprint as well as generics R&D investments, to ensure a reasonable return on investment as well as overall cost management.

Overall outlook

We are gradually ramping up our global specialty business. We plan to increase its contribution to our consolidated revenues in the long term. This will entail significant front-ended investments, with commensurate revenue streams accruing only over a period of time.

Some of our key specialty products are likely to be commercialised in the US in FY19 and hence we expect to incur significant pre-launch and branding costs along with increasing sales force costs.

The short-term outlook for the US generics market continues to be challenging given the pricing pressures. We expect normalisation of the India business in FY19 post the disruption in FY18 due to GST implementation. Favourable demographics will ensure reasonable volume growth in India. However, government-mandated price reductions/policy changes continue to be potential risks for this business. We are also expecting reasonable growth in our emerging markets business, however, as always, currency fluctuations continue to be a risk.

Given these factors, we expect a low double-digit topline growth in our consolidated revenues for FY19 over FY18. Our consolidated R&D investments for FY19 will be about 8-9% of revenues.

Our talented team of employees will be the key driver of all the above initiatives. We are also grateful to our Board of Directors for their guidance and support.

We are thankful for your support as a shareholder. You have continuously supported our endeavors over the past many years and we hope that you will continue to repose your confidence in us.

Warm regards,

Dilip Shanghvi
Managing Director
Sun Pharmaceutical Industries Ltd.

Management Discussion and Analysis

The global spending on medicines is expected to reach over US\$ 1.4 Trillion by 2022, growing at an average CAGR of 3-6% from US\$ 1.13 Trillion in 2017.

Global pharmaceutical industry¹

The global spending on medicines is expected to reach over US\$ 1.4 Trillion by 2022, growing at an average compound annual growth rate (CAGR) of 3-6% from US\$ 1.13 Trillion in 2017. Demographic changes in population and advances in medical treatments are expected to translate into a rise in spending. Innovation in medicines, along with economic progress, will result in a rise in volume for the pharmaceutical industry. Market growth is likely to occur concurrently with greater pharmaceutical cost controls, improving access and affordability.

In developed markets, ageing population and development of new specialty medicines will continue to drive pharmaceutical growth. In developing nations, growing population and rising disposable incomes among the middle-class, increasing aspirations for better healthcare and gradually increasing penetration of insurance coverage will drive the growth momentum.

Chart 1 Global medicine spending and growth 2007-2022²





Table 1 Global pharmaceutical spending and growth²

(US\$ Billion)

Regions	2017	2013-17 CAGR	2022	2018-22 CAGR
Developed Markets	753.2	5.8%	915-945	2-5%
Pharmerging Markets	269.6	9.7%	345-375	6-9%
Other Markets	112.3	2.0%	125-155	2-5%
Global Pharmaceutical Market	1,135.1	6.2%	1,415-1,445	3-6%

Chart 2 Global spending by region²**Table 2** Leading therapy-wise spending and growth in selected developed and pharmerging markets²

(US\$ Billion)

Therapy areas	2017	2012-17 CAGR	2022	2017-22 CAGR
Oncology	81.1	11.8%	115-130	7-10%
Diabetes	72.2	16.9%	105-115	8-11%
Pain	76.1	5.7%	80-95	2-5%
Autoimmune	47.5	16.8%	65-75	7-10%
Respiratory	38.5	4.8%	40-50	2-5%
Antibiotics & vaccines	38.3	3.2%	40-48	1-4%
Cardiovascular	40.6	-1.8%	36-44	(-2)-1%
HIV	26.7	11.5%	32-40	5-8%
Mental health	36.1	-2.6%	32-38	(-2)-1%
Antivirals	23.8	25%	16-20	(-7)-(-4)%
All other therapies	368.3	5.1%	445-460	3-6%

Selected Developed and Pharmerging Markets: Includes 8 Developed and 6 Pharmerging countries of the US, France, Germany, Italy, Spain, UK, Japan, Canada, China, Brazil Russia, India, Turkey and Mexico

Emerging trends for 2018-22¹


Pharmaceutical spending in developed markets is likely to grow at 2-5% CAGR between 2018-22 compared to 5.8% in the 2013-17 period. While launch of innovative products is likely to drive growth, is expected to be balanced by patent expiries of existing products.

- Specialty medicines will drive medicine spending in developed markets, partly offsetting the decline in spending on traditional medicines.
- The requirement to replenish product portfolios impacted by patent expiries will continue to drive acquisitions and in-licensing for the specialty segment.
- For pharmerging markets, policies designed to achieve universal healthcare will be an intricate formula that induces investment, while protecting affordability. However, sluggish economic conditions in these markets and relatively higher out-of-pocket costs for patients will offset some of the gains in access. Medicine spending in these markets is likely to grow at 6-9% CAGR for 2018-22 compared to nearly 10% for the 2013-17 period.

- Innovation in new drug development, immunotherapy, next generation biotherapeutics, including cell-based gene therapies and digital health tools will gain importance in the future of the global healthcare industry.


- Generic medicines will continue to be an important part of the efforts to reduce overall global healthcare costs.

Innovation in new drug development, immunotherapy, next generation biotherapeutics, including cell-based gene therapies and digital health tools will gain importance in the future of the global healthcare industry.

Chart 3 Global medicine spending by product type in 2022²


Global generics market³

The global generics market is estimated to grow at 5% CAGR for the 2017-22 period to reach US\$ 104 Billion by 2022. Governments worldwide are facing pressures of rising healthcare costs, thus emphasising on the importance of generics and their role in making pharmaceutical products affordable to those in need. Patent expiry for branded drugs in developed markets has a bearing on the potential of generics in those markets. In the emerging world, the branded generics markets will be driven primarily by rising per capita incomes, increasing healthcare awareness and enhanced incidence of chronic ailments.

Chart 4 Global generics market growth³ (US\$ Billion)


Growth enablers of global pharmaceutical industry⁴

Ageing population

Global population is likely to cross 9.3 Billion by 2050 and the proportion of individuals aged 60 and above will account for 21% of it. The growing average life expectancy has been accompanied by a rise in different diseases, leading to the deployment of more resources for research and innovation to improve the quality of life for an ageing population.

Rising pollution

Rising air and water pollution is resulting in increased incidence of various diseases, leading to higher pharmaceutical consumption.

Changing lifestyles

Individual lifestyle choices are increasingly affected by stress, resulting in higher risk for obesity, hypertension, depression, diabetes and cardiovascular problems. Moreover, with rise in disposable incomes for global middle-class families, the demand for better healthcare is gradually increasing.

Cost controls

Governments, particularly in emerging economies, are shifting towards affordable, universal healthcare with reduced out-of-pocket spending for patients. Although they deepen market access, the cost-containment policies of governments will neutralise some of these gains for the pharmaceutical industry.

Technology

Empowered by technological advances such as mobile apps, wearable healthcare devices and greater awareness, patients are increasingly taking better and more well-informed healthcare choices.

Outlook

Changing lifestyles will increasingly make chronic diseases a global health issue. Developed markets growth will be driven by ageing population and adoption of emerging medical technologies.

In developing markets, besides growing populations, the pharmaceutical industry will benefit from higher incomes of consumers. The entry of wearables in the global market will facilitate access to accurate, real-world data. Subsequently, the quality of diagnostic services will improve thus leading to increased pharmaceutical consumption.

Specialty medicines¹

In the previous decade, new medications have witnessed a gradual and continuous shift towards specialty medicines (defined as those that treat chronic, complex or rare conditions). The share of specialty medicines in global spend in 2017 stood at 32%, up from 19% in 2007.

In the US and EU5 markets, the contribution of specialty medicines to overall pharmaceutical spending has almost doubled over the preceding 10 years. This trend is likely to continue. While specialty medicines are more expensive than traditional therapies, the availability of insurance funding is helping in making them affordable to the population of these countries.

The share of specialty medicines in pharmerging markets has not grown much over the preceding 10 years. This is primarily due to the higher proportion of out-of-pocket funding by patients in these countries, which limits affordability of higher priced specialty medicines.

Developed markets¹

Pharmaceutical spending in developed markets is estimated to grow at 2-5% CAGR from US\$ 753.2 Billion in 2017 to US\$ 915-945 Billion in 2022. The US will continue to be the key contributor of the growth in developed markets. In other such markets, where access and costs are mostly managed by single payers growth will be sluggish.

Table 3 Pharmaceutical spending and growth in developed markets²

(US\$ Billion)

Region/Country	2017	2013-17 CAGR	2022	2018-22 CAGR
US	466.6	7.3%	585-615	4-7%
EU5	154.4	4.4%	170-200	1-4%
Germany	45.1	4.9%	51-61	2-5%
France	33.1	1.3%	36-40	0-3%
Italy	29.0	5.5%	34-38	2-5%
UK	25.7	6.9%	29-33	2-5%
Spain	21.5	4.6%	24-28	1-4%
Japan	84.8	2.0%	85-89	0-4%
Canada	20.7	3.9%	23-27	1-4%
South Korea	13.7	4.5%	15-19	3-6%
Australia	13.1	4.7%	12-16	1-4%
Total	753.2	5.8%	915-945	2-5%

US

The US pharmaceutical market is estimated to grow by 4-7% CAGR from US\$ 466.6 Billion in 2017 to US\$ 585-615 Billion in 2022. The gains from a free-market pricing will continue to be partly offset by price rebates negotiated by payers. Patent expiry and subsequent loss of brand exclusivity will continue to aggravate the situation, whereas price increases and introduction of new specialty medicines will drive the spending growth.

Europe (EU5)

The CAGR for the next five years for EU5 markets is estimated at 1-4%, with overall spending in these markets likely to escalate from US\$ 154.4 Billion in 2017 to US\$ 170-200 Billion in 2022. Spending will be primarily driven by the ageing population of countries and increased incidence of chronic ailments coupled with increasing adoption of specialty medicines.

Chart 5 US pharmaceutical spending and growth (US\$ Billion)





Chart 6 EU5 pharmaceutical spending and growth (US\$ Billion)



Japan

Spending on pharmaceuticals in Japan is likely to continue to grow at a sluggish pace, from US\$ 84.8 Billion in 2017 to US\$ 85-89 Billion in 2022. High life expectancy with low birth and migration rates have contributed to a declining Japanese population.

Challenges in the form of complex regulatory framework and periodic price cuts have hampered the sector's growth. However, the volume share of generic drugs in Japan has nearly doubled in recent years, with government policies promoting the use of generics. This trend is expected to continue.


Pharmerging markets¹

The pharmaceutical spending in pharmerging markets stood at around US\$ 269.6 Billion in 2017. It is estimated to grow at 6-9% CAGR during 2018-22 to reach US\$ 345-375 Billion in 2022.

It is likely to be driven by the efforts of individual governments to expand public access to healthcare, higher incidence of chronic ailments and rising per capita incomes, leading to enhanced healthcare awareness.

Branded generic medicines comprise the largest proportion of medicine spending in these economies. Payments, primarily out-of-pocket for consumers, reflect a correlation between economic growth and pharmaceutical spending growth.

Chart 7 Pharmaceutical spending and growth in pharmerging markets (US\$ Billion)



Spending in pharmerging markets, driven mainly by volume increases and the use of generics, is likely to grow by 7-8% in 2018, making it the third consecutive year that the growth will be less than 10%. China, the largest pharmerging market, will grow at a modest 5-8% in the next half decade, reaching US\$ 145-175 Billion in 2022.

India and Russia are expected to grow faster, in comparison, averaging at 10% in the same time span, while the other pharmerging markets will average 6-9%. India's spending on medicines will propel its entry into the top 10 countries in 2018, and to the ninth position overall between 2019 and 2022.

Table 4 Pharmaceutical spending and growth in pharmerging markets (US\$ Billion)

Region/Country	2017	2013-17 CAGR	2022	2018-22 CAGR
China	122.6	9.4%	145-175	5-8%
Tier 2 markets	67.3	11.2%	89-93	7-10%
Brazil	33.1	11.5%	38-42	5-8%
India	19.3	11.0%	26-30	9-12%
Russia	14.9	10.8%	20-24	7-10%
Tier 3 markets	79.7	8.9%	95-125	6-9%
Total	269.6	9.7%	345-375	6-9%

Global consumer healthcare industry⁵

The global consumer healthcare (GCH) market grew by 4.1% in 2017 to reach US\$ 127 Billion. The US and China continue to be the largest GCH markets and together account for 46% of the global share. For 2017, North America and European markets recorded 2.5-3% growth, Asia-Pacific was up 4.3%, while Latin America (+11.8%) and the Middle East & Africa (+6.7%) grew fastest. Among emerging markets, Brazil, Russia and India account for almost 9% of the global market.

Vitamins, minerals & supplements, cough, cold and allergy segments account for over 50% of market spend. Growing healthcare awareness and internet penetration have empowered people to seek various available treatments. This is leading to self-medication and driving market momentum.

Active Pharmaceutical Ingredients (API)⁶

Geriatric healthcare solutions, biopharmaceutical sector growth and advancements in API manufacturing will be the key drivers for the API

industry. The prevalence of chronic diseases such as cancer, diabetes and cardiovascular ailments contribute to the market growth. Growing demand for quick action, efficient drugs and innovations in drug manufacturing also fuel its growth.

Led by increasing expenditure on medical research, North America will continue to dominate the global API market. Asia-Pacific regions are increasingly favoured for setting up API manufacturing facilities due to the availability of affordable labour and low manufacturing costs.

Indian pharmaceutical market^{7,8}

India's pharmaceutical industry is the world's largest supplier of generic drugs, accounting for 20% of global export volume. The domestic market accounts for over 3% of the global pharmaceutical industry in value terms and 10% in volume. It is predicted to grow at a CAGR of 9-12% in the 2018-22 period to reach a size of US\$ 26-30 Billion.


Branded generic drugs account for nearly 80% of the Indian pharmaceutical market by sales. The market is highly fragmented and competitive. Cost-efficiency coupled with a skilled workforce continues to make it an attractive destination for investment and research.

Out-of-pocket expenses for patients in India continue to constitute the biggest share of total medical spending for the average

household. As a proportion of GDP, the average healthcare expenditure for India is one of the lowest among BRICS nations.


The Government of India has made efforts to make pharmaceutical products more affordable and step up the promotion of generics. Moreover, government-sponsored programmes provide healthcare benefits for the low-income section of the population.

Chart 8 India – Estimated per capita pharmaceutical spending versus other emerging markets¹ (US\$ per person/year)



Notes: Spending per capita, per capita growth and overall spending growth in Constant US\$.

Growth drivers of Indian pharmaceutical market



Sun Pharmaceutical Industries Ltd. (Sun Pharma)

Sun Pharma is the world's fifth largest specialty generics pharmaceutical company. It is also India's largest and most valuable pharmaceutical enterprise by size and market capitalisation. A vertically integrated business, economies of scale and a skilled team enable it to deliver well-timed quality products at affordable prices.

The Company is deepening its global footprint as a highly trusted pharmaceutical company among consumers and healthcare professionals in over 100 countries. It has multiple manufacturing facilities and R&D centres across the world. The Company has 32,000+ global employee base that comprises over 50 nationalities. As an innovation driven enterprise, it has robust R&D capabilities with investments of over 8.6% of annual revenues.

Sun Pharma's Global Consumer Healthcare (GCH) business is ranked among the top 10 across four emerging markets. Its API business

footprint is strengthened through 14 world-class API manufacturing facilities around the world.

The Company has operations spanning segments like specialty products, branded generics, complex and pure generics, over-the-counter (OTC) products, anti-retrovirals (ARVs), and active pharmaceutical ingredients (APIs). It also manufactures intermediates for specialty APIs, offering a full range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids.

In India, Sun Pharma enjoys leadership across 13 classes of doctors with 32 brands featuring among the top 300 pharmaceutical brands. Internationally, the Company has a strong presence in the US, emerging markets, Western Europe, Japan, Canada, Israel, Australia and New Zealand (A&NZ). It has multiple production units approved by various regulatory authorities, including the USFDA.

Value creation framework

Growing and sustaining our prominence across markets, therapeutic segments and products.

Growth pillars



US\$ 4 Bn

Global revenue as on
31st March, 2018



> 100

Markets served



> 2,000

Products marketed



68%

Contribution to sales from
international markets



42

Manufacturing facilities across
six continents



> 32,000


Employees worldwide

Sun Pharma is deepening its global footprint as a highly trusted pharmaceutical company among consumers and healthcare professionals in over 100 countries. It has multiple manufacturing facilities and R&D centres across the world. The Company has 32,000+ global employee base that comprises over 50 nationalities. As an innovation driven enterprise, it has robust R&D capabilities with R&D investments of over 8.6% of annual revenues.

Global Presence

US Formulations	India Branded Generics	Emerging Markets	Western Europe, Canada, Japan, A&NZ and others
<ul style="list-style-type: none"> Fifth-largest generics Company in the US with one of the largest ANDAs pipeline (139 ANDAs and 3 NDAs awaiting approval). Largest Indian pharmaceutical enterprise in the US. Presence in generics and branded specialty segments with a portfolio of over 400 products. 	<ul style="list-style-type: none"> No. 1 pharmaceutical Company in India. No. 1 ranked with 13 classes of doctor categories. Leading position in high-growth chronic therapies. Specialises in technically complex products. 	<ul style="list-style-type: none"> Among one of the largest Indian pharmaceutical companies in Emerging Markets. Presence in over 100 countries across Africa, Latin America, Asia and Eastern & Central Europe. Key focus markets – Russia, Brazil, Romania, Mexico, Africa, and complementary and affiliated markets. 	<ul style="list-style-type: none"> Presence across majority of markets in Western Europe, Canada, Japan and A&NZ. Product portfolio includes differentiated offerings for hospitals, injectables and generics for retail market.

Growth Strategies



Building a robust specialty portfolio

- In-licensed ILUMYA™ (a monoclonal antibody targeting IL-23) from MSD for treating chronic plaque psoriasis in 2014. Biologics Licence Application (BLA) for ILUMYA™ filed with the USFDA and EMA for the European market and subsequently received final approval from USFDA in March 2018. Launch preparations for commercialising the product in the US are ongoing.
- Acquired Ocular Technologies for access to global rights for OTX-101 for treating Dry Eye Disease; announced positive outcomes from confirmatory Phase-3 trials in January 2017; filed NDA with USFDA in December 2017; evaluating other markets for filing OTX-101.
- Acquired branded oncology product – Odomzo – in December 2016; the product is approved in 30 countries, including the US, Europe and Australia; currently marketed in the US and Germany.
- Launched BromSite – first specialty ophthalmology product in the US – in November 2016.
- Currently marketing Levulan Kerastick (a drug-device combination for treating actinic keratosis) and Absorica (for treating acne) in the US dermatology market.
- Two ophthalmic molecules undergoing clinical trials as a part of the InSite Vision pipeline.
- In-licensed Xelpros (ophthalmology) and Elepsia (CNS) products from Sun Pharma Advanced Research Company (SPARC). Both these products are awaiting USFDA approval.


Table 5 Key acquisitions and joint ventures (JV)

Year	Deals	Country	Acquisition Rationale
2016	Acquired global rights for OTX-101 and Odomzo	Global Markets	Enhances specialty pipeline
2016	Acquired Biosintez	Russia	Access to local manufacturing capability to enhance presence in the Russian market
2016	Licensing agreement with Almirall for ILUMYA™ for Psoriasis	Europe	Strengthening the distribution of ILUMYA™ in Europe
2016	Acquired 14 brands from Novartis	Japan	Entry into Japan
2016	Distribution agreement with AstraZeneca	India	Distribution services agreement in India for brand 'Oxra' and 'Oxramet'® (brands of dipagliflozin, used for diabetes treatment)
2015	Acquisition of InSite Vision	US	Strengthens branded ophthalmic portfolio in the US
2015	Acquisition of GSK's Opiates Business	Global Markets	Vertical integration for controlled substances business
2015	Distribution agreement with AstraZeneca	India	Distribution services agreement in India for brand 'Axcer'® (brand of ticagrelor, used for the treatment of acute coronary syndrome)
2015	Sun Pharma – Ranbaxy Merger	Global Markets	Fifth-largest Global Specialty Generics Pharma Company and No.1 Pharma Company in India with strong positioning in emerging markets
2014	In-licensing agreement with Merck for ILUMYA™ a biologic for psoriasis	Global Markets	Strengthened the specialty product pipeline
2014	Acquired Pharmedica	US	Sterile injectable capacity in the US, supported by strong R&D capabilities
2013	Acquired URL's generics business	US	Addition to the US generics portfolio
2012	Acquired DUSA Pharma, Inc.	US	Access to branded derma product
2010	Acquired Taro Pharmaceutical Industries Ltd.	Israel	Enhanced presence in the US generics market, especially the dermatology segment
2008	Acquired Chattem Chemicals, Inc.	Tennessee, US	Access to controlled substance facility with DEA registration
2005	Assets of Able Labs Formulation plant in Bryan	New Jersey, US Ohio, US	Access to formulations plant (NJ, US)
1997	Acquired Caraco	Detroit, US	Entry into the US generics market


Key performance indicators

GROSS SALES


(₹ Billion)

**EBITDA***


(₹ Billion)

**NET PROFIT AFTER MINORITY INTEREST**


(₹ Billion)

**ADJUSTED EARNING PER SHARE (post exceptional items)**


(₹ per share)

**BOOK VALUE PER SHARE**


(₹ per share)

**MARKET CAPITALISATION (as on 31st March)**




(US\$ Billion)

**NET WORTH**

(₹ Billion)

**PROPERTY, PLANT & EQUIPMENT AND OTHER INTANGIBLE ASSETS (at cost/deemed cost)**

(₹ Billion)

**BUSINESS-WISE REVENUE SHARE****BUSINESS MIX**

*EBITDA = Gross Sales - (Cost of Material Consumed + Purchase of stock-in-trade + Change in inventories of Finished Goods, Work-in Progress and Stock-in-Trade + Employee Benefits Expense + Other Expenses)

FY18 operational highlights

- In May 2017, the Company received the U.S. Food and Drug Administration (USFDA) acceptance of the Biologics Licence Application (BLA) for ILUMYA™. The USFDA filing acceptance followed the acceptance of the regulatory filing of ILUMYA™ by the European Medicines Agency (EMA) in March 2017. ILUMYA™ is an IL-23p19 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis in the US. The BLA filing for ILUMYA™ with the USFDA was based on two pivotal Phase III trials (reSURFACE 1 and 2), which included over 1,800 patients across more than 200 clinical trial sites, including some patients who have been treated with ILUMYA™ for up to three-and-a-half years. Data from these trials were presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting and previously presented at the 25th European Academy of Dermatology and Venereology Congress. Subsequently, in March 2018, Sun Pharma announced USFDA approval for ILUMYA™ (tildrakizumab-asmn) to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- In June 2017, the Company received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for generic version of Zetia® (ezetimibe) Tablets 10mg. These generic ezetimibe tablets are therapeutic equivalents of Merck's Zetia® tablets. According to IQVIA, ezetimibe tablets had annual sales of approximately US\$ 2.7 Billion in the US for the 12 months ended April 2017.
- In June 2017, Sun Pharma in partnership with The National Institute of Virology (NIV), Pune, an institution of the Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare, New Delhi, announced that they have signed an agreement for testing phyto-pharmaceutical, biologic and chemical entities developed by Sun Pharma against zika, chikungunya and dengue viruses. Sun Pharma will provide drug molecules to NIV for testing against zika, chikungunya and dengue in model systems. Candidate molecules with encouraging data will then be taken forward for commercial development. Sun Pharma and NIV aim to promote discovery sciences, translational health research and development of medical products, which is in sync with the direction provided by the Government of India's 'Make In India' initiative. Sun Pharma's agreement with NIV follows its MoU with the Indian Council of Medical Research (ICMR) for conducting joint scientific research and innovation for testing of drugs, biosimilars and vaccines for disease control and elimination programmes.
- In July, 2017, Sun Pharma and Samsung BioLogics announced a strategic long-term manufacturing agreement for ILUMYA™. The agreement was entered into by Sun Pharma's wholly-owned subsidiary and Samsung BioLogics. According to the agreement, Sun Pharma has appointed Samsung BioLogics to manufacture future supplies of ILUMYA.
- In September 2017, Sun Pharma announced that one of its wholly-owned subsidiaries has received approval from the USFDA for a new label for Odomzo® (sonidegib), an oral hedgehog inhibitor to treat patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. Odomzo® was approved by the USFDA in July 2015, based on 12-month follow-up results from the pivotal Phase II Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) clinical trial, a multicentre, double-blind study involving 194 patients with laBCC and 36 patients with metastatic basal cell carcinoma (mBCC). The new label incorporates long-term data from the 30-month analysis of BOLT trial, in which Odomzo® continued to show sustained durable tumour response of 26 months with no new safety concerns.
- In October 2017, Sun Pharma announced that one of its wholly-owned subsidiaries has received final approval from the USFDA for its ANDA for generic version of Coreg CR®, (carvedilol phosphate) extended release capsules, 10mg, 20mg, 40mg and 80mg, which are therapeutic equivalents of GSK's Coreg CR® extended release capsules. As per IQVIA, Coreg CR® had annual sales of approximately US\$ 208 Million in the US for the 12 months ended August 2017.
- In December 27, 2017, the Company announced that the USFDA has accepted a New Drug Application (NDA), filed by its wholly-owned subsidiary, for OTX-101 (cyclosporine A, ophthalmic solution) 0.09%, a novel nanomicellar formulation of cyclosporine A 0.09% in a clear, preservative-free aqueous solution. OTX-101 is currently under review for approval by the USFDA.
- In January 2018, Sun Pharma announced that its wholly-owned subsidiaries have reached an agreement with Ironwood Pharmaceuticals, Inc. and Allergan plc. to resolve the patent litigation regarding submission of an ANDA for a generic version of Linzess® (Linaclotide capsules) in the US. Pursuant to the terms of the settlement, Sun Pharma's wholly owned subsidiaries will be eligible to market a generic version of Linzess® in the United States beginning 01 February, 2031, (subject to USFDA approval) or earlier under certain circumstances.
- In February 2018, Sun Pharma's Halol facility underwent an inspection by the USFDA. Post the closure of the inspection, the USFDA issued the Form-483 to the facility citing three deviations. Sun Pharma filed its response to the USFDA in March 2018, citing proposed measures to address the deviations. Subsequently in June 2018, the USFDA issued the establishment inspection report (EIR) for Halol, thus clearing the facility.
- In February 2018, Sun Pharma Science Foundation, a non-profit organisation announced the Sun Pharma Science Awards to Indian scientists for their outstanding work and exemplary contribution to medical research. The awards were presented in two categories:
 - The Sun Pharma Research Awards for outstanding scientists.
 - Sun Pharma Science Scholar Awards for young researchers.
 The winners for both these awards are identified in two sub-categories:
 - Medical Sciences
 - Pharmaceutical Sciences

An eminent jury panel comprising well-known scientists from India selected the winners. These awards are presented annually to Indian scientists and young researchers working in India and abroad.

FY19 outlook and guidance

The US generics industry continues to face pricing pressure driven by increasing competitive intensity and customer consolidation. Despite these adverse dynamics, the Company expects low double-digit growth in consolidated revenues for FY19.

Sun Pharma continues to invest in enhancing its global specialty and complex generics pipeline. Investments will also continue for setting

up the requisite front-end capabilities for the specialty business in the US as well as on clinical trials for some of the specialty products. These investments may not have commensurate revenues in FY19 but are likely to drive growth in the longer-term. The consolidated R&D investments for FY19 will be about 8-9% of consolidated revenues. The Company expects a gradually increasing tax rate over the next few years.

Business segment review

US business

34%

Revenue contribution

₹87,466 Mn

Revenues for FY18

7%

FY13-18 revenue CAGR

561

Cumulative ANDAs filed

422

Cumulative ANDAs approved

39

Cumulative NDA/BLA approved

As on 31st March, 2018

Sun Pharma is the fifth largest specialty generics pharmaceutical company in the US market with presence across generics, specialty, branded and OTC segments. Its primary focus areas include CNS, dermatology, cardiology, oncology and ophthalmics, among others. It has integrated manufacturing facilities with the capability of

manufacturing products, both onshore and offshore, across a variety of dosage forms including liquids, creams, gels, sprays, injectables, tablets, capsules and drug-device combinations. The Company's comprehensive portfolio includes 561 ANDAs and 42 NDAs filed and 422 ANDAs and 39 NDAs approved across multiple therapies.

ANDA pipeline

Sun Pharma had 139 ANDAs and 3 NDAs pending USFDA approval as of 31 March 2018. This pipeline includes a combination of complex generics, First-to-File (FTF) opportunities and normal generics.

US business milestones

FY18

FY17

FY16

FY15

FY14

FY13

FY10

FY98-FY10

FY98

- Launched Odomzo in the US
- Launched Generic Coreg CR® in the US
- Acceptance and approval for ILUMYA™ (tildrakizumab) in the US
- Filed NDA for OTX-101 with USFDA
- Acquired Ocular Technologies - giving access to OTX-101, a product for treating dry eyes
- Launched BromSite - Sun Pharma's first specialty ophthalmic product - in the US
- Acquired Odomzo - branded oncology product from Novartis
- Acquired InSite vision to strengthen the specialty ophthalmic portfolio
- Expanded presence in the US with the addition of Ranbaxy's US business
- Acquired Pharmedica to get access to sterile injectables capability
- Acquired DUSA, marking entry into the specialty dermatology market
- Acquired URL's generics business
- Acquired Taro Pharma and forayed into the generics dermatology market
- Enhanced and strengthened the US business
- Entered into the US market by acquiring Caraco

Progress in FY18


The Company's consolidated US revenues de-grew by 36% in FY18 to ₹87,466 Million. The US generics market continues to face a challenging environment driven by customer consolidation and faster pace of generics approvals by the USFDA. Revenues were also impacted by delay in approvals from the Halol facility for the US market.

Key products which drove revenues down were:

1. **Imatinib Mesylate** – Revenues declined as expected post the expiry of the 180-day exclusivity
2. **Absorica** – Revenues declined due to changes in co-pay programme
3. **Liposomal Doxorubicin** – Faced increased competition from other generics
4. **Authorised generic versions of Olmesartan** – These were launched in FY17 and hence faced competitive intensity in FY18


The US revenues for Taro (a 75% subsidiary) declined by 25% for FY18, driven primarily by a difficult generics pricing environment. This resulted from a more intense competition among manufacturers, new market entrants, buying consortium pressures, and a higher ANDA approval rate from the USFDA.

Chart 9 ANDAs Filed and Approved



(Cumulative numbers for FY16 are lower than FY15 due to Bryan facility divestment. URL ANDA numbers added since March 2013 and Ranbaxy ANDA numbers added for March'15)

Chart 10 ANDA Approvals by Therapeutic Area



(As of March 2018)

Future growth drivers

- Launch of specialty products
- Patent expiries and the US government's focus on reducing healthcare costs will continue to favour growth of low-cost generics

Focus areas

- Enhancing the share of specialty business.
- Focussing on complex generics and high-entry barrier segments.
- Ensuring a broad offering to customers across multiple dosage forms.
- Improving service levels for customers through round-the-clock cGMP compliance, product robustness and supply chain

Indian branded generic business

31%

Revenue contribution

₹80,293 Mn

Revenues for FY18

22%

FY13-18 revenue CAGR

No. 1


Ranked in Indian pharmaceutical market, with 8.5% market share

No. 1

Ranked by prescriptions with 13 different doctor categories

As on 31 March, 2018

Sun Pharma is India's largest pharmaceutical company with 8.5% market share in the domestic market. It is one of the leaders in the chronic segment and enjoys strong positioning in the acute segment. The Company has a well-diversified product portfolio with low brand concentration. It has one of the widest reach in India's medical fraternity with a 9,200+ strong sales force reaching around 600,000 doctors. The sales force has one of the highest productivity metrics among India's key players.




Sun Pharma specialises in technically complex products, offering a comprehensive therapy basket, and owns 32 of the top 300 pharmaceutical brands in India

Progress in FY18

- Revenue from Indian business increased by 4% to ₹80,293 Million in FY18.
- This growth was achieved despite the implementation of the Goods & Services Tax (GST) in India, which resulted in a temporary disruption in the Indian pharmaceutical market distribution chain.

Chart 11 Therapeutic revenue break-up⁹

(%)



(As of March 2018)

Table 5 Leadership in prescription rankings¹⁰

Specialists	February 2017	Specialists	February 2018
Psychiatrists	1	Psychiatrists	1
Neurologists	1	Neurologists	1
Cardiologists	1	Cardiologists	1
Orthopaedic	1	Orthopaedic	1
Gastroenterologists	1	Gastroenterologists	1
Nephrologists	1	Nephrologists	1
Diabetologists	1	Diabetologists	1
Consulting Physicians	1	Consulting Physicians	1
Dermatologists	1	Dermatologists	1
Urologists	1	Urologists	1
Oncologists	1	Oncologists	1
Ophthalmologists	2	Ophthalmologists	1
Chest Physicians	2	Chest Physicians	1

Outlook & future growth drivers

- India's pharmaceutical market offers good long-term potential, driven by increasing per capita income, rising healthcare awareness, higher incidence of chronic ailments and gradually increasing insurance coverage.
- Government-mandated price controls and other regulatory changes coupled with competitive intensity will continue to be the key industry challenges.

Future focus

- Enhancing the productivity of domestic business and strengthening leadership in a hyper-competitive landscape.
- Innovating consistently to ensure high brand equity with doctors.
- Widening the product basket through in-house drug development and in-licensing.

Emerging markets

18%

Revenue contribution

47%
FY14-18
revenue CAGR
₹48,392 Mn

Revenues for FY18

100+ countries

Presence across emerging markets

As on 31 March, 2018

Sun Pharma ranks among the bellwether Indian companies in emerging markets with an extensive portfolio of branded products. It has presence across 100+ countries spanning emerging and advanced markets. The Company is focusing on key markets of Brazil, Mexico, Russia, Romania, South Africa and complementary and affiliated markets. The large front-end infrastructure, a part of the Ranbaxy acquisition, is being gradually leveraged to expand presence in individual markets. Sun Pharma also has local manufacturing assets in some of these countries to enable a more meaningful participation in the respective markets.

**Emerging
Markets Sales
Force**

Sun Pharma has a 2,300-member sales force, which capitalises on opportunities available in these markets.

Progress in FY18

- Revenue from emerging markets grew by 7% to ₹48,392 Million in FY18.
- The growth is broad-based among emerging markets.

Future growth drivers

- Given the favourable macroeconomic parameters, emerging markets offer encouraging long-term potential.
- This will be counterbalanced by efforts from various governments to make pharmaceutical products more affordable to their population.

Future focus

- Focus on developing and commercialising more products across therapeutic segments to exploit this growth opportunity.
- Explore opportunities to enhance presence in key markets.
- Improve business profitability in emerging markets by launching complex products and reducing presence in low profitable non-core product segments.

Rest of the World (RoW) - Western Europe, Canada, Japan, ANZ and other markets

11%

Revenue contribution

₹29,740 Mn

Revenues for FY18

36%

FY14-18 revenue CAGR

As on 31 March, 2018

Sun Pharma's presence in the Rest of the World (RoW) spans across Western Europe, Japan, Canada, Israel, Australia, New Zealand and other markets. Its product portfolio comprises injectables, hospital products as well as products for the retail market.

Progress in FY18

- Revenues for RoW markets increased by 15% to ₹29,740 Million in FY18.
- Growth was primarily driven by the full-year inclusion of sales of acquired brands in Japan.

Future growth drivers

- Enhanced drug demand in geriatric care and lifestyle diseases such as obesity, hypertension, depression and diabetes will drive pharmaceutical consumption in these markets.
- Adoption of newer medical technologies as well as government policies of promoting low-cost generics will propel growth in these markets.

Outlook and future focus

- Ramping up presence in Japan post transfer of Novartis brands to Sun Pharma.
- Improving profitability for overall portfolio.

Active Pharmaceutical Ingredients (API) business

6%

Revenue contribution

₹13,993 Mn

Revenues for FY18

13%

FY13-18 revenue CAGR

14

API manufacturing units

291


DMF/CEP approvals

396

DMF/CEP filings

As on 31 March, 2018

Sun Pharma's API capability is of strategic importance as it provides cost competitiveness and supply reliability through backward integration. A significant portion of API production acts as inputs for the Company's formulations business. Besides captive consumption, Sun Pharma also supplies APIs to external customers comprising large generics and innovator companies.



Sun Pharma manufactures over 300 APIs across 14 locations, adding approximately 20 APIs to its portfolio, annually.

Progress in FY18

- Revenue from APIs and other sources declined by 12% to ₹13,993 Million in FY18.

Future growth drivers

- Increasing adoption of generics worldwide and rising cancer prevalence are some of the factors that propel the growth of the pharmaceutical ingredients market.

Focus areas

- Expanding API portfolio to enhance the scale and scope of API operations.
- Ensuring long-term supply relationships with global customers.

Global consumer healthcare business

20

Key brands

350+

Sales and distribution representatives in India

20+

Country presence

390,000+

Market reach - outlets in India

As on 31st March, 2018

Sun Pharma is among the top 10 consumer healthcare companies in India, Romania, Nigeria and Myanmar. It is also ranked No. 1 in the Romania OTC market. The Company's major markets are India, Russia, Romania, Nigeria, South Africa and Myanmar. It also has significant presence in Ukraine, Poland, Belarus, Kazakhstan, Thailand, Morocco and UAE, where it is scaling up at a steady pace. The Company has presence across OTC sub-categories like Vitamins and Minerals, Cold and Flu, Analgesics, Digestive and Dermatology.

Progress in FY18

As per Euromonitor 2017 report, Sun Pharma's consumer healthcare business in India recorded over 10% growth during the year and has grown at 12.6% CAGR over the preceding six years. Sun Pharma commands a 2.8% market share in India's consumer healthcare market.

Future growth drivers

- Indian consumer healthcare market will be driven by emerging middle-class and rising healthcare consumption.
- Globally, emerging markets like Russia, Romania, Nigeria, South Africa and Myanmar are projected to see sustained growth, driven by enhanced healthcare awareness.

Focus areas

- Continuing to invest in the accelerating OTC business across key markets through brand building and brand extensions.
- Expanding presence across OTC sub-categories in various markets.
- Maintaining leadership in existing markets by offering innovative solutions to consumers.

Research & development - delivering through innovation

Sun Pharma services both regulated and emerging pharmaceutical markets with its diverse product range of branded and generics products. Its robust research and development (R&D) capabilities has helped the Company develop technology-intensive products and deliver them at affordable prices to international markets. It has a wide-ranging portfolio of 2,000+ products across the world.

The Company's capable team of research scientists underpins its research and development capacities. It has many state-of-the-art research centres located across the world that provide facilities for developing generic drugs, Active Pharmaceutical Ingredients (APIs) and Novel Drug Delivery Systems (NDDS). Moreover, it is focussing on development of New Chemical Entities (NCEs) for global markets and has made significant investments in this field. Sun Pharma's R&D centres have been successfully audited and approved by international regulatory authorities, including the USFDA and European authorities.

The Company has commercialised a formidable product pipeline with successful offerings in liposomal products, lyophilised injections, nasal sprays, ointments, liquids and oral products among others.


R&D is critical for Sun Pharma and remains a key determinant of its future growth. Thus, Sun Pharma spent 8.6% of its sales on R&D during FY18. The Company is focussing more on developing specialty products and technically complex offerings to differentiate itself from competition. It also has a robust Intellectual Property Rights team, enabling it to patent its innovations globally and develop non-infringing products.

₹130 Bn

Sun Pharma's cumulative R&D investment

As on 31 March, 2018

Chart 12 R&D investment



561

Cumulative ANDAs filed

422

Cumulative ANDAs Approved

42

Cumulative NDA/BLA filed

39

Cumulative NDA/BLA approved

396

DMF/CEP cumulative applications filed

291

DMF/CEP cumulative applications approved

1,106

Total patent applications Submitted

1,065

Total patents granted

32

ANDAs filed in FY18

21

ANDAs approved in FY18

19

DMFs filed in FY18

19

DMFs approved in FY18

Global manufacturing footprint

Sun Pharma owns 42 manufacturing units, spanning six continents. The production units are located in India the US, Russia, Canada, Hungary, Israel, Bangladesh, Romania, Nigeria, South Africa, Malaysia and Australia.

The Company ensures that these units are world-class with latest equipment and technologies to provide best-in-class products to patients worldwide. It has vertically integrated operations that equip the Company to maintain a high-quality and low-cost value chain for quick market entry across geographies.


The Company focuses on producing generics, branded generics, specialty products, over-the-counter (OTC) products, anti-retrovirals (ARVs) and Active Pharmaceutical Ingredients (APIs). It has capabilities to manufacture the full range of dosage forms, including tablets, capsules, injectables, ointments, creams and liquids. Moreover, its operations are involved in the production of specialty APIs, including controlled substances, steroids, peptides and anti-cancers. Sun Pharma is among the few enterprises that has comprehensively integrated

manufacturing operations to produce oncology, hormones, peptides, controlled substances and steroidal drugs.

The Company complies with globally relevant regulatory policies and procedures. Its manufacturing facilities have been certified by regulatory authorities of the US (USFDA), Europe (EMA), the UK

(MHRA), Australia (TGA), South Africa (MCC) and Germany (BfArM), ANVISA (Brazil), WHO (Geneva), KFDA (Korea) and PMDA (Japan). The Company emphasises on round-the-clock compliance to cGMP standards which are imperative for a global pharmaceutical business.

Global manufacturing footprint



28 finished dosage manufacturing sites	14 API manufacturing sites
<ul style="list-style-type: none"> India: 14 US: 4 One each at Canada, South Africa, Malaysia, Russia, Hungary, Israel, Bangladesh, Romania, Egypt and Nigeria 	<ul style="list-style-type: none"> India: 9 Australia: 2 One each at Israel, US and Hungary
Delivery formats	Key API Plants
<ul style="list-style-type: none"> Orals: Tablets/Capsules, Semisolid, Liquids and Suppository 	<ul style="list-style-type: none"> The Panoli and Ahmednagar (both India) has USFDA and European approvals. They have standalone units for peptides, anti-cancer, steroids and sex hormones, among others The plants in Australia, Hungary and the US (Tennessee) manufacture controlled substances
<ul style="list-style-type: none"> Injectables/Sterile: Vials, Ampoules, Pre-filled Syringes, Gels, Lyophilized Units, Dry powder, Eye drops, MDI and Aerosols Topicals: Creams and Ointments 	

Managing talent

Sun Pharma has a global and diverse talent pool comprising over 50 nationalities. The Company considers its human assets to be its pivotal driving force and harbours a congenial work culture that encourages people (irrespective of race, gender and nationality) to contribute their best and accomplish the organisation's common objectives.

The Company offers several skill development opportunities to its 32,000+ workforce which includes various management programmes for employees to enhance their skills. Moreover, it has a wide range of knowledge sharing platforms that empower employees to grow professionally and be future-ready.

The Company promotes equal opportunities for all and values a healthy work-life balance. It has several employee engagement initiatives that minimise attrition.

Quality adherence

Quality is considered critical at all Sun Pharma's R&D centres, manufacturing units and testing and distribution facilities. It is committed to implementing a robust global quality management system. This dedication stems from Sun Pharma's determination to sustain a culture of operational excellence and meeting and exceeding stakeholders' — regulators, patients and customers — expectations. The Company firmly believes in the motto of 'putting patients first'.

Sun Pharma's global Quality Management Team ensures every product it manufactures and distributes complies with internationally accepted good practices and standards of quality, purity, efficacy and safety. The Company has distinct procedures and systems in every facility to maintain global quality standards, and to ensure compliance with the requirements of the Current Good Manufacturing Practices (cGMP), WHO, PICs and EU GMP. Sun Pharma ensures that its operating procedures meet the exacting standards of all global regulators like the USFDA, EMA, WHO and TGA, among others.

Sun Pharma has well-trained personnel for quality control at each site, who along with a regulatory affairs department, ensure strict adherence to quality systems and procedures. The teams are guided by a Corporate Quality Unit (CQU). CQU supervises the translation of the latest GMP updates to guidelines, standard operating procedures (SOPs) and protocols. The teams oversee the implementation of these guidelines to deliver quality products every time. Additionally, Sun Pharma's manufacturing plants are audited by an autonomous Corporate Compliance Department to establish 24x7 compliance and conformance.

During FY18, many of the Company's facilities underwent successful audits by various global regulatory authorities, including the USFDA. The Halol facility underwent a re-inspection by the USFDA in February 2018. On completion of the re-inspection, the USFDA issued three observations for the facility. Subsequently in June 2018, the USFDA issued the establishment inspection report (EIR) for Halol, thus clearing it.

Internal control

Sun Pharma believes that internal control is a prerequisite of the principle of governance and that freedom should be exercised within a framework of checks and balances. The Company has a well-established internal control framework, which is designed to continuously assess the adequacy, effectiveness and efficiency of financial and operational controls. The management is committed to ensuring an effective internal control environment, commensurate with the size and complexity of the business, which provides an assurance on compliance with internal policies, applicable laws, regulations and protection of resources and assets.

An independent and empowered Global Internal Audit Function at the corporate level carries out risk-focused audits across all businesses (both in India and overseas), which actively identifies areas, where business process controls are ineffective or may need enhancement. These reviews include financial, operational and compliance controls and risk mitigation plans. The Audit Committee of the Board periodically reviews key findings and provides strategic guidance. The Company's operating management closely monitors the internal control environment and ensures that the recommendations are effectively implemented.

Disclaimer

Statements in this 'Management Discussion and Analysis' describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events are 'forward-looking statements' within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. Important factors that could make a difference to the Company's operations include global and Indian demand supply conditions, finished goods prices, feedstock availability and prices, competitors' pricing in the Company's principal markets, changes in Government regulations, tax regimes, economic conditions within India and the countries within which the Company conducts businesses and other factors, such as litigation and labour unrest or other difficulties. The Company assumes no responsibility to publicly update, amend, modify or revise any forward-looking statements, based on any subsequent development, new information or future events or otherwise except as required by applicable law. Unless the context otherwise requires, all references in this document to 'we', 'us' or 'our' refers to Sun Pharmaceutical Industries Limited and consolidated subsidiaries.

Bibliography

1. IQVIA Institute, October 2017
2. IQVIA Market Prognosis, September 2017; IQVIA Institute, October 2017
3. Evaluate Pharma World Preview 2018
4. United Nations Population Fund
5. Nicholas Hall 2017
6. Research and Markets
7. India Brand Equity Foundation
8. IndiaSpend
9. AIOCD AWACS, March 2018
10. SMSRC Prescription Rankings

Board's Report

Your Directors take pleasure in presenting the Twenty-Sixth Annual Report and Company's Audited Financial Statements for the financial year ended March 31, 2018.

FINANCIAL RESULTS

(₹ in Million)

Particulars	Standalone		Consolidated	
	Year ended March 31, 2018	Year ended March 31, 2017*	Year ended March 31, 2018	Year ended March 31, 2017
Revenue from operations	79,476.0	77,932.0	264,894.6	315,784.4
Profit / (Loss) before tax but after exceptional item	(5199.8)	(168.0)	34,789.8	90,478.7
Tax Expense:				
-Current Tax	20.2	57.7	6,628.0	4,046.4
-Deferred Tax Charge / (Credit)	(274.1)	2.7	(720.6)	8,069.3
-Deferred tax charge / (Credit) - exceptional	-	-	2,544.5	-
Profit / (Loss) after tax	(4,945.9)	(228.4)	26,337.9	78,363.0
Profit / (Loss) after Tax but before Share in profit / (loss) of associates / joint ventures	-	-	26,337.9	78,363.0
Share of Profit/ (loss) of associates / joint ventures (Net)	-	-	(254.4)	99.3
Profit for the year before non-controlling interests	-	-	26,083.5	78,462.3
Non-controlling interests	-	-	4,468.0	8,818.6
Profit for the year attributable to owners of the Company	-	-	21,615.5	69,643.7
Total other Comprehensive Income	494.9	(634.5)	5,232.5	(14,871.9)
Total Comprehensive Income / (Loss) for the year attributable to:	(4,451.0)	(862.9)	31,316.0	63,590.4
-Owners of the Company	(4,451.0)	(862.9)	26,370.3	56,306.1
-Non-Controlling Interest	-	-	4,945.7	7,284.3
Opening balance in Retained Earnings	124,860.0	126,353.4	306,456.9	2,51,630.4
Additions:				
Transfer on Merger*	-	1,824.8	-	-
Amount available for appropriation	(4,511.5)	(829.2)	22,123.2	68,933.4
Less: Appropriations				
Dividend on Equity Shares	7,977.4	2,406.8	7,977.4	2,406.8
Dividend Distribution Tax	3.4	74.7	1,624.0	490.0
Transfer to various Reserves:				
-Capital redemption Reserve	-	7.5	-	7.5
-Debenture redemption Reserve	-	-	(833.4)	1,041.7
-Capital reserve	-	-	-	50.6
-Buy-back of equity shares by overseas subsidiary company	-	-	2,168.1	10,110.3
-Legal reserve	-	-	2.5	-
-General reserve	-	-	-	-
Closing balance in Retained Earnings	112,367.7	124,860.0	317,641.5	306,456.9

*Refer Note 56(13) of Standalone Financial Statements (Note 18 of Abridged Standalone Financial Statements)

DIVIDEND

Your Directors have recommended a dividend of ₹2.00 (Rupees Two only) per equity share of ₹1/- each [previous year ₹3.50/- per equity share of ₹1/- each] for the year ended March 31, 2018, subject to the approval of the equity shareholders at the ensuing 26th Annual General Meeting of the Company.

The dividend payout is in accordance with the Company's Dividend Distribution Policy. The Dividend Distribution Policy of the Company is provided as 'Annexure - A' to this Report. The policy is also

available on the website of the Company and can be accessed through the web link: <http://www.sunpharma.com/policies>.

CHANGES IN CAPITAL STRUCTURE

During the year under review, the Company has allotted 18893 equity shares of ₹1/- each under Sun Employee Stock Option Scheme - 2015 and 13106 equity shares of ₹1/- each under Sun Employee Stock Option Plan - 2015 thereby the paid up share capital of the Company increased to ₹2,399,323,180/- (Rupees Two Billion Three Hundred Ninety-Nine Million Three Hundred Twenty-Three Thousand One Hundred Eighty only) as on March 31, 2018.

Further, on May 24, 2018, the Company has allotted 1314 equity shares of ₹1/- each under Sun Employee Stock Option Scheme – 2015.

SCHEME OF ARRANGEMENTS

1. During the year, the Hon'ble National Company Law Tribunal of Gujarat at Ahmedabad had vide its order dated August 11, 2017 sanctioned the Scheme of Arrangement among Sun Pharma Medisales Private Limited, Ranbaxy Drugs Limited, Gufic Pharma Limited, Vidyut Investments Limited (collectively "Transferor Companies") wholly owned subsidiaries of the Company and the Company ("Transferee Company") and their respective members and creditors ("Scheme") whereby the Transferor Companies stand amalgamated with the Company w.e.f. September 08, 2017 with appointed date being April 01, 2017. Pursuant to the Scheme no consideration was paid.
2. During the year, the Board of Directors at its meeting held on November 14, 2017 has approved another Scheme of Arrangement among Sun Pharma Global FZE ("Transferor Company"), a wholly owned subsidiary of the Company and the Company and their respective members and creditors ("Scheme") for demerger of the Specified Undertaking (as defined in the Scheme) of Transferor Company into the Company. The Hon'ble National Company Law Tribunal of Gujarat, at Ahmedabad ("NCLT") had dispensed with convening of meeting of secured creditors of the Company and ordered to convene the meeting of equity shareholders and unsecured creditors of the Company on June 01, 2018 to approve the Scheme with appointed date as April 01, 2017 or such other date as may be agreed between the Transferor Company and the Company and approved by the NCLT. Pursuant to said Scheme, no consideration shall be paid and no shares of the Company shall be issued and allotted to the Transferor Company. The Scheme will result in strengthening of the business, synergistic benefits, economies of scale, faster decision making, integration of supply chain, reduction in operating costs, strengthening the focus, increased ability to face the competitive regulatory environment, increasing profitability, higher market share etc.
3. Further the Board of Directors at its meeting held on May 25, 2018 has also approved a Composite Scheme of Arrangement among the Company and Sun Pharma (Netherlands) B.V. and Sun Pharmaceutical Holdings USA Inc, wholly owned subsidiaries of the Company and their respective members and creditors ("Scheme"), for demerger of Specified Investment Undertaking -1 (as defined in the Scheme) of the Company into Sun Pharma (Netherlands) B.V. and Specified Investment Undertaking -2 (as defined in the Scheme) of the Company into Sun Pharmaceutical Holdings USA Inc. This demerger shall enable the Company to address the risks and policies, ability to strategize the remaining business for long term growth, strengthening of the investment portfolio, consolidation and creation of shareholder value. The Company shall be making the necessary application to the Hon'ble National Company Law Tribunal of Gujarat, at Ahmedabad and such other authorities as may be required for obtaining necessary approvals for the aforesaid Scheme.

EXTRACT OF ANNUAL RETURN

The extract of Annual Return as required under sub-section (3) of Section 92 of the Companies Act, 2013 ('the Act') in form MGT-9 is provided as 'Annexure – B' to this Report.

SUBSIDIARIES/ JOINT VENTURES/ ASSOCIATE COMPANIES

The statement containing the salient features of the Financial Statements of the Company's subsidiaries/ joint ventures/ associate companies is given in Form AOC – 1, provided in notes to the Consolidated Financial Statements, forming part of the Annual Report.

The highlights of performance of subsidiaries, joint ventures and associate companies and their contribution to the overall performance of the Company during the financial year is given under 'Annexure A of the Consolidated Financial Statements' forming part of the Annual Report.

Details pertaining to companies that became subsidiaries/ joint ventures/associates and those that ceased to be the subsidiaries/ joint ventures/associates of the Company during the year are provided in Note no. 39 of the notes to the Consolidated Financial Statements, forming part of the Annual Report.

DIRECTORS AND KEY MANAGERIAL PERSONNEL

Mr. Dilip S. Shanghvi, Managing Director and Mr. Sudhir V. Valia, Whole-time Director of the Company retire by rotation and being eligible offer themselves for reappointment at the ensuing 26th Annual General Meeting of the Company.

The present term of appointment of Mr. Sudhir V. Valia and Mr. Sailesh T. Desai as Whole-time Directors will expire on March 31, 2019. They have made significant contributions to the overall growth of the Company's business. Your Directors recommend the re-appointment of Mr. Sudhir V. Valia and Mr. Sailesh T. Desai for a further period of 5 (Five) years from April 01, 2019 to March 31, 2024, and remuneration for a period of 3 (Three) years from April 01, 2019 to March 31, 2022 due to inadequacy of profits, for approval of the members at the ensuing 26th Annual General Meeting of the Company.

Further the present term of appointment of Mr. Kalyanasundaram Subramanian as Whole-time Director will expire on February 13, 2019. He has made significant contribution to the overall growth of the Company's business. Your Directors recommend the re-appointment of Mr. Kalyanasundaram Subramanian for a further period of 2 (Two) years from February 14, 2019 to February 13, 2021, without any remuneration, for approval of the members at the ensuing 26th Annual General Meeting of the Company.

Mr. Vivek Chaand Sehgal and Mr. Gautam Doshi were appointed as Additional Independent Directors of the Company w.e.f. November 14, 2017 and May 25, 2018 respectively in accordance with the provisions of Section 149 and 161(1) of the Act and they both hold office upto the date of ensuing 26th Annual General Meeting. The Board recommends appointment of Mr. Vivek Chaand Sehgal and Mr. Gautam Doshi as Independent Directors of the Company for a term of 5(Five) years effective from November 14, 2017 and May 25, 2018 respectively for approval of the members at the ensuing 26th Annual General Meeting of the Company.

Pursuant to Regulation 17(1A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") to be effective from April 01, 2019, the consent of the members by way of Special Resolution is required for continuation of a Non-Executive Director of a company beyond the age of seventy five years. Mr. Israel Makov, Non-Executive Director and the Chairman of the Company, having attained an age of 79 years, the Board has recommended his continuation as a Director of the Company for approval of the members at the ensuing 26th Annual General Meeting of the Company.

Mr. Hasmukh Shah had resigned as an Independent Director of the Company effective from November 15, 2017. The Board of Directors places on record their appreciation for contributions made by Mr. Hasmukh Shah during his tenure as an Independent Director of the Company.

Appropriate resolutions for the appointment / re-appointment of the Directors are being placed for your approval at the ensuing 26th Annual General Meeting. Your Directors recommend the appointment/reappointment of the aforesaid Directors by the members at the ensuing 26th Annual General Meeting of the Company.

As informed in the previous year's Board's Report, Mr. C.S. Muralidharan has been appointed as Chief Financial Officer of the Company w.e.f June 19, 2017 and Mr. Uday Baldota had resigned as Chief Financial Officer w.e.f. June 19, 2017 to assume office as the Director and Chief Executive Officer of Taro Pharmaceutical Industries Limited, a subsidiary of the Company.

DECLARATION BY INDEPENDENT DIRECTORS

The Company has received declarations from all the Independent Directors of the Company confirming that they meet with the criteria of independence as prescribed under sub-section (6) of Section 149 of the Act and under Listing Regulations.

REMUNERATION POLICY FOR DIRECTORS, KEY MANAGERIAL PERSONNEL AND OTHER EMPLOYEES AND CRITERIA FOR APPOINTMENT OF DIRECTORS

For the purpose of selection of any Director, the Nomination and Remuneration Committee identifies persons of integrity who possess relevant expertise, experience and leadership qualities required for the position. The Committee also ensures that the incumbent fulfills such criteria with regard to qualifications, positive attributes, independence, age and other criteria as laid down under the Act, Listing Regulations or other applicable laws. The Board has, on the recommendation of the Nomination and Remuneration Committee framed a policy on remuneration of Directors, Key Managerial Personnel and other Employees. The Remuneration Policy of the Company is enclosed as 'Annexure B to Corporate Governance Report', which forms part of this Report

FAMILIARISATION PROGRAMME FOR THE INDEPENDENT DIRECTORS

In compliance with the requirements of Regulation 25(7) of the Listing Regulations, the Company has put in place a Familiarisation Programme for the Independent Directors to familiarise them with the Company, their roles, rights, responsibilities in the Company, nature of the industry in which the Company operates, business model etc. The details of the Familiarisation Programme conducted

are available on the website of the Company www.sunpharma.com and may be accessed through the web link: <http://www.sunpharma.com/policies>.

NUMBER OF MEETINGS OF THE BOARD

The Board of Directors of the Company met 5 (Five) times during the year under review on May 26, 2017; August 11, 2017; September 26, 2017; November 14, 2017; and February 14, 2018. The particulars of attendance of the Directors at the said meetings are detailed in the Corporate Governance Report, which forms a part of this Report. The intervening gap between the meetings was within the period prescribed under the Act and Listing Regulations.

EVALUATION OF PERFORMANCE OF THE BOARD, ITS COMMITTEES AND INDIVIDUAL DIRECTORS

During the year, the evaluation of the annual performance of individual Directors including the Chairman of the Company and Independent Directors, Board and Committees of the Board was carried out under the provisions of the Act, relevant Rules, and the Corporate Governance requirements as prescribed under Regulation 17 of Listing Regulations and based on the circular issued by SEBI dated January 5, 2017 with respect to Guidance Note on Board Evaluation. The Nomination and Remuneration Committee had approved the criteria for the performance evaluation of the Board, its Committees and individual Directors as per the SEBI Guidance Note on Board Evaluation.

The Chairman of the Company interacted with each Director individually, for evaluation of performance of the individual Directors. The evaluation for the performance of the Board as a whole and of the Committees were conducted by way of questionnaires.

In a separate meeting of Independent Directors, performance of Non Independent Directors and performance of the Board as a whole was evaluated. Further, they also evaluated the performance of the Chairman of the Company, taking into account the views of the Executive Directors and Non-executive Directors.

The performance of the Board was evaluated by the Board after seeking inputs from all the Directors on the basis of various criteria such as structure and diversity of the Board, competency of Directors, experience of Director, strategy and performance evaluation, secretarial support, evaluation of risk, evaluation of performance of the management and feedback, independence of the management from the Board etc. The performance of the Committees was evaluated by the Board after seeking inputs from the Committee members on the basis of criteria such as mandate and composition, effectiveness of the committee, structure of the committee and meetings, independence of the committee from the Board and contribution to decisions of the Board. The Nomination and Remuneration Committee reviewed the performance of the individual Directors on the basis of the criteria such as qualification, experience, knowledge and competency, fulfillment of functions, availability and attendance, initiative, integrity, contribution and commitment etc, and the Independent Directors were additionally evaluated on the basis of independence, independent views and judgement etc. Further the evaluation of Chairman of the Board, in addition to the above criteria for individual Directors, also included evaluation based on effectiveness of leadership and ability to steer the meetings, impartiality, etc.

HUMAN RESOURCES

We continue to believe that our organizational plans are fuelled by our employees and in an ever-changing business environment, it is critical to have credible and transparent people management practices and policies. The Human Resources agenda focuses on employee welfare, productivity and performance as a priority. We believe nurturing a high performance culture is imperative. Your company is proud to have talent which is varied and deep in its experiences and expertise across manufacturing, R & D, sales and other functions. Globally, the Company (including subsidiary and associate companies) has a dedicated human capital of over 30,000 employees at various locations across our various offices, R & D Centers & more than 40+ active manufacturing locations and dedicated sales professionals across various geographies. Your Directors would also like to take this opportunity to express their appreciation for the hard work and commitment of the employees of the Company and look forward to their continued contribution.

Information as per Section 197 (12) of the Act read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is provided in 'Annexure - C' to this Report. Further, the information pertaining to Rule 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, pertaining to the names and other particulars of employees is available for inspection at the Registered office of the Company during business hours and pursuant to the second proviso to Section 136(1) of the Act, the Report and the accounts are being sent to the members excluding this. Any shareholder interested in obtaining a copy of the same may write to the Company Secretary/Compliance Officer at Corporate office or Registered office address of the Company.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

Your Company strongly believes in providing a safe and harassment free workplace for each and every individual working for the Company through various interventions and practices. It is the continuous endeavor of the Management of the Company to create and provide an environment to all its employees that is free from discrimination and harassment including sexual harassment. The Company has adopted a policy on prevention, prohibition and redressal of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules made thereunder. The Company has arranged various interactive awareness workshops in this regard for the employees at the manufacturing sites, R & D set ups & corporate office during the year under review. The Company has submitted the Annual Returns to the local authorities under the above mentioned Act. During the financial year ended March 31, 2018, 1 complaint pertaining to sexual harassment was received and the same was resolved by the Company. There are no complaints pending as at the end of the financial year.

AUDITORS

Statutory Auditors

S R B C & Co LLP, Chartered Accountants, (Firm's Regn. No. 324982E/E300003), were appointed as the Statutory Auditors of the Company

for a period of 5 (five) years at the 25th Annual General Meeting of the Company to hold office till 30th Annual General Meeting of the Company.

The Auditor's Report for the financial year ended March 31, 2018, has been issued with an unmodified opinion, by the Statutory Auditors.

Secretarial Auditor

The Company had appointed Messrs C. J. Goswami & Associates, Practicing Company Secretaries, Mumbai to undertake the Secretarial Audit of the Company for the financial year ended March 31, 2018. The Secretarial Audit Report in the Form No. MR - 3 for the year is provided as 'Annexure - D' to this Report. The Secretarial Audit Report for the year does not contain any qualification, reservation or adverse remark.

Cost Auditor

The Company has appointed Messrs Kailash Sankhlecha & Associates, Cost Accountants, Vadodara as Cost Auditor of the Company for conducting Cost Audit in respect of Bulk Drugs & Formulations of your Company for the financial year 2018-19.

SECRETARIAL STANDARDS

The Company has complied with the applicable Secretarial Standards as amended from time to time.

LOANS, GUARANTEES & INVESTMENTS

The particulars of loans, guarantees and investments have been disclosed in the Financial Statements.

RELATED PARTY TRANSACTIONS

The policy on Related Party Transactions as approved by the Board is available on the website of the Company and can be accessed through the web link <http://www.sunpharma.com/policies>. All contracts/arrangements/transactions entered by the Company during the year under review with the related parties were in the ordinary course of business and on an arm's length basis.

As required under Section 134(3)(h) of the Act, details of transactions entered with Related Parties under the Act exceeding ten percent of the annual consolidated turnover as per the last audited financial statements are given in Form AOC-2 provided as 'Annexure - E' to this Report.

AUDIT COMMITTEE COMPOSITION

The details pertaining to composition of Audit Committee are included in the Corporate Governance Report, which forms part of this Report.

RISK MANAGEMENT

The Company has developed & implemented an integrated Enterprise Risk Management Framework through which it identifies monitors, mitigates & reports key risks that impacts its ability to meet the strategic objectives. The Board of Directors have constituted a Risk Management Committee which is entrusted with the responsibility of overseeing various strategic, operational and financial risks that the organisation faces, along with the adequacy of mitigation plans to address such risks. There is an overarching Risk Management Policy in place that was reviewed and approved by the

Board. The Corporate Governance Report, which forms part of this Report, contains the details of Risk Management Committee of the Company.

INTERNAL FINANCIAL CONTROLS

The Company has in place well defined and adequate internal financial control framework. During the year under review, such controls were tested and no material weaknesses were observed both in their design or operations.

CORPORATE SOCIAL RESPONSIBILITY

In compliance with the requirements of Section 135 of the Act read with the Companies (Corporate Social Responsibility) Rules, 2014, the Board of Directors have constituted a Corporate Social Responsibility (CSR) Committee of the Company. The details of membership of the Committee and the meetings held are detailed in the Corporate Governance Report, forming part of this Report. During the year under review, the Board of Directors have approved certain amendments in CSR policy pertaining to the projects and CSR activities to be undertaken by the Company. The contents of the CSR Policy of the Company as approved by the Board on the recommendation of the CSR Committee are available on the website of the Company and can be accessed through the web link: <http://www.sunpharma.com/policies>. The average net profit of the Company for last three financial years is negative, therefore the Company was not required to spend on CSR activities during the year, however, the Company has voluntarily spent on CSR activities. The annual report on CSR activities containing details of voluntary expenditure incurred by the Company and brief details on the CSR activities are provided in 'Annexure – F' to this Report.

PUBLIC DEPOSITS

The Company has not accepted any deposit from the Public during the year under review, under the provisions of the Act and the rules framed thereunder.

MANAGEMENT DISCUSSION AND ANALYSIS

The Management Discussion and Analysis as prescribed under Part B of Schedule V read with Regulation 34(3) of the Listing Regulations is provided in a separate section and forms part of this Report.

CORPORATE GOVERNANCE REPORT

Report on Corporate Governance and Certificate of the Auditors of the Company regarding compliance of the conditions of Corporate Governance as stipulated in Part C of Schedule V of the Listing Regulations, are provided in a separate section and forms part of this Report.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo as stipulated under Section 134(3)(m) of the Act read with Rule 8 of the Companies (Accounts) Rules, 2014, is provided as 'Annexure – G' to this Report.

EMPLOYEES' STOCK OPTION SCHEMES

The Company has two Employees' Stock Option Schemes, one through Trust Route and the other by Direct Route, both inherited from erstwhile Ranbaxy Laboratories Limited ("Ranbaxy"). The scheme through Direct Route has been named as Sun Pharma

Employee Stock Option Scheme – 2015, and the one through Trust Route as Sun Pharma Employee Stock Option Plan – 2015. Both the schemes were adopted by the Company with certain amendments consequent upon merger of erstwhile Ranbaxy into the Company. Both the Schemes are in compliance with Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014. The Scheme through Trust Route i.e. Sun Pharma Employee Stock Option Plan – 2015 has been completed in August 2017.

Disclosures with respect to the Employees' Stock Option Schemes in compliance with Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014 are available on the Company's website and can be accessed at: <http://www.sunpharma.com/pdflist/all-documents>.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS

There are no significant and material orders passed by the regulators or courts or tribunals which impact the going concern status and Company's operations in future.

WHISTLE BLOWER POLICY/ VIGIL MECHANISM

To create enduring value for all stakeholders and ensure the highest level of honesty, integrity and ethical behaviour in all its operations, the Company has adopted a 'Global Whistle Blower Policy' for Sun Pharmaceutical Industries Limited and all its subsidiaries, in addition to the existing Global Code of Conduct that governs the actions of its employees. Further details on vigil mechanism of the Company are provided in the Corporate Governance Report, forming part of this Report.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to the requirements under Section 134(5) read with Section 134(3)(c) of the Act, with respect to Directors' Responsibility Statement, it is hereby confirmed that:

- a) in the preparation of the annual accounts for the financial year ended March 31, 2018, the applicable accounting standards have been followed and there are no material departures from the same;
- b) the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at March 31, 2018 and of the loss of the Company for the year ended on that date;
- c) the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d) the Directors have prepared the annual accounts on a going concern basis;
- e) the Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively; and

- f) the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

CONSOLIDATED ACCOUNTS

The consolidated financial statements for the year ended March 31, 2018 have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015.

CREDIT RATING

ICRA Ltd. has reaffirmed the highest credit rating of '[ICRA] A1+'/'[ICRA] AAA(Stable)' for the bank facilities, long term/short term borrowings and commercial paper programs of the Company.

Further, CRISIL Ltd. has also reaffirmed the highest credit rating of 'CRISIL A1+ and CRISIL AAA/Stable' for short term & long term bank facilities and commercial paper programs of the Company.

BUSINESS RESPONSIBILITY REPORTING

The Business Responsibility Report of the Company for the year ended March 31, 2018, is made available on the website of the Company at <http://www.sunpharma.com/pdflist/all-documents> and forms part of the Annual Report, and is also available at the Registered office / Corporate office of the Company for inspection. A copy of the aforesaid report shall be made available to such of those shareholders who are desirous and interested, upon receipt of a written request from them.

ABRIDGED ANNUAL REPORT

In terms of the provision of Section 136(1) of the Act, Rule 10 of Companies (Accounts) Rules, 2014 and Regulation 36 of the Listing

Regulations and to support Green Initiative, the Board of Directors has decided to circulate the physical copy of Abridged Annual Report containing salient features of Financial Statements and other documents for financial year 2017-18 to the members, who have not registered their e-mail ids. All the annexures to the Board's Report referred herein viz., Annexure - A to Annexure - G and the Corporate Governance Report (including its annexures) have been excluded from the Abridged Annual Report which is being circulated to the members who have not registered their e-mail id.

The members who are desirous of receiving the full version of the Annual Report may write to the Company's Registrar and Share Transfer Agent for a copy of the same. Full version of the Annual Report can also be accessed from the Company's website: www.sunpharma.com

ACKNOWLEDGEMENTS

Your Directors wish to thank all stakeholders, employees and business partners, Company's bankers, medical professionals and business associates for their continued support and valuable cooperation.

The Directors also wish to express their gratitude to investors for the faith that they continue to repose in the Company.

For and on behalf of the Board of Directors

Place: Mumbai
Date: May 25, 2018

Israel Makov
Chairman

Independent Auditor's Report

To the Members of Sun Pharmaceutical Industries Limited

Report on the Abridged Standalone Ind AS Financial Statements

The accompanying Abridged Standalone Ind AS Financial Statements of Sun Pharmaceutical Industries Limited ("the Company"), which comprise the Abridged Balance Sheet as at March 31, 2018, the Abridged Statement of Profit and Loss (including Other Comprehensive Income), Abridged Cash Flow Statement and the Abridged Statement of Changes in Equity for the year then ended, and related notes, are derived from the audited Standalone Ind AS Financial Statements of the Company as at and for the year ended March 31, 2018. We expressed an unmodified audit opinion on those financial statements in our report dated May 25, 2018.

The Abridged Standalone Ind AS Financial Statements do not contain all the disclosures required by the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013 ("the Act") read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. Reading the Abridged Standalone Ind AS Financial Statements, therefore, is not a substitute for reading the audited Standalone Ind AS Financial Statements of the Company.

Management's Responsibility for the Abridged Standalone Ind AS Financial Statements

The Company's Board of Directors is responsible for the preparation of Abridged Standalone Ind AS Financial Statements in accordance with Section 136(1) read with Rule 10 of the Companies (Accounts) Rule, 2014, as amended and are based on audited Standalone Ind AS Financial Statements as at and for the year ended March 31, 2018, prepared in accordance with Indian Accounting Standards specified under Section 133 of the Act, read with the Companies (Indian Accounting Standard) Rules, 2015, as amended. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the Abridged Standalone Ind AS Financial Statements.

Auditor's Responsibility

Our responsibility is to express an opinion on the Abridged Standalone Ind AS Financial Statements based on our procedures, which were conducted in accordance with Standard on Auditing (SA) 810, "Engagements to Report on Summary Financial Statements" issued by the Institute of Chartered Accountants of India. In performing those procedures, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Abridged Standalone Ind AS Financial Statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

Opinion

In our opinion and to the best of our information and explanations given to us, the accompanying Abridged Standalone Ind AS Financial Statements, prepared in accordance with Section 136(1) read with Rule 10 of the Companies (Accounts) Rules, 2014, as amended are derived from the audited Standalone Ind AS Financial Statements of the Company as at and for the year ended March 31, 2018, prepared in accordance with the Indian Accounting Standards specified under Section 133 of the Act, read with the Companies (Indian Accounting Standard) Rules, 2015, as amended and are a fair summary of those Standalone Ind AS Financial Statements.

Other Matter

The Standalone Ind AS Financial Statements of the Company for the year ended March 31, 2017, included in the Standalone Ind AS Financial Statements, have been audited by the predecessor auditor who expressed an unmodified opinion on those statements on May 26, 2017.

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration No.: 324982E/E300003

per **PAUL ALVARES**

Partner

Membership No.: 105754

Place: Mumbai

Date: May 25, 2018

Independent Auditor's Report

To the Members of Sun Pharmaceutical Industries Limited

Report on the Standalone Ind AS Financial Statements

We have audited the accompanying standalone Ind AS financial statements of Sun Pharmaceutical Industries Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2018, the Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Standalone Ind AS Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone Ind AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial control that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone Ind AS financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder. We conducted our audit of the standalone Ind AS financial statements in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India, as specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone Ind AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the standalone Ind AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the standalone Ind AS financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone Ind AS financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the standalone Ind AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2018, its loss including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Other Matter

The Ind AS financial statements of the Company for the year ended March 31, 2017, included in these standalone Ind AS financial statements, have been audited by the predecessor auditor who expressed an unmodified opinion on those statements on May 26, 2017.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the Annexure 1 a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by section 143 (3) of the Act, we report that:

Independent Auditor's Report

To the Members of Sun Pharmaceutical Industries Limited

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- (c) The Balance Sheet, Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
- (d) In our opinion, the aforesaid standalone Ind AS financial statements comply with the Accounting Standards specified under section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended;
- (e) On the basis of written representations received from the directors as on March 31, 2018, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2018, from being appointed as a director in terms of section 164 (2) of the Act;
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company with reference to these standalone Ind AS financial statements and the operating effectiveness of such controls, refer to our separate Report in "Annexure 2" to this report;
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its standalone Ind AS financial statements – Refer Note 40 to the standalone Ind AS financial statements;
 - ii. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts – Refer Note 25 and 30 to the standalone Ind AS financial statements
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company, except a sum of ₹ 16.9 Million, which is held in abeyance due to pending legal cases.

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration No.: 324982E/E300003

per **PAUL ALVARES**

Partner

Membership No.: 105754

Place: Mumbai

Date: May 25, 2018

ANNEXURE 1 REFERRED TO IN PARAGRAPH 1 UNDER THE HEADING “REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENT” OF OUR REPORT OF EVEN DATE

Re: Sun Pharmaceutical Industries Limited (‘the Company’)

- (i) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
- (b) All fixed assets have not been physically verified by the management during the year but there is a regular programme of verification which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.
- (c) According to the information and explanations given by the management, the title deeds of immovable properties, included in property, plant and equipment are held in the name of the Company, except for the following immovable properties for which registration of title deeds is in process:

Particulars of Freehold Land and building	Gross Block (₹ in millions)	Net Block (₹ in millions)	Remarks
Freehold Land located in Himachal Pradesh	76.3	76.3	The title deeds are in the name of Ranbaxy Laboratories Limited, erstwhile company that was merged with the Company under Sections 391 to 394 of the Companies Act, 1956 in terms of the approval of the Honourable High Courts of Gujarat and of Punjab and Haryana.
Freehold Land located in Punjab	27.2	27.2	
Freehold Land located in Haryana	109.0	109.0	
Freehold Land located in Madhya Pradesh	5.8	5.8	
Freehold Land located in Karnataka	28.3	28.3	
Freehold Land located in Punjab	2.5	2.5	The title of this land is under dispute in respect of which we have been informed by the Management of the Company that they have filed a Special Leave Petition with the Honourable Supreme Court against the order passed by the Honourable High Court of Punjab and Haryana and the matter is under adjudication.
Freehold Land located in Chennai	11.3	7.7	The titles are in the name of Tamilnadu Dadha Pharmaceuticals Limited / Pradeep Drug Company Limited, erstwhile companies that were merged with the Company under Sections 391 to 394 of the Companies Act, 1956 in terms of the approval of the Honourable High Courts of Gujarat and of Tamilnadu / order of the New Delhi Bench of Board of Industrial and Financial Reconstruction respectively.
Land and Building situated at Village Bhatauli Kalan, PO Barotiwala, Nalagarh, District Solan (HP)	122.7	86.2	The title deeds are in the name of Solrex Pharmaceuticals, erstwhile Partnership firm that was merged with the Company under Sections 230 to 232 of the Companies Act, 2013.
Land and Building situated at Vill. Bhatauli Kalan, PO Barotiwala, Nalagarh, District Solan (HP)			

In respect of building where the Company is entitled to the right of occupancy and use and disclosed as property, plant and equipment in the standalone Ind AS financial statements, we report that the agreement / non-convertible preference shares / compulsorily convertible debentures entitling the right of occupancy and use of building, are in the name of the Company as at the balance sheet date.

ANNEXURE 1 REFERRED TO IN PARAGRAPH 1 UNDER THE HEADING “REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENT” OF OUR REPORT OF EVEN DATE

Re: Sun Pharmaceutical Industries Limited (‘the Company’)

In respect of immovable properties of land and buildings that have been taken on lease and disclosed as property, plant and equipment in the standalone Ind AS financial statements, the lease agreements are in the name of the Company, where the Company is the lessee in the agreement, except for the following:

Particulars of Leasehold Land	Cost or deemed cost as at 31st March 2018 (₹ in millions)	Carrying amount as at 31st March 2018 (₹ in millions)	Remarks
Located In Maharashtra	17.4	17.1	The lease agreements are in the name of Crosslands Research Laboratories Limited which was merged with Ranbaxy Laboratories Limited, erstwhile company that was merged with the Company under Sections 391 to 394 of the Companies Act, 1956 in terms of the approval of the Honourable High Courts of Gujarat and of Punjab and Haryana.
Located in Goa	2.7	2.6	
Located in Punjab.	213.2	205.9	The lease agreements are in the name of Ranbaxy Laboratories Limited, erstwhile company that was merged with the Company under Sections 391 to 394 of the Companies Act, 1956 in terms of the approval of the Honourable High Courts of Gujarat and of Punjab and Haryana.
Located in Madhya Pradesh.	222.4	215.5	
Located in Gujarat	0.7	0.3	The lease agreements are in the name of Gujarat Lyca Limited, erstwhile company that was merged with the Company under Sections 391 to 394 of the Companies Act, 1956 in terms of the approval of the Honourable High Courts of Gujarat.

- (ii) The inventory has been physically verified by the management during the year. In our opinion, the frequency of verification is reasonable. No material discrepancies were noticed on such physical verification. Inventories lying with third parties have been confirmed by them and no material discrepancies were noticed in respect of such confirmations.
- (iii) (a) The Company has granted loans to one Company covered in the register maintained under section 189 of the Companies Act, 2013. In our opinion and according to the information and explanations given to us, the terms and conditions of the grant of such loans are not prejudicial to the Company’s interest.
- (b) The Company has granted loans that are re-payable on demand, to a firm covered in the register maintained under section 189 of the Companies Act, 2013. The schedule of repayment of principal and payment of interest has been stipulated for the loans granted and the repayment/receipts are regular.
- (c) There are no amounts of loans granted to companies, firms or other parties listed in the register maintained under section 189 of the Companies Act, 2013 which are overdue for more than ninety days.
- (iv) In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of Section 186 of the Act in respect of grant of loans, making investments and providing guarantees and securities as applicable. During the year, the Company has not granted any loans covered under Section 185 of the Act.
- (v) The Company has not accepted any deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of clause 3(v) of the Order are not applicable.
- (vi) We have broadly reviewed the books of account maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under section 148(1) of the Companies Act, 2013, related to the manufacture of pharmaceutical products, and are of the opinion that prima facie, the specified accounts and records have been made and maintained. We have not, however, made a detailed examination of the same.
- (vii) (a) Undisputed statutory dues including provident fund, employees’ state insurance, income-tax, sales-tax, service tax, duty of custom, duty of excise, value added tax, goods and service tax, cess and other statutory dues have generally been regularly deposited with the appropriate authorities though there has been a slight delay in a few cases.
- (b) According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, employees’ state insurance, income-tax, service tax, sales-tax, duty of custom, duty of excise, value added tax, goods and service tax, cess and other statutory dues were outstanding, at the year end, for a period of more than six months from the date they became payable.

ANNEXURE 1 REFERRED TO IN PARAGRAPH 1 UNDER THE HEADING “REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENT” OF OUR REPORT OF EVEN DATE

Re: Sun Pharmaceutical Industries Limited ('the Company')

- (c) According to the records of the Company, the dues of income-tax, sales-tax, service tax, duty of custom, duty of excise, value added tax and cess on account of any dispute, are as follows:

Name of the statute	Nature of dues	Forum where the dispute is pending	Period to which the amount relates	Amount* (₹ in Million)
Income Tax Act, 1961	Income Tax, Interest and penalty	Income Tax Appellate Tribunal (ITAT)	1995-96, 2007-08, 2009-10 to 2011-12	20,308.4
Sales Tax Act/VAT (Various States)	Sales Tax, Interest and Penalty	Commissioner (Appeals)	2003-04, 2013-14, 2014-15	10,517.1
		Assistant / Additional /Senior Joint Commissioner	1999-00, 2000-01, 2003-04, 2004-05 & 2013-14 to 2015-16	31.8
		Appellate Authority	1998-99, 2008-09, 2014-15 & 2015-16	14.9
		Tribunal	1998-99 to 2003-04, 2008-09 & 2009-10	5.7
		High Court	1999-00 to 2010-11	53.2
The Central Excise Act, 1944	Service Tax	Assistant / Additional /Senior Joint Commissioner	2006-07 to 2015-16	46.6
		Customs, Excise and Service Tax Appellate Tribunal (CESTAT), Delhi	2012-13 to 2014-15	3.1
		Commissioner (Appeals)	2008-09 to 2012-13 & 2014-15	21.6
Customs Act, 1962	Customs Duty, Penalty and Interest	CESTAT	2010-11, 2011-12 & 2012-13	116.0
The Central Excise Act, 1944	Excise Duty, Interest and Penalty	CESTAT	2003-04 to 2015-16	1,162.4
		Commissioner (Appeals)	2003-04 to 2016-17	80.8
		High Court	2003-04 to 2005-06 & 2008-09 to 2013-14	63.2

* Net of amount paid / adjusted under protest. Amount included herein includes interest till the date of the order.

- (viii) In our opinion and according to the information and explanations given by the management, the Company has not defaulted in repayment of loans or borrowing to a financial institution, bank or government. The Company did not have any outstanding dues to debenture holders during the year.
- (ix) In our opinion and according to the information and explanations given by the management, the Company has utilised the monies raised by way term loans for the purposes for which they were raised. The Company has not raised any money way of initial public offer / further public offer / debt instruments.
- (x) Based upon the audit procedures performed for the purpose of reporting the true and fair view of the financial statements and according to the information and explanations given by the management, we report that no fraud by the Company or no material fraud on the Company by the officers and employees of the Company has been noticed or reported during the year.
- (xi) According to the information and explanations given by the management, the managerial remuneration has been paid / provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act, 2013.
- (xii) In our opinion, the Company is not a nidhi Company. Therefore, the provisions of clause 3(xii) of the order are not applicable to the Company and hence not commented upon.
- (xiii) According to the information and explanations given by the management, transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the notes to the financial statements, as required by the applicable accounting standards.
- (xiv) According to the information and explanations given to us and on an overall examination of the balance sheet, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review and hence, reporting requirements under clause 3(xiv) are not applicable to the Company and, not commented upon.
- (xv) According to the information and explanations given by the management, the Company has not entered into any non-cash transactions with directors or persons connected with him as referred to in section 192 of the Companies Act, 2013.
- (xvi) According to the information and explanations given to us, the provisions of section 45-IA of the Reserve Bank of India Act, 1934 are not applicable to the Company.

For **S R B C & CO LLP**
Chartered Accountants
ICAI Firm Registration No.: 324982E/E300003

per **PAUL ALVARES**
Partner
Membership No.: 105754

Place: Mumbai
Date: May 25, 2018

ANNEXURE 2 TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF SUN PHARMACEUTICAL INDUSTRIES LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of Sun Pharmaceutical Industries Limited ("the Company") as of March 31, 2018 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's Management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting with reference to these standalone financial statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing as specified under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting with reference to these standalone financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls over financial reporting with reference to these standalone financial statements and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting with reference to these standalone financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls over financial reporting with reference to these standalone financial statements.

Meaning of Internal Financial Controls over Financial Reporting with Reference to these Financial Statements

A company's internal financial control over financial reporting with reference to these standalone financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting with reference to these standalone financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

ANNEXURE 2 TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE STANDALONE FINANCIAL STATEMENTS OF SUN PHARMACEUTICAL INDUSTRIES LIMITED

Inherent Limitations of Internal Financial Controls over Financial Reporting with Reference to these Standalone Financial Statements

Because of the inherent limitations of internal financial controls over financial reporting with reference to these standalone financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting with reference to these standalone financial statements to future periods are subject to the risk that the internal financial control over financial reporting with reference to these standalone financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, adequate internal financial controls over financial reporting with reference to these standalone financial statements and such internal financial controls over financial reporting with reference to these standalone financial statements were operating effectively as at March 31, 2018, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration No.: 324982E/E300003

per **PAUL ALVARES**

Partner

Membership No.: 105754

Place: Mumbai

Date: May 25, 2018

Abridged Standalone Balance Sheet

as at March 31, 2018

Particulars	₹ in Million	
	As at March 31, 2018	As at March 31, 2017
ASSETS		
(1) Non-current assets		
(a) Property, plant and equipment	43,756.5	38,693.5
(b) Capital work-in-progress	8,303.9	10,551.1
(c) Goodwill	1,208.0	1,208.0
(d) Other intangible assets	620.8	484.8
(e) Intangible assets under development	437.4	453.9
(f) Investments in the nature of equity in subsidiaries	182,225.7	191,865.1
(g) Investments in the nature of equity in associates	-	-
(h) Financial assets		
(i) Investments	879.3	1,067.8
(ii) Loans	34.2	48.7
(iii) Other financial assets	489.7	990.6
(i) Deferred tax assets (Net)	7,517.0	7,490.6
(j) Income tax assets (Net)	20,742.4	17,848.7
(k) Other non-current assets	3,953.6	4,108.0
Total non-current assets	270,168.5	274,810.8
(2) Current assets		
(a) Inventories	21,356.4	23,082.8
(b) Financial assets		
(i) Investments	447.6	400.1
(ii) Trade receivables	28,469.6	27,147.0
(iii) Cash and cash equivalents	1,094.3	1,533.3
(iv) Bank balances other than (iii) above	458.4	169.5
(v) Loans	520.5	138.5
(vi) Other financial assets	882.9	672.5
(c) Other current assets	15,845.5	10,738.2
Total current assets	69,075.2	63,881.9
TOTAL ASSETS	339,243.7	338,692.7

Abridged Standalone Balance Sheet

as at March 31, 2018

Particulars	₹ in Million	
	As at March 31, 2018	As at March 31, 2017
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	2,399.3	2,399.3
(b) Other equity	195,301.7	207,725.4
Total equity	197,701.0	210,124.7
Liabilities		
(1) Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	15,646.9	7,606.4
(ii) Other financial liabilities	9.1	6.8
(b) Provisions	3,451.8	11,328.3
Total non-current liabilities	19,107.8	18,941.5
(2) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	52,138.1	40,540.4
(ii) Trade payables	24,899.4	20,726.0
(iii) Other financial liabilities	18,567.4	28,145.1
(b) Other current liabilities	2,575.1	1,740.7
(c) Provisions	24,254.9	18,474.3
Total current liabilities	122,434.9	109,626.5
Total liabilities	141,542.7	128,568.0
TOTAL EQUITY AND LIABILITIES	339,243.7	338,692.7

The accompanying notes are an integral part of the abridged standalone financial statements

As per our report of even date

For **S R B C & CO LLP**
Chartered Accountants
ICAI Firm Registration No. : 324982E/E300003

per **PAUL ALVARES**
Partner
Membership No. : 105754
Mumbai, May 25, 2018

C. S. MURALIDHARAN
Chief Financial Officer

SUNIL R. AJMERA
Company Secretary

For and on behalf of the Board of Directors of
Sun Pharmaceutical Industries Limited

DILIP S. SHANGHVI
Managing Director

SUDHIR V. VALIA
Wholetime Director

SAILESH T. DESAI
Wholetime Director
Mumbai, May 25, 2018

Abridged Standalone Statement of Profit and Loss

for the year ended March 31, 2018

₹ in Million

Particulars	Year ended March 31, 2018	Year ended March 31, 2017
(I) Revenue from operations	79,476.0	77,932.0
(II) Other income	11,280.4	5,150.8
(III) Total income (I + II)	90,756.4	83,082.8
(IV) Expenses		
Cost of materials consumed	21,675.2	22,284.5
Purchases of stock-in-trade	11,659.9	12,365.0
Changes in inventories of finished goods, stock-in-trade and work-in-progress	1,592.6	(1,678.6)
Employee benefits expense	16,176.9	14,998.8
Finance costs	3,883.1	2,235.7
Depreciation and amortisation expense	4,322.3	4,222.8
Other expenses	27,141.2	28,822.6
Total expenses (IV)	86,451.2	83,250.8
(V) Profit / (loss) before exceptional item and tax (III - IV)	4,305.2	(168.0)
(VI) Exceptional item (Refer Note 12)	9,505.0	-
(VII) Loss before tax (V - VI)	(5,199.8)	(168.0)
(VIII) Tax expense		
Current tax	20.2	57.7
Deferred tax	(274.1)	2.7
Total tax expense (VIII)	(253.9)	60.4
(IX) Loss for the year (VII - VIII)	(4,945.9)	(228.4)
(X) Other comprehensive income		
A) Items that will not be reclassified to the statement of profit or loss		
a. Remeasurements of the defined benefit plans	664.3	(600.8)
Income tax on above	(229.9)	-
b. Equity instruments through other comprehensive income	67.2	(7.1)
Income tax on above	(23.2)	-
Total - (A)	478.4	(607.9)
B) Items that may be reclassified to the statement of profit or loss		
a. Effective portion of gains and loss on designated portion of hedging instruments in a cash flow hedge	26.6	(26.6)
b. Debt instruments through other comprehensive income	(15.5)	-
Income tax on above	5.4	-
Total - (B)	16.5	(26.6)
Total other comprehensive income (A+B) (X)	494.9	(634.5)
(XI) Total comprehensive loss for the year (IX+X)	(4,451.0)	(862.9)
Earnings per equity share (face value per equity share - ₹ 1)		
Basic (in ₹)	(2.1)	(0.1)
Diluted (in ₹)	(2.1)	(0.1)

The accompanying notes are an integral part of the abridged standalone financial statements

As per our report of even date

For **S R B C & CO LLP**
Chartered Accountants
ICAI Firm Registration No. : 324982E/E300003

per **PAUL ALVARES**
Partner
Membership No. : 105754
Mumbai, May 25, 2018

C. S. MURALIDHARAN
Chief Financial Officer

SUNIL R. AJMERA
Company Secretary

For and on behalf of the Board of Directors of
Sun Pharmaceutical Industries Limited

DILIP S. SHANGHVI
Managing Director

SUDHIR V. VALIA
Wholetime Director

SAILESH T. DESAI
Wholetime Director
Mumbai, May 25, 2018

Abridged Standalone Statement of Changes in Equity

for the year ended March 31, 2018

for the year ended March 31, 2018													₹ in Million	
Particulars	Equity share capital	Other equity							Other comprehensive income (OCI)			Total		
		Share application money pending allotment	Capital reserve	Securities premium reserve	Share options outstanding account	Reserve and surplus		Capital redemption reserve	General reserve	Retained earnings	Equity instrument through OCI		Debt instrument through OCI	Effective portion of cash flow hedges
						Amalgamation reserve								
Balance as at March 31, 2016	2,406.6	6.7	36,660.0	18,585.2	48.9	43.8	-	-	34,779.3	126,353.4	23.1	-	-	218,907.0
Add - Transfer on merger [Refer Note 18]	-	-	(535.6)	-	-	-	-	-	-	1,824.8	-	-	-	1,289.2
Adjusted balance as at March 31, 2016	2,406.6	6.7	36,124.4	18,585.2	48.9	43.8	-	-	34,779.3	128,178.2	23.1	-	-	220,196.2
Loss for the year	-	-	-	-	-	-	-	-	-	(228.4)	-	-	-	(228.4)
Other comprehensive income for the year	-	-	-	-	-	-	-	-	-	^ (600.8)	(7.1)	-	(26.6)	(634.5)
Total comprehensive income for the year	-	-	-	-	-	-	-	-	-	(829.2)	(7.1)	-	(26.6)	(862.9)
Payment of dividend	-	-	-	-	-	-	-	-	-	(2,406.8)	-	-	-	(2,406.8)
Dividend distribution tax	-	-	-	-	-	-	-	-	-	(74.7)	-	-	-	(74.7)
Recognition of share-based payments to employees	-	-	-	-	32.3	-	-	-	-	-	-	-	-	32.3
Issue of equity shares	0.2	(6.7)	-	31.3	-	-	-	-	-	-	-	-	-	24.8
Buy-back of equity shares	(7.5)	-	-	(6,742.5)	-	-	-	-	-	-	-	-	-	(6,750.0)
Expenditure on buy-back of equity shares	-	-	-	(34.2)	-	-	-	-	-	-	-	-	-	(34.2)
Transfer to capital redemption reserve on buy-back of equity shares	-	-	-	-	-	-	-	7.5	-	(7.5)	-	-	-	-
Transfer on exercise of share options	-	-	-	54.8	(54.8)	-	-	-	-	-	-	-	-	-
Balance as at March 31, 2017	2,399.3	* 0.0	36,124.4	11,894.6	26.4	43.8	7.5	34,779.3	124,860.0	16.0	-	(26.6)	-	210,124.7
Loss for the year	-	-	-	-	-	-	-	-	(4,945.9)	-	-	-	-	(4,945.9)
Other comprehensive income for the year	-	-	-	-	-	-	-	-	^434.4	44.0	(10.1)	26.6	-	494.9
Total comprehensive income for the year	-	-	-	-	-	-	-	-	(4,511.5)	44.0	(10.1)	26.6	-	(4,451.0)
Payment of dividend	-	-	-	-	-	-	-	-	(7,977.4)	-	-	-	-	(7,977.4)
Dividend distribution tax	-	-	-	-	-	-	-	-	(3.4)	-	-	-	-	(3.4)
Recognition of share-based payments to employees	-	-	-	-	(1.0)	-	-	-	-	-	-	-	-	(1.0)
Issue of equity shares	@ 0.0	*(0.0)	-	9.1	-	-	-	-	-	-	-	-	-	9.1
Transfer on exercise of share options	-	-	-	25.4	(25.4)	-	-	-	-	-	-	-	-	-
Balance as at March 31, 2018	2,399.3	-	36,124.4	11,929.1	-	43.8	7.5	34,779.3	112,367.7	60.0	(10.1)	-	-	197,701.0

^ Represents remeasurements of the defined benefit plans

* : ₹ 7,177

@ : ₹ 62,365

The accompanying notes are an integral part of the abridged standalone financial statements

As per our report of even date

For **S R B C & CO LLP**
Chartered Accountants
ICAI Firm Registration No. : 324982E/E300003

per **PAUL ALVARES**

Partner
Membership No. : 105754
Mumbai, May 25, 2018

For and on behalf of the Board of Directors of
Sun Pharmaceutical Industries Limited

DILIP S. SHANGHVI
Managing Director

SUDHIR V. VALIA
Wholtime Director

SAILESH T. DESAI
Wholtime Director
Mumbai, May 25, 2018

C. S. MURALIDHARAN
Chief Financial Officer

SUNIL R. AJMERA
Company Secretary

Abridged Standalone Cash Flow Statement

for the year ended March 31, 2018

₹ in Million

Particulars	Year ended March 31, 2018	Year ended March 31, 2017
Net cash used in operating activities	(11,840.6)	(16,210.0)
Net cash from investing activities	14,044.5	23,813.8
Net cash used in financing activities	(2,721.0)	(7,529.9)
Net increase/ (decrease) in cash and cash equivalents	(517.1)	73.9
Cash and cash equivalents at the beginning of the year	1,475.2	1,409.9
Effect of exchange differences on restatement of foreign currency cash and cash equivalents	19.9	(8.6)
Cash and cash equivalents at the end of the year	978.0	1,475.2

The accompanying notes are an integral part of the abridged standalone financial statements

As per our report of even date

For **S R B C & CO LLP**
Chartered Accountants
ICAI Firm Registration No. : 324982E/E300003

per **PAUL ALVARES**
Partner
Membership No. : 105754
Mumbai, May 25, 2018

C. S. MURALIDHARAN
Chief Financial Officer

SUNIL R. AJMERA
Company Secretary

For and on behalf of the Board of Directors of
Sun Pharmaceutical Industries Limited

DILIP S. SHANGHVI
Managing Director

SUDHIR V. VALIA
Wholetime Director

SAILESH T. DESAI
Wholetime Director
Mumbai, May 25, 2018

Notes to the Abridged Standalone Financial Statements

for the year ended March 31, 2018

1 Complete Standalone Balance Sheet, Standalone Statement of Profit and Loss, Standalone Statement of Changes in Equity, Standalone Cash Flow Statement and other statements and notes thereto of Sun Pharmaceutical Industries Limited ("the Company") are prepared as per requirements of Division II to the Schedule III to the Companies Act, 2013 are available at the Company's website www.sunpharma.com. Copy of financial statement is also available for inspection at the registered office of the Company during working hours for a period of 21 days before the date of AGM.

2 BASIS OF PREPARATION AND PRESENTATION

These abridged standalone financial statements have been prepared on the basis of complete set of the standalone financial statements for the year ended March 31, 2018, in accordance with the proviso to sub-section (1) of section 136 of the Companies Act, 2013 ("the Act") and Rule 10 of the Companies (Accounts) Rules, 2014, as amended.

3 SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies used in preparing the annual standalone financial statements in accordance with the Indian Accounting Standards ("IND AS") prescribed under section 133 of the Act read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Accounting Standards) Amendment Rules, 2016 are set out in Note 2 to the standalone financial statements.

4 CASH AND CASH EQUIVALENTS

(Refer Note 16 of the standalone financial statements)

	₹ in Million	
	As at March 31, 2018	As at March 31, 2017
Balances with banks		
In current accounts	1,091.3	1,522.3
In deposit accounts with original maturity less than 3 months	0.6	-
Cheques on hand	-	4.5
Cash on hand	2.4	6.5
	1,094.3	1,533.3

5 BANK BALANCES OTHER THAN CASH AND CASH EQUIVALENTS

(Refer Note 17 of the standalone financial statements)

	₹ in Million	
	As at March 31, 2018	As at March 31, 2017
Deposit accounts	60.6	38.0
Earmarked balances with banks		
Unpaid Dividend Accounts	73.0	59.3
Balances held as margin money or security against guarantees and other commitments (*)	324.8	72.2
	458.4	169.5

* having original maturity of more than 12 months.

6 REVENUE FROM OPERATIONS

(Refer Note 31 of the standalone financial statements)

	₹ in Million	
	Year ended March 31, 2018	Year ended March 31, 2017
Sale of products	76,963.3	75,096.7
Other operating revenues	2,512.7	2,835.3
	79,476.0	77,932.0

Post implementation of Goods and Service Tax ("GST") with effect from July 01, 2017, sale of products is disclosed net of GST. Sale of products for the previous year included excise duty which is now subsumed in GST. Sale of products for the year ended March 31, 2018 includes excise duty for the period ended June 30, 2017. Accordingly, sale of products for the year ended March 31, 2018 are not comparable with year ended March 31, 2017.

Notes to the Abridged Standalone Financial Statements

for the year ended March 31, 2018

7 OTHER EXPENSES

(Refer Note 37 of the standalone financial statements)

	₹ in Million	
	Year ended March 31, 2018	Year ended March 31, 2017
Consumption of materials, stores and spare parts	4,704.5	4,293.3
Conversion and other manufacturing charges	1,999.1	2,317.9
Power and fuel	3,761.7	3,492.3
Rent	224.4	232.6
Rates and taxes	1,469.6	1,079.8
Insurance	513.2	420.3
Selling and distribution	3,261.7	4,576.2
Commission on sales	466.9	472.4
Repairs and maintenance	2,214.1	2,120.8
Printing and stationery	225.4	327.3
Travelling and conveyance	1,678.5	1,759.9
Freight outward and handling charges	1,781.0	1,602.2
Communication	278.2	263.9
Provision / write off / (reversal) for doubtful trade receivables / advances	(135.7)	38.5
Professional, legal and consultancy	3,983.0	3,813.1
Impairment in value of investment, net	(562.2)	-
Excise duty on sales	237.6	1,092.4
Donations	30.8	15.8
Loss on sale/write off of property, plant and equipment and intangible assets, net	63.7	112.2
(Decrease) / increase of excise duty on inventories	(235.9)	(49.4)
Net (gain) / loss on foreign currency transactions	(518.1)	(1,746.2)
Payments to auditors (net of input credit, wherever applicable)		
For audit	17.1	24.8
For other services	10.2	11.0
Reimbursement of expenses	1.6	0.4
Provision in respect of losses of a subsidiary	254.3	165.4
Miscellaneous expenses	1,416.5	2,385.7
	27,141.2	28,822.6

- 8 In accordance with Ind AS 108 "Operating Segments", segment information has been given in the abridged consolidated financial statements, and therefore, no separate disclosure on segment information is given in these financial statements.

Notes to the Abridged Standalone Financial Statements

for the year ended March 31, 2018

9 CONTINGENT LIABILITIES AND COMMITMENTS (TO THE EXTENT NOT PROVIDED FOR)

(Refer Note 40 of the standalone financial statements)

	₹ in Million	
	As at March 31, 2018	As at March 31, 2017
i) Contingent liabilities		
Claims against the Company not acknowledged as debts	592.7	355.0
Liabilities disputed - appeals filed with respect to :		
Income tax on account of disallowances / additions	47,107.7	45,998.3
Sales tax on account of rebate / classification	122.5	45.7
Excise duty on account of valuation / cenvat credit	1,055.0	1,102.2
ESIC contribution on account of applicability	130.5	132.8
Drug Price Equalisation Account [DPEA] on account of demand towards unintended benefit, enjoyed by the Company	3,488.2	3,488.2
Demand by JDGFT for import duty with respect to import alleged to be in excess of entitlement as per the advanced license scheme	17.4	16.7
Fine imposed for anti-competitive settlement agreement by European Commission	830.7	715.4
Octroi demand on account of rate difference	171.0	171.0
Other matters - state electricity board, Punjab Land Preservation Act related matters etc.	77.4	67.5
Note : includes, interest till the date of demand, wherever applicable		
Legal Proceedings:		
The Company and/or its subsidiaries are involved in various legal proceedings including product liability, contracts, employment claims, anti-trust and other regulatory matters relating to conduct of its business. Most of these legal proceedings involve various complex issues on account of which, making a reliable estimate of the expected financial effect is not always attainable and involves significant uncertainties. To the extent that the Company concludes that a liability is probable and estimable based on the status of these cases, advice of the counsel, management assessment of the likely damages etc. the Company records a provision in the financial statements. The Company carries product liability insurance / is contractually indemnified by the manufacturer, for an amount it believes is sufficient for its needs. In respect of other claims, the Company believes, these claims do not constitute material litigation matters and with its meritorious defences the ultimate disposition of these matters are not expected to have material adverse effect on its Financial Statements.		
Footnote:		
Future cash outflows in respect of the above matters are determinable only on receipt of judgements / decisions pending at various forums / authorities.		
ii) Commitments		
Estimated amount of contracts remaining to be executed on capital account [net of advances].	3,062.4	4,235.4
Uncalled liability on partly paid investments.	0.5	0.5
For derivatives related commitments refer Note 45 of standalone financial statements.		
For non-cancellable lease related commitments refer Note 49 of standalone financial statements.		
Letters of credit for imports	1,060.5	2,312.0
iii) Guarantees given by the bankers on behalf of the Company	2,434.4	1,962.7

Notes to the Abridged Standalone Financial Statements

for the year ended March 31, 2018

10 RELATED PARTY DISCLOSURES (IND AS 24) AS PER ANNEXURE "A"

- 11** Zenotech Laboratories Limited ("Zenotech"), an associate of the Company, undertook a rights issue of its equity shares in which the Company participated and subscribed to equity shares worth ₹ 855 Million. On account of such participation, Zenotech became a subsidiary of the Company effective July 25, 2017. In compliance with the relevant provisions of IND AS 103, the Company has reversed impairment in the books to the extent of fair value of equity shares determined on the basis of rights issue price amounting to ₹ 725.7 Million.
- 12** The Company is a defendant in respect of a civil antitrust litigation relating to a product Modafinil, in which the plaintiff's have alleged that the Company excluded its generic version of Modafinil from the US market and hence have claimed damages under the Sherman Act of US. This case is pending in the United States District Court for the Eastern District of Pennsylvania. The Company and one of its wholly owned subsidiaries entered into settlements with certain plaintiffs (Apotex Corporation and Retailer Purchasers) in the month of July 2017 and September 2017 whereby the Company agreed to pay an aggregate amount of USD 147 Million (₹ 9,505.0 Million). This amount has been provided for in the financial statements and disclosed as an exceptional item. The Company continues to litigate the case against the other plaintiff's (other than those settled).
- 13** Since the US-FDA import alert at Karkhadi facility in March 2014, the Company remained fully committed to implement all corrective measures to address the observations made by the US-FDA with the help of third party consultant. Substantial progress has been made at the Karkhadi facility in terms of completing all the action items to address the observations made by the US-FDA in its warning letter issued in May 2014. The Company is continuing to work closely and co-operatively with the US-FDA to resolve the matter. The contribution of this facility to Company's revenues is not significant.
- 14** The US-FDA, on January 23, 2014, had prohibited using API manufactured at Toansa facility for manufacture of finished drug products intended for distribution in the U.S. market. Consequentially, the Toansa manufacturing facility was subject to certain provisions of the consent decree of permanent injunction entered in January 2012 by erstwhile Ranbaxy Laboratories Ltd (which was merged with Sun Pharmaceutical Industries Ltd in March 2015). In addition, the Department of Justice of the USA ('US DOJ'), United States Attorney's Office for the District of New Jersey had also issued an administrative subpoena dated March 13, 2014 seeking information primarily related to Toansa manufacturing facility for which a Form 483 containing findings of the US-FDA was issued in January 2014. The Company is continuing to fully co-operate and provide requisite information to the US DOJ.
- 15** In December 2015, the USFDA issued a warning letter to the manufacturing facility at Halol. Post the November 2016 inspection, the USFDA re-inspected Halol facility in February 2018. At the conclusion of the inspection, USFDA issued a Form-483 with three observations. The Company has submitted its response documenting the corrective measures to resolve the Form-483 observations. The Company continues to manufacture and distribute products to the U.S from Halol facility and at the same time is working closely and co-operatively with the USFDA to resolve the matter.
- 16** In September 2013, the USFDA had put the Mohali facility under import alert and was also subjected to certain provisions of the consent decree of permanent injunction entered in January 2012 by erstwhile Ranbaxy Laboratories Ltd (which was merged with Sun Pharmaceutical Industries Ltd in March 2015). In March 2017, the USFDA lifted the import alert and indicated that the facility was in compliance with the requirements of cGMP provisions mentioned in the consent decree. The facility will continue to demonstrate sustainable cGMP compliance for a fixed period of time as required by the consent decree. The Company has started manufacturing and distributing products to the U.S from Mohali facility.

Notes to the Abridged Standalone Financial Statements

for the year ended March 31, 2018

- 17** The board of directors of the Company at its meeting held on May 25, 2018, approved the scheme of arrangement between the Company, Sun Pharma (Netherlands) B.V. and Sun Pharmaceutical Holdings USA Inc. (both being wholly owned subsidiaries of the Company) which inter-alia, envisages spin-off of the specified investment undertaking of the Company. Further, the board of directors of the Company at its meeting held on November 14, 2017, had approved the scheme of arrangement between Company and Sun Pharma Global FZE (wholly owned subsidiary of the Company) which inter-alia, envisages demerger of unbranded generic pharmaceutical undertaking of Sun Pharma Global FZE into the Company. The above schemes shall be effective post receipt of required approvals and accordingly, the above results do not reflect the impact, if any, on account of the schemes.
- 18** The Board of Directors of the Company at their meeting held on November 10, 2016 and the shareholders and unsecured creditors of the Company at their respective meetings held on June 20, 2017 approved the proposed scheme of arrangement u/s 230 to 232 of the Companies Act, 2013 for amalgamation of Sun Pharma Medisales Private Limited, Ranbaxy Drugs Limited, Gufic Pharma Limited and Vidhut Investments Limited into the Company with effect from April 01, 2017, the appointed date. On completion of all the formalities of the merger of the above companies with the Company, the said merger became effective September 8, 2017.

Consequent to the amalgamation prescribed by the Scheme, all the assets and liabilities of transferor companies were transferred to and vested in the Company with effect from April 01, 2017 ("the Appointed Date")

The amalgamation was accounted under the "pooling of interest" method prescribed under Ind AS 103 - Business Combinations, as prescribed by the Scheme.

Accordingly, all the assets, liabilities and other reserves of transferor companies were aggregated with those of the Company at their respective book values from the earliest period presented. As prescribed by the Scheme no consideration was paid as the transferor Companies were wholly owned subsidiaries of the Company. Accordingly, the resultant difference amounting to ₹ 535.6 Million was credited to capital reserve account.

As per our report of even date

For **S R B C & CO LLP**
Chartered Accountants
ICAI Firm Registration No. : 324982E/E300003

per **PAUL ALVARES**
Partner
Membership No. : 105754
Mumbai, May 25, 2018

C. S. MURALIDHARAN
Chief Financial Officer

SUNIL R. AJMERA
Company Secretary

For and on behalf of the Board of Directors of
Sun Pharmaceutical Industries Limited

DILIP S. SHANGHVI
Managing Director

SUDHIR V. VALIA
Wholetime Director

SAILESH T. DESAI
Wholetime Director
Mumbai, May 25, 2018

Notes to the Abridged Standalone Financial Statements

for the year ended March 31, 2018

IND AS - 24 - "RELATED PARTY DISCLOSURES"

ANNEXURE "A"

(I) Names of related parties and description of relationships	
a Subsidiaries	
Green Eco Development Centre Limited	Dusa Pharmaceuticals New York, Inc. (Refer Footnote 4)
Sun Pharmaceutical (Bangladesh) Limited	Sirius Laboratories Inc (Refer Footnote 4)
Sun Pharmaceutical Industries, Inc.	Mutual Pharmaceutical Company Inc.
Sun Farmaceutica Do Brasil Ltda.	Dungan Mutual Associates, LLC
Sun Pharma De Mexico S.A. DE C.V.	URL PharmPro, LLC
SPIL De Mexico S.A. DE C.V.	2 Independence Way LLC
Sun Pharmaceutical Peru S.A.C.	Thallion Pharmaceutical Inc., (Refer Footnote 11)
OOO "Sun Pharmaceutical Industries" Limited	Universal Enterprises Private Limited
Sun Pharma De Venezuela, C.A.	Sun Pharma Switzerland Limited
Sun Pharma Laboratories Limited	Sun Pharma East Africa Limited
Faststone Mercantile Company Private Limited	Pharmalucence, Inc.
Neetnav Real Estate Private Limited	PI Real Estate Ventures, LLC
Realstone Multitrade Private Limited	Sun Pharma ANZ Pty Ltd (formerly known as Ranbaxy Australia Pty Ltd)
Skisen Labs Private Limited	Ranbaxy Farmaceutica Ltda.
Sun Pharma Holdings	Ranbaxy Pharmaceuticals Canada Inc.
Softdeal Trading Company Private Limited	Sun Pharma Egypt Limited LLC (Formerly Known as Ranbaxy Egypt Ltd)
Ranbaxy Pharmacie Generiques SAS	Rexcel Egypt LLC
Ranbaxy Drugs Limited (Refer Footnote 6)	Office Pharmaceutique Industriel Et Hospitalier
Vidyut Investments Limited (Refer Footnote 6)	Basics GmbH
Gufic Pharma Limited (Refer Footnote 6)	Ranbaxy GmbH
Sun Pharma Medisales Private Limited (Formerly known as Solrex Pharmaceuticals Company) (Refer Footnote 5 & 6)	Ranbaxy Ireland Limited
Ranbaxy (Malaysia) Sdn. Bhd.	Ranbaxy Italia S.P.A.
Ranbaxy Nigeria Limited	Sun Pharmaceutical Industries S.A.C. (formerly known as Ranbaxy - PRP (Peru) S.A.C.)
Sun Pharma (Netherlands) B.V. (Formerly known as Ranbaxy (Netherlands) B.V.)	Ranbaxy (Poland) Sp. Z o.o.
Foundation for Disease Elimination and Control of India (Refer Footnote 2)	Terapia SA
Zenotech Laboratories Limited (Refer Footnote 7)	AO Ranbaxy (formerly known as ZAO Ranbaxy)
Chattem Chemicals Inc.	Ranbaxy South Africa (Pty) Ltd.
The Taro Development Corporation	Ranbaxy Pharmaceutical (Pty) Ltd.
Alkaloida Chemical Company Zrt.	Be-Tabs Investments (Pty) Ltd.
Sun Pharmaceuticals UK Limited	Sonke Pharmaceuticals Proprietary Limited
Sun Pharmaceutical Industries (Australia) Pty Limited	Laboratorios Ranbaxy, S.L.U.
Aditya Acquisition Company Ltd.	Ranbaxy (U.K.) Limited
Sun Pharmaceutical Industries (Europe) B.V.	Ranbaxy Holdings (U.K.) Limited
Sun Pharmaceuticals Italia S.R.L.	Ranbaxy Europe Limited (Refer Footnote 12)
Sun Pharmaceuticals Spain, S.L.U. (Refer Footnote 4)	Ranbaxy Inc.
Sun Pharmaceuticals Germany GmbH	Ranbaxy Pharmaceuticals, Inc. (Refer Footnote 13)
Sun Pharmaceuticals France	Ranbaxy (Thailand) Company Limited
Sun Pharma Global FZE	Ohm Laboratories, Inc.
Sun Pharmaceuticals (SA) (Pty) Ltd.	Ranbaxy Laboratories, Inc. (Refer Footnote 13)
Sun Global Canada Pty. Ltd.	Ranbaxy Signature LLC
Sun Pharma Philippines, Inc.	Sun Pharmaceuticals Morocco LLC (formerly known as Ranbaxy Morocco LLC)
Sun Pharmaceuticals Korea Ltd.	"Ranbaxy Pharmaceuticals Ukraine" LLC
Sun Global Development FZE	Perryton Wind Power LLC (Refer Footnote 4)
Caraco Pharmaceuticals Private Limited	Insite Vision Incorporated
Sun Pharma Japan Ltd.	Insite Vision Ltd. (Refer Footnote 3)
Sun Pharma Healthcare FZE	Sun Pharmaceutical Medicare Limited (Refer Footnote 2)

Notes to the Abridged Standalone Financial Statements

for the year ended March 31, 2018

IND AS - 24 – “RELATED PARTY DISCLOSURES”

ANNEXURE “A”

(i) Names of related parties and description of relationships	
Morley & Company, Inc.	Ocular Technologies SARL (Refer Footnote 14)
Sun Laboratories FZE	JSC Biosintez (Refer Footnote 2)
Taro Pharmaceutical Industries Ltd. (TARO) (Refer Footnote 8)	Sun Pharmaceuticals Holdings USA, INC (Refer Footnote 2)
Taro Pharmaceuticals Inc.	Zenotech Laboratories Nigeria Limited
Taro Pharmaceuticals U.S.A., Inc.	Zenotech Inc
Taro Pharmaceuticals North America, Inc.	Zenotech Farmaceutica Do Brasil Ltda
Taro Pharmaceuticals Europe B.V.	
Taro Pharmaceuticals Ireland Limited (Refer Footnote 9)	
Taro International Ltd.	
Taro Pharmaceuticals (UK) Limited (Refer Footnote 10)	
Taro Hungary Intellectual Property Licensing Limited Liability Company (Refer Footnote 4)	
3 Skyline LLC	
One Commerce Drive LLC	
Taro Pharmaceutical Laboratories Inc	
Taro Pharmaceuticals Canada, Ltd.	
Taro Pharmaceutical India Private Limited (Refer Footnote 3)	
Alkaloida Sweden AB	
Dusa Pharmaceuticals, Inc.	

Names of related parties where there are transactions and description of relationships

b Joint Ventures	
S & I Ophthalmic LLC (Refer Footnote 3)	
Artes Biotechnology GmbH	
c Associate	
Zenotech Laboratories Limited (Refer Footnote 7)	
Daiichi Sankyo (Thailand) Ltd. (Refer Footnote 15)	
Medinstill Development LLC	
d Key Managerial Personnel (KMP)	
Dilip S. Shanghvi	Managing Director
Sudhir V. Valia	Executive Director
Sailesh T. Desai	Executive Director
Israel Makov	Chairman and Non-Executive Director
Kalyansundaram Subramanian (w.e.f. February 14, 2017)	Executive Director
e Non-Executive Directors	
S. Mohanchand Dadha	
Hasmukh S. Shah (resigned w.e.f. November 15, 2017)	
Keki M. Mistry	
Ashwin S. Dani	
Rekha Sethi	
Vivek C. Sehgal (w.e.f. November 14, 2017)	
f Relatives of Key Managerial Personnel	
Aalok Shanghvi	
Vidhi Shanghvi	
g Others (Entities in which the KMP and relatives of KMP have control or significant influence)	
Makov Associates Limited	
Sun Pharma Advanced Research Company Limited.	
Sun Petrochemicals Private Limited	
Ramdev Chemicals Private Limited	
Sidmak Laboratories (India) Private Limited	
Aditya Medisales Limited	
United Medisales Private Limited	

Notes to the Abridged Standalone Financial Statements

for the year ended March 31, 2018

IND AS - 24 – “RELATED PARTY DISCLOSURES”

ANNEXURE “A”

Footnote
1 Incorporated / Acquired during year
2 Incorporated / Acquired during the previous year
3 Dissolved / Liquidated during the year
4 Dissolved / Liquidated during the previous year
5 During the previous year Solrex Pharmaceuticals Company, a partnership firm has been converted into private limited company which is known as Sun Pharma Medisales Private Limited.
6 Pursuant to scheme of arrangement u/s 230 to 232 of Companies Act 2013, for amalgamation of Sun Pharma Medisales Private Limited, Ranbaxy Drugs Limited, Gufic Pharma Limited and Vidyut Investments Limited into the company with effect from April 01, 2017 (Refer Note 18).
7 Zenotech Laboratories Limited has ceased to be an associate and has become subsidiary of Sun Pharmaceutical Industries Limited with effect from July 27, 2017 (Refer Note 11).
8 Holds voting power of 83.21% (beneficial ownership 74.82%) [March 31, 2017: 81.87% (beneficial ownership 72.81%)]
9 Taro Pharmaceuticals Ireland Limited is under Liquidation.
10 Taro Pharmaceuticals (UK) Limited is under Liquidation.
11 Thallion Pharmaceutical Inc., was acquired and merged with Taro Pharmaceuticals Inc. during the previous year.
12 Ranbaxy Europe Limited is under Liquidation.
13 Merged with Sun Pharmaceutical Industries Inc.
14 Merged with Sun Pharma Switzerland Limited.
15 Daiichi Sankyo (Thailand) Ltd.'s shares were sold during the previous year

(II) Detail of related party transaction during the year ended March 31, 2018:

Type of Transaction	₹ in Million	
	Year ended March 31, 2018	Year ended March 31, 2017
Purchase of goods	2,035.4	1,432.8
Subsidiaries	1,885.9	1,404.6
Associates	-	12.9
Others	149.5	15.3
Purchase of property, plant and equipment	681.7	283.8
Subsidiaries	43.2	283.8
Others	638.5	-
Sale of goods	58,994.8	26,126.3
Subsidiaries	29,220.4	26,070.2
Associates	-	38.8
Others	29,774.4	17.3
Sale of property, plant and equipment	22.0	17.9
Subsidiaries	21.5	17.9
Others	0.5	-
Receiving of service	872.6	1,373.9
Subsidiaries	559.6	1,060.7
Joint Ventures	40.9	-
Others	272.1	313.2
Reimbursement of expenses paid	10,758.3	1,160.2
Subsidiaries	10,693.4	1,142.4
Associates	5.7	2.8
Others	59.2	15.0
Rendering of service	964.1	860.3
Subsidiaries	785.8	712.5
Joint Ventures	0.1	11.6
Others	178.2	136.2

Notes to the Abridged Standalone Financial Statements

for the year ended March 31, 2018

IND AS - 24 – “RELATED PARTY DISCLOSURES”

ANNEXURE “A”

Type of Transaction	₹ in Million	
	Year ended March 31, 2018	Year ended March 31, 2017
Reimbursement of expenses received	152.6	203.8
Subsidiaries	110.5	162.3
Others	42.1	41.5
Purchase of Investment	855.0	7.7
Subsidiaries	855.0	7.7
Loans / Deposit given	-	0.4
Subsidiaries	-	0.4
Loans received back	512.0	4.8
Subsidiaries	512.0	4.8
Interest on loans received back	183.3	-
Subsidiaries	183.3	-
Advance given	2.5	-
Subsidiaries	2.5	-
Advance received back	2.5	-
Subsidiaries	2.5	-
Sales of investment	12,384.5	32,318.4
Subsidiaries	12,384.5	32,318.4
Loan taken	28,122.1	9,200.0
Subsidiaries	28,122.1	9,200.0
Loan repaid	22,655.1	17,219.9
Subsidiaries	22,655.1	17,219.9
Dividend income on preference shares	80.0	40.0
Subsidiaries	80.0	40.0
Dividend income on equity shares	8,074.8	2,000.7
Subsidiaries	8,074.8	2,000.7
Interest income	257.7	70.4
Subsidiaries (March 31, 2017 ₹ 24,066)	5.0	0.0
Associates	19.1	70.4
Others	233.6	-
Interest expense	647.4	116.4
Subsidiaries	647.4	116.4
Rent income	26.6	23.5
Subsidiaries	17.6	19.3
Others	9.0	4.2
Rent expense	1.0	0.7
Subsidiaries	1.0	0.7
Provision for doubtful loans and interest accrued and due on loans	-	63.4
Associates	-	63.4
Provision in respect of losses of a subsidiary	254.3	165.4
Subsidiaries	254.3	165.4
Provision for diminution in the value of Investment (net)	(562.2)	-
Subsidiaries	(562.2)	-
Provision for doubtful debt	27.8	-
Subsidiaries	27.8	-
Remuneration	(2.9)	90.6
Key managerial personnel (*)	(23.0)	77.3
Relatives of key managerial personnel	20.1	13.3

(*) Remuneration to Key Managerial Personnel includes the refund received from Key Managerial Personnel in respect of excess remuneration paid for financial year 2014-15, 2015-16 & 2016-17.

Notes to the Abridged Standalone Financial Statements

for the year ended March 31, 2018

IND AS - 24 – “RELATED PARTY DISCLOSURES”

ANNEXURE “A”

(III) Balance Outstanding as at the end of the year

	₹ in Million	
	As at March 31, 2018	As at March 31, 2017
Receivables	23,901.0	15,518.0
Subsidiaries	20,406.9	15,051.5
Others	3,494.1	466.5
Payable	5,299.6	4,764.5
Subsidiaries	4,751.8	4,176.2
Associates	-	137.7
Key managerial personnel	2.7	4.2
Relatives of key managerial personnel	0.8	0.6
Others	544.3	445.8
Loan taken	6,049.7	-
Subsidiaries	6,049.7	-
Loan given	53.3	-
Subsidiaries*	53.3	-
Deposit given	62.5	62.5
Subsidiaries	62.5	62.5
Other liabilities	14,892.1	14,298.5
Subsidiaries	14,892.1	14,298.5
Advance from customers	34.3	83.5
Subsidiaries	30.9	83.5
Others	3.4	-
Advance from supply of goods/services	0.1	-
Others	0.1	-
Capital advance	212.9	212.9
Associates	212.9	212.9

* Net of Provision for doubtful loans and interest accrued and due thereon of March 31, 2017 : ₹ 726.9 Million

Key Managerial Personnel who are under the employment of the Company are entitled to post employment benefits and other long term employee benefits recognised as per Ind AS 19 - 'Employee Benefits' in the financial statements. As these employee benefits are lump sum amounts provided on the basis of actuarial valuation, the same is not included above and there is no Share-based payments to key managerial personnel of the Company.

Independent Auditor's Report

To the Members of Sun Pharmaceutical Industries Limited

Report on the Abridged Consolidated Ind AS Financial Statements

The accompanying Abridged Consolidated Ind AS Financial Statements, which comprise the Abridged Balance Sheet as at March 31, 2018, the Abridged Statement of Profit and Loss (including Other Comprehensive Income), Abridged Cash Flow Statement and the Abridged Statement of Changes in Equity for the year then ended, and related notes, are derived from the audited Consolidated Ind AS Financial Statements of Sun Pharmaceutical Industries Limited ('the Company'), its subsidiaries (the Company and its subsidiaries together referred to as 'the Group'), its associates and joint ventures, as at and for the year ended March 31, 2018. We expressed an unmodified audit opinion on those financial statements in our report dated May 25, 2018.

The Abridged Consolidated Ind AS Financial Statements do not contain all the disclosures required by the accounting principles generally accepted in India, including the Indian Accounting Standards specified under Section 133 of the Companies Act, 2013 ("the Act") read with the Companies (Indian Accounting Standards) Rules, 2015. Reading the Abridged Consolidated Ind AS Financial Statements, therefore, is not a substitute for reading the audited Consolidated Ind AS Financial Statements of the Group.

Management's Responsibility for the Abridged Consolidated Ind AS Financial Statements

The Company's Board of Directors is responsible for the preparation of Abridged Consolidated Ind AS Financial Statements in accordance with Section 136(1) read with Rule 10 of the Companies (Accounts) Rule, 2014, as amended and are based on audited Consolidated Ind AS Financial Statements as at and for the year ended March 31, 2018, prepared in accordance with Indian Accounting Standards specified under Section 133 of the Act, read with the Companies (Indian Accounting Standard) Rules, 2015, as amended. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the Abridged Consolidated Ind AS Financial Statements.

Auditor's Responsibility

Our responsibility is to express an opinion on the Abridged Consolidated Ind AS Financial Statements based on our procedures, which were conducted in accordance with Standard on Auditing (SA) 810, "Engagements to Report on Summary Financial Statements" issued by the Institute of Chartered Accountants of India. In performing those procedures, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Abridged Consolidated Ind AS Financial Statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

Opinion

In our opinion and to the best of our information and explanations given to us, the accompanying Abridged Consolidated Ind AS Financial Statements, prepared in accordance with Section 136(1) read with Rule 10 of the Companies (Accounts) Rules, 2014, as amended are derived from the audited Consolidated Ind AS Financial Statements of the Group as at and for the year ended March 31, 2018, prepared in accordance with the Indian Accounting Standards specified under Section 133 of the Act, read with the Companies (Indian Accounting Standard) Rules, 2015, as amended and are a fair summary of those Consolidated Ind AS Financial Statements.

Other Matter

- (a) We did not audit the financial statements and other financial information, in respect of 24 subsidiaries, whose Ind AS Financial Statements, without giving effect to elimination of intra group transactions, include total assets of ₹ 566,133.5 Million and net assets of ₹ 418,322.5 Million as at March 31, 2018, and total revenues of ₹ 185,173.2 Million and net cash outflows of ₹ 6,056.8 Million for the year ended on that date. These financial statement and other financial information have been audited by other auditors, which financial statements, other financial information and auditor's reports have been furnished to us by the management. The Consolidated Ind AS Financial Statements also include the Group's share of net loss of ₹ 254.4 Million for the year ended March 31, 2018, as considered in the Consolidated Financial Statements, in respect of 8 associates and joint ventures, whose financial statements, other financial information have been audited by other auditors and whose reports have been furnished to us by the Management. Our opinion on the Consolidated Ind AS Financial Statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, and our report in terms of sub-sections (3) of Section 143 of the Act, in so far as it relates to the aforesaid subsidiaries, joint ventures and associates, is based solely on the reports of such other auditors.

Certain of these subsidiaries are located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's management has converted the financial statements of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Company's

Independent Auditor's Report

To the Members of Sun Pharmaceutical Industries Limited

management. Our opinion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Company and audited by us.

- (b) The accompanying Abridged Consolidated Ind AS Financial Statements include unaudited financial statements and other unaudited financial information in respect of 39 subsidiaries, whose financial statements and other financial information, without giving effect to elimination of intra group transactions, reflect total assets of ₹ 217,210.8 Million and net assets of ₹ 208,537.0 Million as at March 31, 2018, and total revenues of ₹ 6,131.0 Million and net cash outflows of ₹ 496.9 Million for the year ended on that date. These unaudited financial statements and other unaudited financial information have been furnished to us by the management. Our opinion, in so far as it relates amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, and our report in terms of sub-sections (3) of Section 143 of the Act in so far as it relates to the aforesaid subsidiaries, joint ventures and associates, is based solely on such unaudited financial statement and other unaudited financial information. In our opinion and according to the information and explanations given to us by the Management, these financial statements and other financial information are not material to the Group.
- (c) The Consolidated Ind AS Financial Statements of the Company for the year ended March 31, 2017, included in the Consolidated Ind AS Financial Statements, have been audited by the predecessor auditor who expressed an unmodified opinion on those statements on May 26, 2017.

Our opinion above on the Consolidated Ind AS Financial Statements, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial statements and other financial information certified by the Management.

For **S R B C & CO LLP**
Chartered Accountants
ICAI Firm Registration No.: 324982E/E300003

per **PAUL ALVARES**
Partner
Membership No.: 105754

Place: Mumbai
Date: May 25, 2018

Independent Auditor's Report

To the Members of Sun Pharmaceutical Industries Limited

Report on the Consolidated Ind AS Financial Statements

We have audited the accompanying consolidated Ind AS financial statements of Sun Pharmaceutical Industries Limited (hereinafter referred to as "the Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") its associates and joint ventures, comprising of the consolidated Balance Sheet as at March 31, 2018, the consolidated Statement of Profit and Loss including other comprehensive income, the consolidated Cash Flow Statement, the consolidated Statement of Changes in Equity for the year then ended, and a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the consolidated Ind AS financial statements").

Management's Responsibility for the Consolidated Ind AS Financial Statements

The Holding Company's Board of Directors is responsible for the preparation of these consolidated Ind AS financial statements in terms of the requirement of the Companies Act, 2013 ("the Act") that give a true and fair view of the consolidated financial position, consolidated financial performance including other comprehensive income, consolidated cash flows and consolidated statement of changes in equity of the Group including its Associates and Joint Ventures in accordance with accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act, read with the Companies (Indian Accounting Standard) Rules, 2015, as amended. The respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and of its associates and joint ventures and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated Ind AS financial statements by the Directors of the Holding Company, as aforesaid.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated Ind AS financial statements based on our audit. While conducting the audit, we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder. We conducted our audit in accordance with the Standards on Auditing, issued by the Institute of Chartered Accountants of India, as specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Holding Company's preparation of the consolidated Ind AS financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Holding Company's Board of Directors, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in sub-paragraph (a) of the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the consolidated Ind AS financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate financial statements and on the other financial information of the subsidiaries, associates and joint ventures, the aforesaid consolidated Ind AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the consolidated state of affairs of the Group, its associates and joint ventures as at March 31, 2018, their consolidated profit including other comprehensive income, their consolidated cash flows and consolidated statement of changes in equity for the year ended on that date.

Other Matter

- (a) We did not audit the financial statements and other financial information, in respect of 24 subsidiaries, whose Ind AS financial statements, without giving effect to elimination of intra group transactions, include total assets of ₹ 566,133.5 Million and net assets of ₹ 418,322.5 Million as at March 31, 2018, and total revenues of ₹ 185,173.2 Million and net cash outflows of ₹ 6,056.8 Million for the year ended on that date. These financial statement and other financial information have been audited by other auditors, which financial

Independent Auditor's Report

To the Members of Sun Pharmaceutical Industries Limited

statements, other financial information and auditor's reports have been furnished to us by the management. The consolidated Ind AS financial statements also include the Group's share of net loss of ₹ 254.4 Million for the year ended March 31, 2018, as considered in the consolidated financial statements, in respect of 8 associates and joint ventures, whose financial statements, other financial information have been audited by other auditors and whose reports have been furnished to us by the Management. Our opinion on the consolidated Ind AS financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, and our report in terms of sub-sections (3) of Section 143 of the Act, in so far as it relates to the aforesaid subsidiaries, joint ventures and associates, is based solely on the reports of such other auditors.

Certain of these subsidiaries are located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's management has converted the financial statements of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Company's management. Our opinion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Company and audited by us.

- (b) The accompanying consolidated Ind AS financial statements include unaudited financial statements and other unaudited financial information in respect of 39 subsidiaries, whose financial statements and other financial information, without giving effect to elimination of intra group transactions, reflect total assets of ₹ 217,210.8 Million and net assets of ₹ 208,537.0 Million as at March 31, 2018, and total revenues of ₹ 6,131.0 Million and net cash outflows of ₹ 496.9 Million for the year ended on that date. These unaudited financial statements and other unaudited financial information have been furnished to us by the management. Our opinion, in so far as it relates amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, and our report in terms of sub-sections (3) of Section 143 of the Act in so far as it relates to the aforesaid subsidiaries, joint ventures and associates, is based solely on such unaudited financial statement and other unaudited financial information. In our opinion and according to the information and explanations given to us by the Management, these financial statements and other financial information are not material to the Group.
- (c) The consolidated Ind AS financial statements of the Company for the year ended March 31, 2017, included in these consolidated Ind AS financial statements, have been audited by the predecessor auditor who expressed an unmodified opinion on those statements on May 26, 2017.

Our opinion above on the consolidated Ind AS financial statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the financial statements and other financial information certified by the Management.

Report on Other Legal and Regulatory Requirements

As required by section 143 (3) of the Act, based on our audit and on the consideration of report of the other auditors on separate financial statements and the other financial information of subsidiaries, associates and joint ventures, as noted in the 'other matter' paragraph we report, to the extent applicable, that:

- (a) We / the other auditors whose reports we have relied upon have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the aforesaid consolidated Ind AS financial statements;
- (b) In our opinion proper books of account as required by law relating to preparation of the aforesaid consolidation of the financial statements have been kept so far as it appears from our examination of those books and reports of the other auditors;
- (c) The consolidated Balance Sheet, consolidated Statement of Profit and Loss including the Statement of Other Comprehensive Income, the consolidated Cash Flow Statement and consolidated Statement of Changes in Equity dealt with by this Report are in agreement with the books of account maintained for the purpose of preparation of the consolidated Ind AS financial statements;
- (d) In our opinion, the aforesaid consolidated Ind AS financial statements comply with the Indian Accounting Standards specified under section 133 of the Act, read with Companies (Indian Accounting Standard) Rules, 2015, as amended;

Independent Auditor's Report

To the Members of Sun Pharmaceutical Industries Limited

- (e) On the basis of the written representations received from the directors of the Holding Company as on March 31, 2018 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors who are appointed under Section 139 of the Act, of its subsidiary companies, associate companies and joint ventures incorporated in India, none of the directors of the Group's companies, its associates and joint ventures incorporated in India is disqualified as on March 31, 2018 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy and the operating effectiveness of the internal financial controls over financial reporting with reference to these consolidated Ind AS financial statements of the Holding Company and its subsidiary companies, refer to our separate report in "Annexure 1" to this report;
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the report of the other auditors on separate financial statements as also the other financial information of the subsidiaries, associates, joint ventures, as noted in the 'Other matter' paragraph:
- i. The consolidated Ind AS financial statements disclose the impact of pending litigations on its consolidated financial position of the Group, its associates and joint ventures – Refer Note 40 to the consolidated Ind AS financial statements;
 - ii. Provision has been made in the consolidated Ind AS financial statements, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts – Refer (a) Note 23 and Note 29 to the consolidated Ind AS financial statements in respect of such items as it relates to the Group, its associates and joint ventures and (b) the Group's share of net profit/loss in respect of its associates;
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Holding Company, its subsidiaries, associates and joint ventures incorporated in India, except a sum of ₹ 16.9 Million, which is held in abeyance due to pending legal cases.

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration No.: 324982E/E300003

per **PAUL ALVARES**

Partner

Membership No.: 105754

Place: Mumbai

Date: May 25, 2018

ANNEXURE 1 TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF SUN PHARMACEUTICAL INDUSTRIES LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

In conjunction with our audit of the consolidated financial statements of Sun Pharmaceutical Industries Limited as of and for the year ended March 31, 2018, we have audited the internal financial controls over financial reporting of Sun Pharmaceutical Industries Limited (hereinafter referred to as the "Holding Company") and its subsidiary companies, which are companies incorporated in India, as of that date.

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding Company, its subsidiary companies, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the company's internal financial controls over financial reporting with reference to these consolidated financial statements based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, both, issued by Institute of Chartered Accountants of India, and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting with reference to these consolidated financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls over financial reporting with reference to these consolidated financial statements and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting with reference to these consolidated financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors in terms of their reports referred to in the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls over financial reporting with reference to these consolidated financial statements.

Meaning of Internal Financial Controls Over Financial Reporting With Reference to these Consolidated Financial Statements

A company's internal financial control over financial reporting with reference to these consolidated financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting with reference to these consolidated financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

ANNEXURE 1 TO THE INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE CONSOLIDATED FINANCIAL STATEMENTS OF SUN PHARMACEUTICAL INDUSTRIES LIMITED

Inherent Limitations of Internal Financial Controls Over Financial Reporting With Reference to these Consolidated Financial Statements

Because of the inherent limitations of internal financial controls over financial reporting with reference to these consolidated financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting with reference to these consolidated financial statements to future periods are subject to the risk that the internal financial control over financial reporting with reference to these consolidated financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Holding Company and its subsidiary companies, which are companies incorporated in India, have, maintained in all material respects, adequate internal financial controls over financial reporting with reference to these consolidated financial statements and such internal financial controls over financial reporting with reference to these consolidated financial statements were operating effectively as at March 31, 2018, based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Other Matters

Our report under Section 143(3)(i) of the Act on the adequacy and operating effectiveness of the internal financial controls over financial reporting with reference to these consolidated financial statements of the Holding Company, insofar as it relates to these 3 subsidiary companies, which are companies incorporated in India, is based on the corresponding reports of the auditors of such subsidiary, incorporated in India.

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration No.: 324982E/E300003

per **PAUL ALVARES**

Partner

Membership No.: 105754

Place: Mumbai

Date: May 25, 2018

Abridged Consolidated Balance Sheet

as at March 31, 2018

Particulars	₹ in Million	
	As at March 31, 2018	As at March 31, 2017
ASSETS		
(1) Non-current assets		
(a) Property, plant and equipment	91,590.3	84,952.9
(b) Capital work-in-progress	14,344.7	15,647.6
(c) Goodwill (Net)	56,067.1	55,362.2
(d) Other intangible assets	40,869.1	36,436.6
(e) Intangible assets under development	10,306.9	12,366.2
(f) Investments in associates	2,748.6	4,605.4
(g) Investments in joint ventures	252.8	429.5
(h) Financial assets		
(i) Investments	27,521.1	4,575.1
(ii) Loans	22,424.7	698.1
(iii) Other financial assets	1,049.2	6,452.2
(i) Deferred tax assets (Net)	21,937.8	24,928.2
(j) Income tax assets (Net)	31,896.6	31,250.1
(k) Other non-current assets	5,660.1	6,861.8
Total non-current assets	326,669.0	284,565.9
(2) Current assets		
(a) Inventories	68,806.9	68,328.1
(b) Financial assets		
(i) Investments	40,906.2	2,308.8
(ii) Trade receivables	78,152.8	72,026.1
(iii) Cash and cash equivalents	79,253.7	86,628.0
(iv) Bank balances other than (iii) above	20,040.1	64,780.4
(v) Loans	914.3	10,190.8
(vi) Other financial assets	4,795.5	2,258.5
(c) Other current assets	23,489.5	22,949.9
	316,359.0	329,470.6
Assets classified as held for sale	-	65.9
Total current assets	316,359.0	329,536.5
TOTAL ASSETS	643,028.0	614,102.4

Abridged Consolidated Balance Sheet

as at March 31, 2018

Particulars	₹ in Million	
	As at March 31, 2018	As at March 31, 2017
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	2,399.3	2,399.3
(b) Other equity	378,606.3	363,997.4
Equity attributable to the equity shareholders of the Company	381,005.6	366,396.7
Non-controlling interests	38,841.6	37,908.6
Total equity	419,847.2	404,305.3
Liabilities		
(1) Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	17,720.9	14,360.8
(ii) Other financial liabilities	316.5	1,048.0
(b) Provisions	4,044.6	12,111.1
(c) Deferred tax liabilities (Net)	2,189.6	3,147.9
(d) Other non-current liabilities	266.0	259.1
Total non-current liabilities	24,537.6	30,926.9
(2) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	79,797.0	66,549.2
(ii) Trade payables	47,662.0	43,953.9
(iii) Other financial liabilities	13,377.2	22,116.3
(b) Other current liabilities	5,382.1	4,620.5
(c) Provisions	51,096.6	40,159.1
(d) Current tax liabilities (Net)	1,328.3	1,471.2
Total current liabilities	198,643.2	178,870.2
Total liabilities	223,180.8	209,797.1
TOTAL EQUITY AND LIABILITIES	643,028.0	614,102.4

The accompanying notes are an integral part of the abridged consolidated financial statements

As per our report of even date

For **S R B C & CO LLP**
Chartered Accountants
ICAI Firm Registration No. : 324982E/E300003

per **PAUL ALVARES**
Partner
Membership No. : 105754
Mumbai, May 25, 2018

C. S. MURALIDHARAN
Chief Financial Officer

SUNIL R. AJMERA
Company Secretary

For and on behalf of the Board of Directors of
Sun Pharmaceutical Industries Limited

DILIP S. SHANGHVI
Managing Director

SUDHIR V. VALIA
Wholetime Director

SAILESH T. DESAI
Wholetime Director
Mumbai, May 25, 2018

Abridged Consolidated Statement of Profit and Loss

for the year ended March 31, 2018

Particulars	₹ in Million	
	Year ended March 31, 2018	Year ended March 31, 2017
(I) Revenue from operations	264,894.6	315,784.4
(II) Other income	8,387.6	6,231.5
(III) Total income (I+II)	273,282.2	322,015.9
(IV) Expenses		
Cost of materials consumed	44,626.0	51,246.1
Purchases of stock-in-trade	27,313.8	32,777.6
Changes in inventories of finished goods, stock-in-trade and work-in-progress	2,307.0	(2,716.3)
Employee benefits expense	53,670.5	49,023.0
Finance costs	5,175.7	3,998.0
Depreciation and amortisation expense	14,998.4	12,647.5
Other expenses	80,896.0	84,561.3
Total expenses (IV)	228,987.4	231,537.2
(V) Profit before exceptional items and tax (III-IV)	44,294.8	90,478.7
(VI) Exceptional item (Refer note 11)	(9,505.0)	-
(VII) Profit before tax (V+VI)	34,789.8	90,478.7
(VIII) Tax expense		
Current tax	6,628.0	4,046.4
Deferred tax		
a) Deferred tax charge/(credit)	(720.6)	8,069.3
b) Deferred tax charge/(credit) - exceptional (Refer note 13)	2,544.5	-
Total tax expense (VIII)	8,451.9	12,115.7
(IX) Profit for the year before share of profit/(loss) of associates and joint ventures (VII-VIII)	26,337.9	78,363.0
(X) Share of profit/(loss) of associates (net of tax)	(246.6)	299.6
(XI) Share of profit/(loss) of joint ventures (net of tax)	(7.8)	(200.3)
(XII) Profit for the year before non-controlling interests (IX+X+XI)	26,083.5	78,462.3
(XIII) Non-controlling interests	4,468.0	8,818.6
(XIV) Profit for the year attributable to owners of the Company	21,615.5	69,643.7
(XV) Other comprehensive income		
(A) Items that will not be reclassified to profit or loss		
(a) Re-measurements of the defined benefit plans	782.7	(766.9)
Income tax on above	(274.8)	56.6
	507.9	(710.3)
(b) Equity instruments through other comprehensive income	1,288.3	(3,741.4)
Income tax on above	(23.2)	-
	1,265.1	(3,741.4)
Total (A)	1,773.0	(4,451.7)
(B) Items that may be reclassified to profit or loss		
(a) Debt instruments through other comprehensive income	(98.3)	(4.7)
Income tax on above	8.7	-
	(89.6)	(4.7)
(b) Effective portion of gains and loss on designated portion of hedging instruments in a cash flow hedge	(75.7)	46.2
(c) Exchange differences in translating the financial statements of foreign operations	4,025.7	(10,461.7)
(d) Exchange differences on translation of net investment in a foreign operations	(400.9)	-
Total (B)	3,459.5	(10,420.2)
(XV) Total other comprehensive income (A + B)	5,232.5	(14,871.9)
(XVI) Total comprehensive income for the year (XII+XV)	31,316.0	63,590.4

Abridged Consolidated Statement of Profit and Loss

for the year ended March 31, 2018

Particulars	₹ in Million	
	Year ended March 31, 2018	Year ended March 31, 2017
Other comprehensive income for the year attributable to:		
- Owners of the Company	4,754.8	(13,337.6)
- Non-controlling interests	477.7	(1,534.3)
Total comprehensive income for the year attributable to:		
- Owners of the Company	26,370.3	56,306.1
- Non-controlling interests	4,945.7	7,284.3
Earnings per equity share (face value per equity share - ₹ 1)		
Basic (in ₹)	9.0	29.0
Diluted (in ₹)	9.0	29.0

The accompanying notes are an integral part of the abridged consolidated financial statements

As per our report of even date

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration No. : 324982E/E300003

per **PAUL ALVARES**

Partner

Membership No. : 105754

Mumbai, May 25, 2018

C. S. MURALIDHARAN

Chief Financial Officer

SUNIL R. AJMERA

Company Secretary

For and on behalf of the Board of Directors of

Sun Pharmaceutical Industries Limited

DILIP S. SHANGHVI

Managing Director

SUDHIR V. VALIA

Wholetime Director

SAILESH T. DESAI

Wholetime Director

Mumbai, May 25, 2018

Abridged Consolidated Statement of Changes in Equity

for the year ended March 31, 2018

Particulars	Equity share capital	Share application money pending allotment	Capital reserve	Securities premium reserve	Debt redemption reserve	Share option outstanding account	Reserves and surplus	Capital redemption reserve	Legal reserve	General reserve	Retained earnings	Other comprehensive income (OCI)	Debt instrument through OCI	Equity instrument through OCI	Foreign currency translation reserve	Effective portion of cash flow hedges	Attributable to owners of Parent Company	Non-controlling interests	TOTAL
Balance as at March 31, 2016	2,406.6	6.7	456.9	18,585.2	1,041.7	48.9	43.8	-	1.1	35,578.0	251,630.4	1.3	4,081.1	15,943.1	-	-	329,824.8	40,852.5	370,677.3
Profit for the year	-	-	-	-	-	-	-	-	-	-	69,643.7	-	-	-	-	-	69,643.7	8,818.6	78,462.3
Exchange difference arising on translation of foreign operations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(8,927.4)	-	(8,927.4)	(1,534.3)	(10,461.7)
Other comprehensive income for the year, net of income tax	-	-	-	-	-	-	-	-	-	-	*(710.3)	(4.7)	(3,741.4)	-	-	46.2	(4,410.2)	-	(4,410.2)
Total comprehensive income for the year	-	-	-	-	-	-	-	-	-	-	68,933.4	(4.7)	(3,741.4)	(8,927.4)	46.2	-	56,306.1	7,284.3	63,590.4
Payment of dividend	-	-	-	-	-	-	-	-	-	-	(2,406.8)	-	-	-	-	-	(2,406.8)	(30.4)	(2,437.2)
Dividend distribution tax	-	-	-	-	-	-	-	-	-	-	(490.0)	-	-	-	-	-	(490.0)	-	(490.0)
Recognition of share-based payments to employees	-	-	-	-	-	32.3	-	-	-	-	-	-	-	-	-	-	32.3	-	32.3
Issue of equity shares	0.2	(6.7)	-	31.3	-	-	-	-	-	-	-	-	-	-	-	-	24.8	-	24.8
Buy-back of equity shares	(7.5)	-	-	(6,742.5)	-	-	-	-	-	-	-	-	-	-	-	-	(6,750.0)	-	(6,750.0)
Expenditure on buy-back of equity shares	-	-	-	(34.2)	-	-	-	-	-	-	-	-	-	-	-	-	(34.2)	-	(34.2)
Buy-back of equity shares by overseas subsidiary Company	-	-	-	-	-	-	-	-	-	-	(10,110.3)	-	-	-	-	-	(10,110.3)	(10,447.5)	(20,557.8)
Transfer to capital redemption reserve on buy-back of equity shares	-	-	-	-	-	-	-	7.5	-	-	(7.5)	-	-	-	-	-	-	-	-
Transfer from surplus in consolidated statement of profit and loss	-	-	-	-	1,041.7	-	-	-	-	-	(1,041.7)	-	-	-	-	-	-	-	-
Additional non-controlling interests arising on the acquisition of JSC Biosintez	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	249.7	249.7
Transfer from surplus in consolidated statement of profit and loss as per the local law of an overseas subsidiary	-	-	50.6	-	-	-	-	-	-	-	(50.6)	-	-	-	-	-	-	-	-
Transfer on exercise of share options	-	-	-	54.8	-	(54.8)	-	-	-	-	-	-	-	-	-	-	-	-	-
Balance as at March 31, 2017	2,399.3	# 0.0	507.5	11,894.6	2,083.4	26.4	43.8	7.5	1.1	35,578.0	306,456.9	(3.4)	339.7	7,015.7	46.2	-	366,396.7	37,908.6	404,305.3

Abridged Consolidated Statement of Changes in Equity

for the year ended March 31, 2018

Particulars	Equity share capital	Reserves and surplus										Other comprehensive income (OCI)				Attributable to owners of Parent Company	Non-controlling interests	TOTAL ₹ in Million
		Share application money pending allotment	Capital reserve	Securities premium reserve	Debt redemption reserve	Share option outstanding account	Amalgamation reserve	Capital redemption reserve	Legal reserve	General reserve	Retained earnings	Debt instrument through OCI	Equity through OCI	Foreign currency translation reserve	Effective portion of cash flow hedges			
Profit for the year	-	-	-	-	-	-	-	-	-	21,615.5	-	-	-	-	21,615.5	4,468.0	26,083.5	
Exchange difference arising on translation of foreign operations /net investment in foreign operations	-	-	-	-	-	-	-	-	-	-	-	-	3,104.4	-	3,104.4	520.4	3,624.8	
Other comprehensive income for the year, net of income tax	-	-	-	-	-	-	-	-	-	-	-	507.7	-	-	1,650.4	(42.7)	1,607.7	
Total comprehensive income for the year	-	-	-	-	-	-	-	-	-	-	-	22,123.2	1,308.9	3,104.4	26,370.3	4,945.7	31,316.0	
Payment of dividend	-	-	-	-	-	-	-	-	-	(7,977.4)	-	-	-	-	(7,977.4)	(152.8)	(8,130.2)	
Dividend distribution tax	-	-	-	-	-	-	-	-	-	(1,624.0)	-	-	-	-	(1,624.0)	-	(1,624.0)	
Recognition of share-based payments to employees	-	-	-	-	(1.0)	-	-	-	-	-	-	-	-	-	(1.0)	-	(1.0)	
Issue of equity shares@	0.0	(0.0)	-	9.1	-	-	-	-	-	-	-	-	-	-	9.1	-	9.1	
Transfer to debt redemption reserve	-	-	-	(833.4)	-	-	-	-	-	833.4	-	-	-	-	-	-	-	
Buy-back of equity shares by overseas subsidiaries Company	-	-	-	-	-	-	-	-	-	(2,168.1)	-	-	-	-	(2,168.1)	(4,586.4)	(6,754.5)	
Additional non-controlling interest arising on the acquisition of Zenotech (Refer note 18)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	726.5	726.5	
Transfer from surplus in consolidated statement of profit and loss as per the local law of an overseas subsidiary	-	-	-	-	-	-	-	-	2.5	(2.5)	-	-	-	-	-	-	-	
Transfer on exercise of share options	-	-	-	25.4	-	(25.4)	-	-	-	-	-	-	-	-	-	-	-	
Balance as at March 31, 2018	2,399.3	-	507.5	11,929.1	1,250.0	-	43.8	7.5	3.6	35,578.0	317,641.5	(93.9)	1,648.6	10,120.1	(29.5)	38,841.6	419,847.2	

* Represents re-measurements of the defined benefit plans

(March 31, 2017: ₹ 7,177)

@ (March 31, 2018: ₹ 62,365)

The accompanying notes are an integral part of the abridged consolidated financial statements

As per our report of even date

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration No. : 324 982E/E300003

per **PAUL ALVARES**

Partner

Membership No. : 105754

Mumbai, May 25, 2018

C. S. MURALIDHARAN
Chief Financial Officer

SUNIL R. AJMERA
Company Secretary

For and on behalf of the Board of Directors of
Sun Pharmaceutical Industries Limited

DILIP S. SHANGHVI
Managing Director

SUDHIR V. VALIA
Wholtime Director

SALESH T. DESAI
Wholtime Director
Mumbai, May 25, 2018

Abridged Consolidated Cash Flow Statement

for the year ended March 31, 2018

₹ in Million

Particulars	Year ended March 31, 2018	Year ended March 31, 2017
Net cash generated from operating activities	39,071.5	70,822.1
Net cash used in investing activities	(33,708.1)	(42,216.0)
Net cash used in financing activities	(15,392.6)	(22,853.9)
Net (decrease)/ increase in cash and cash equivalents	(10,029.2)	5,752.2
Cash and cash equivalents at the beginning of the year	86,423.6	80,316.9
Cash and cash equivalents taken over on acquisition of subsidiaries (Refer note 18)	1,197.3	-
Effect of exchange differences on restatement of foreign currency cash and cash equivalents	1,472.8	354.5
Cash and cash equivalents at the end of the year	79,064.5	86,423.6

The accompanying notes are an integral part of the abridged consolidated financial statements

As per our report of even date

For **S R B C & CO LLP**

Chartered Accountants

ICAI Firm Registration No. : 324982E/E300003

per **PAUL ALVARES**

Partner

Membership No. : 105754

Mumbai, May 25, 2018

For and on behalf of the Board of Directors of
Sun Pharmaceutical Industries Limited

DILIP S. SHANGHVI

Managing Director

C. S. MURALIDHARAN

Chief Financial Officer

SUNIL R. AJMERA

Company Secretary

SUDHIR V. VALIA

Wholetime Director

SAILESH T. DESAI

Wholetime Director

Mumbai, May 25, 2018

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

1. Complete Consolidated Balance Sheet, Consolidated Statement of Profit and Loss, Consolidated Statement of Changes in Equity, Consolidated Cash Flow Statement and other statements and notes thereto of Sun Pharmaceutical Industries Limited ("the Parent Company") and its subsidiaries (hereinafter referred to as "the Company" or "the Group") are prepared as per requirements of Division II to the Schedule III to the Companies Act, 2013 are available at the Company's website www.sunpharma.com. Copy of financial statement is also available for inspection at the registered office of the Company during working hours for a period of 21 days before the date of AGM.

2. BASIS OF PREPARATION AND PRESENTATION

These abridged consolidated financial statements have been prepared on the basis of complete set of the consolidated financial statements for the year ended March 31, 2018, in accordance with the proviso to sub-section (1) of section 136 of the Companies Act, 2013 ("the Act") and Rule 10 of the Companies (Accounts) Rules, 2014, as amended.

3. SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies used in preparing the annual consolidated financial statements are in accordance with the Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Accounting Standards) Amendment Rules, 2016 are set out in Note 2 to the consolidated financial statements.

4. CASH AND CASH EQUIVALENTS

(Refer note 14 of the consolidated financial statements)

	₹ in Million	
	As at March 31, 2018	As at March 31, 2017
Balance with banks		
In current accounts	55,137.3	49,192.3
In deposit accounts with original maturity less than 3 months	24,099.3	35,576.1
Cheques, drafts on hand	10.6	1,813.9
Cash on hand	6.5	45.7
	79,253.7	86,628.0

5. BANK BALANCES OTHER THAN DISCLOSED IN NOTE 4 ABOVE

(Refer note 15 of the consolidated financial statements)

	₹ in Million	
	As at March 31, 2018	As at March 31, 2017
Deposit accounts (*)	19,610.3	64,573.9
Earmarked balances with banks		
Unpaid dividend accounts	73.0	59.3
Balances held as margin money or security against guarantees and other commitments (*)	356.8	147.2
	20,040.1	64,780.4

(*) Other bank balances include deposits amounting to ₹ 115.8 Million (March 31, 2017: ₹ 25,700.8 Million) and margin monies amounting to ₹ 327.7 Million (March 31, 2017: ₹ 70.2 Million) which have an original maturity of more than 12 months.

6. REVENUE FROM OPERATIONS

(Refer note 31 of the consolidated financial statements)

	₹ in Million	
	Year ended March 31, 2018	Year ended March 31, 2017
Sale of products (Refer note 14)	260,659.4	302,642.3
Other operating revenues	4,235.2	13,142.1
	264,894.6	315,784.4

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

7. OTHER EXPENSES

(Refer note 37 of the consolidated financial statements)

	₹ in Million	
	Year ended March 31, 2018	Year ended March 31, 2017
Consumption of materials, stores and spare parts	7,511.5	6,531.0
Conversion and other manufacturing charges	6,499.4	6,408.8
Power and fuel	5,599.7	5,250.9
Rent	1,120.8	1,237.8
Rates and taxes	3,237.2	3,022.3
Insurance	1,312.9	1,068.2
Selling and distribution	13,661.6	20,736.5
Commission on sale	1,350.0	1,130.0
Repairs and maintenance	4,263.1	4,097.0
Printing and stationery	612.3	859.7
Travelling and conveyance	5,190.2	5,250.1
Freight outward and handling charges	3,633.9	3,339.9
Communication	801.9	726.1
Provision/write off for doubtful trade receivables/advances	1,095.9	341.8
Professional, legal and consultancy	16,153.1	14,642.6
Donations	254.8	32.1
Loss on sale/write off of property, plant and equipment and intangible assets, net	232.9	127.5
Net (gain) / loss on foreign currency transactions	82.5	(3,730.7)
Excise duty on sales	739.2	2,703.0
(Decrease)/increase of excise duty on inventories	(729.7)	(5.2)
Payment to auditors (net of input credit, where applicable)	196.1	232.9
Impairment in value of investments	(725.7)	6.8
Impairment of property, plant and equipment, goodwill and other intangible assets	26.7	203.6
Miscellaneous expenses	8,775.7	10,348.6
	80,896.0	84,561.3

8. CONTINGENT LIABILITIES (TO THE EXTENT NOT PROVIDED FOR)

(Refer note 40 of the consolidated financial statements)

	₹ in Million	
	As at March 31, 2018	As at March 31, 2017
A) Contingent liabilities		
I) Claims against the Group not acknowledged as debts	855.4	1,147.6
II) Liabilities disputed - appeals filed with respect to:		
Income tax on account of disallowances / additions	59,274.1	56,712.6
Sales tax on account of rebate / classification	122.5	45.7
Excise duty on account of valuation / cenvat credit	2,290.4	4,548.1
Environment cess	23.3	23.3
ESIC Contribution on account of applicability	130.5	132.8
Drug Price Equalisation Account [DPEA] on account of demand towards unintended benefit, enjoyed by the Group	3,488.2	3,488.2
Demand by JDGFT import duty with respect to import alleged to be in excess of entitlement as per the Advanced Licence Scheme	17.4	16.7
Fine imposed for anti-competitive settlement agreement by European Commission	830.7	715.4
Octroi demand on account of rate difference	171.0	171.0
Other matters - State Electricity Board, Punjab Land Preservation Act related matters etc.	77.4	126.0

Note : Includes, interest till the date of demand, wherever applicable

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

₹ in Million		
	As at March 31, 2018	As at March 31, 2017
III) Legal proceedings The Company and/or its subsidiaries are involved in various legal proceedings including product liability, contracts, employment claims, anti-trust and other regulatory matters relating to conduct of its business. Most of these legal proceedings involve various complex issues on account of which, making a reliable estimate of the expected financial effect is not always attainable and involves significant uncertainties. To the extent that the Company concludes that a liability is probable and estimable based on the status of these cases, advice of the counsel, management assessment of the likely damages etc. the Company records a provision in the financial statements. The Company carries product liability insurance / is contractually indemnified by the manufacturer, for an amount it believes is sufficient for its needs. In respect of other claims, the Company believes, these claims do not constitute material litigation matters and with its meritorious defences the ultimate disposition of these matters are not expected to have material adverse effect on its Financial Statements.		
Footnote: Future cash outflows in respect of the above matters are determinable only on receipt of judgements / decisions pending at various forums / authorities.		
B) Guarantees given by the bankers on behalf of the Group	2,850.6	2,250.5

9 COMMITMENTS

(Refer note 41 of the consolidated financial statements)

₹ in Million		
	As at March 31, 2018	As at March 31, 2017
I) Estimated amount of contracts remaining to be executed on capital account (net of advances)	19,579.2	6,089.7
II) Derivative related commitments - forward foreign exchange contracts [Refer note 47 (c) of the consolidated financial statements]		
III) Lease related commitments [Refer note 55 of the consolidated financial statements]		
IV) Investment related commitments	2,873.3	1,715.2
V) Letters of credit for imports	1,300.3	2,362.0

10 SEGMENT REPORTING

(Refer note 53 of the consolidated financial statements)

The Chief Operating Decision Maker ('CODM') evaluates the Group's performance and allocates resources based on an analysis of various performance indicators by reportable segments. The Group's reportable segments are as follows:

1. India
2. United States of America
3. Emerging Markets
4. Rest of World

The reportable segments derives their revenues from the sale of pharmaceuticals products (generics, speciality, API, etc.). The CODM reviews revenue as the performance indicator. The measurement of each segment's revenues, expenses and assets is consistent with the accounting policies that are used in preparation of the Group's consolidated financial statements.

Revenue by Geography			₹ in Million
	Year ended March 31, 2018	Year ended March 31, 2017	
India	84,102.0	80,610.1	
United States of America	88,635.4	138,823.6	
Emerging markets	52,221.6	49,074.2	
Rest of world	35,700.4	34,134.4	
	260,659.4	302,642.3	

In view of the interwoven / intermix nature of business and manufacturing facility, other segmental information is not ascertainable.

Concentration of revenues from two customers of the Group were 38.4% and 35.7% of total revenue for the year ended March 31, 2018 and March 31, 2017 respectively.

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

- 11** The Company is a defendant in respect of a civil antitrust litigation relating to a product Modafinil, in which the plaintiff's have alleged that the Company excluded its generic version of Modafinil from the US market and hence have claimed damages under the Sherman Act of US. This case is pending in the United States District Court for the Eastern District of Pennsylvania. The Company and one of its wholly owned subsidiaries entered into settlements with certain plaintiffs (Apotex Corporation and Retailer Purchasers) in the month of July 2017 and September 2017 whereby the Company agreed to pay an aggregate amount of USD 147 Million (₹ 9,505 Million). This amount has been provided for in the consolidated financial statements and disclosed as an exceptional item. The Company continues to litigate the case against the other plaintiff's (other than those settled).
- 12** a) Since the US-FDA import alert at Karkhadi facility in March 2014, the Company remained fully committed to implement all corrective measures to address the observations made by the US-FDA with the help of third party consultant. Substantial progress has been made at the Karkhadi facility in terms of completing all the action items to address the observations made by the US-FDA in its warning letter issued in May 2014. The Company is continuing to work closely and co-operatively with the US-FDA to resolve the matter. The contribution of this facility to Company's revenues is not significant.
- b) The US-FDA, on January 23, 2014, had prohibited using API manufactured at Toansa facility for manufacture of finished drug products intended for distribution in the U.S. market. Consequentially, the Toansa manufacturing facility was subject to certain provisions of the consent decree of permanent injunction entered in January 2012 by erstwhile Ranbaxy Laboratories Ltd (which was merged with Sun Pharmaceutical Industries Ltd in March 2015). In addition, the Department of Justice of the USA ('US DOJ'), United States Attorney's Office for the District of New Jersey had also issued an administrative subpoena dated March 13, 2014 seeking information primarily related to Toansa manufacturing facility for which a Form 483 containing findings of the US-FDA was issued in January 2014. The Company is continuing to fully co-operate and provide requisite information to the US DOJ.
- c) In December 2015, the USFDA issued a warning letter to the manufacturing facility at Halol. Post the November 2016 inspection, the USFDA re-inspected Halol facility in February 2018. At the conclusion of the inspection, USFDA issued a Form-483 with three observations. The Company has submitted its response documenting the corrective measures to resolve the Form-483 observations. The Company continues to manufacture and distribute products to the U.S from Halol facility and at the same time is working closely and co-operatively with the USFDA to resolve the matter.
- d) In September 2013, the USFDA had put the Mohali facility under import alert and was also subjected to certain provisions of the consent decree of permanent injunction entered in January 2012 by erstwhile Ranbaxy Laboratories Ltd (which was merged with Sun Pharmaceutical Industries Ltd in March 2015). In March 2017, the USFDA lifted the import alert and indicated that the facility was in compliance with the requirements of cGMP provisions mentioned in the consent decree. The facility will continue to demonstrate sustainable cGMP compliance for a fixed period of time as required by the consent decree. The Company has started manufacturing and distributing products to the U.S from Mohali facility.
- 13** Tax expense (exceptional) for the year ended March 31, 2018 includes deferred tax assets of ₹ 2,585.7 Million created on difference on tax and book value on intra-group transfer of certain intangibles. Further, it also includes an impact of ₹ 5,130.2 Million on account of re-measurement of the Group's deferred tax assets as a result of the Tax Cut and Jobs Act enacted in United States of America on December 22, 2017.
- 14** Post implementation of Goods and Service Tax ("GST") with effect from July 01, 2017, sale of products is disclosed net of GST. Sale of products for the previous year included excise duty which is now subsumed in GST. Sale of products for the year ended March 31, 2018 includes excise duty for the period ended June 30, 2017. Accordingly, sale of products for the year ended March 31, 2018 are not comparable with year ended March 31, 2017.
- 15** The Board of Directors of the Company at its meeting held on May 25, 2018, approved the Scheme of Arrangement between the Company, Sun Pharma (Netherlands) B.V. and Sun Pharmaceutical Holdings USA Inc. (both being wholly owned subsidiaries of the Company) which inter-alia, envisages spin-off of the specified investment undertaking of the Company. Further, the Board of Directors of the Company at its meeting held on November 14, 2017 had approved the Scheme of Arrangement between Company and Sun Pharma Global FZE (wholly owned subsidiary of the Company) which inter-alia, envisages demerger of unbranded generic pharmaceutical undertaking of Sun Pharma Global FZE into the Company. The above schemes shall be effective post receipt of required approvals and accordingly, the consolidated financial statements do not reflect the impact, if any, on account of the schemes.

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

16 Disclosures mandated by the Companies Act, 2013 Schedule III Part II by way of additional information is given in Annexure 'A'.

17 RELATED PARTY DISCLOSURES (IND AS-24) - AS PER ANNEXURE 'B'

18 BUSINESS COMBINATIONS

Zenotech Laboratories Limited

With effect from July 27, 2017 Zenotech Laboratories Limited has ceased to be an associate and has become a subsidiary of Sun Pharmaceutical Industries Limited.

The Group has elected to measure the non-controlling interests in the acquiree at its proportionate share of net assets.

The following assets and liabilities were recognised as at the date of acquisition (at fair value):

	₹ in Million
Assets	
Cash and cash equivalents	1,197.3
Trade receivables	0.1
Inventories	17.5
Other current assets	2.0
Other non-current assets	28.7
Property, plant and equipment	1,689.8
Bank balances other than above	8.0
Other financial assets	1.2
Total	2,944.6

	₹ in Million
Liabilities	
Borrowings	512.0
Trade payables	48.3
Other current financial liabilities	297.4
Other current liabilities	184.5
Deferred tax liabilities	-
Provision	190.6
Total	1,232.8
Net worth	1,711.8
Total identifiable assets at fair value	
Non controlling interest	726.5
Goodwill	595.4
Total purchase price	1,580.7
Purchase price paid	855.0
Impairment reversal	725.7

From the date of acquisition, Zenotech Laboratories Limited has contributed revenue of ₹ 60.8 Million and loss before tax of ₹ 60.9 Million to the Group. If the business combinations had taken place at the beginning of the year, revenue would have been ₹ 64.1 Million and the loss before tax would have been ₹ 68.2 Million. In compliance with the relevant provisions of Ind AS 103, the Company has reversed impairment in the books to the extent of fair value of equity shares determined on the basis of right issue price amounting to ₹ 725.7 Million.

As per our report of even date

For **S R B C & CO LLP**
Chartered Accountants
ICAI Firm Registration No. : 324982E/E300003

per **PAUL ALVARES**
Partner
Membership No. : 105754
Mumbai, May 25, 2018

C. S. MURALIDHARAN
Chief Financial Officer

SUNIL R. AJMERA
Company Secretary

For and on behalf of the Board of Directors of
Sun Pharmaceutical Industries Limited

DILIP S. SHANGHVI
Managing Director

SUDHIR V. VALIA
Wholtime Director

SAILESH T. DESAI
Wholtime Director
Mumbai, May 25, 2018

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

Disclosure of additional information pertaining to the Parent Company, subsidiaries, associates and joint ventures as per Schedule III of Companies Act, 2013:

ANNEXURE 'A'

S. No.	Name of the entity	Net Assets, i.e., total assets minus total liabilities		Share in profit or (loss)		Share in other comprehensive income (OCI)		Share in total comprehensive income (TCI)	
		2017-18		2017-18		2017-18		2017-18	
		As % of consolidated net assets	₹ in Million	As % of consolidated profit or (loss)	₹ in Million	As % of consolidated OCI	₹ in Million	As % of consolidated TCI	₹ in Million
	Parent Entity - Sun Pharmaceutical Industries Limited	47.1	1,97,701.0	(22.9)	(4,945.9)	10.4	494.9	(16.9)	(4,451.0)
	Subsidiaries								
	Indian								
1	Green Eco Development Centre Limited	0.0	1.6	(0.0)	(0.1)	-	-	(0.0)	(0.1)
2	Sun Pharma Laboratories Limited	46.9	196,823.7	40.5	8,762.2 [#]	1.6	78.1	33.5	8,840.3 [#]
3	Faststone Mercantile Company Private Limited	0.0	11.5	0.0	0.4	-	-	0.0	0.4
4	Neetnav Real Estate Private Limited	0.7	2,920.9	0.0	0.6	-	-	0.0	0.6
5	Realstone Multitrade Private Limited	0.0	11.5	0.0	0.4	-	-	0.0	0.4
6	Skisen Labs Private Limited	0.0	0.0	0.0	0.0	-	-	0.0	0.0
7	Softdeal Trading Company Private Limited	0.0	11.0	0.0	0.4	-	-	0.0	0.4
8	Universal Enterprises Private Limited	0.0	5.3	0.0	0.0	-	-	0.0	0.0
9	Sun Pharmaceutical Medicare Limited	(0.0)	(83.9)	(0.3)	(61.4)	(0.2)	(11.5)	(0.3)	(72.9)
10	Zenotech Laboratories Limited	0.4	1,553.4	(0.7)	(159.0)**	0.0	0.5	(0.6)	(158.5)**
	Foreign								
1	Sun Pharmaceutical (Bangladesh) Limited	0.3	1,084.7	0.9	187.8	-	-	0.7	187.8
2	Sun Farmaceutica Do Brasil Ltda.	(0.5)	(2,289.9)	(0.9)	(199.1)	-	-	(0.8)	(199.1)
3	Sun Pharma De Mexico S.A. DE C.V.	0.2	717.1	1.0	223.5	-	-	0.8	223.5
4	SPIL De Mexico S.A. DE C.V.	0.0	0.2	-	-	-	-	-	-
5	Sun Pharmaceutical Peru S.A.C.	(0.0)	(149.3)	0.0	1.8	-	-	0.0	1.8
6	OOO "Sun Pharmaceutical Industries" Limited	(0.0)	(187.8)	(0.0)	(10.0)	-	-	(0.0)	(10.0)
7	Sun Pharma De Venezuela, C.A.	(0.0)	(2.6)	(0.0)	(0.7)	-	-	(0.0)	(0.7)
8	Ranbaxy Pharmacie Generiques	(0.5)	(2,199.2)	(1.2)	(257.9)	-	-	(1.0)	(257.9)
9	Ranbaxy (Malaysia) SDN. BHD.	0.2	877.7	2.1	455.7	-	-	1.7	455.7
10	Ranbaxy Nigeria Limited	0.1	211.2	(1.6)	(343.5)	-	-	(1.3)	(343.5)
11	Sun Pharma (Netherlands) B.V (Formerly known as Ranbaxy (Netherlands) B.V.)	12.6	52,694.6	(5.0)	(1,077.4) [#]	3.0	143.1	(3.5)	(934.3) [#]
12	Alkaloida Chemical Company Zrt.	5.8	24,387.2	(0.8)	(163.4)	-	-	(0.6)	(163.4)

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

Disclosure of additional information pertaining to the Parent Company, subsidiaries, associates and joint ventures as per Schedule III of Companies Act, 2013:

ANNEXURE 'A'

S. No.	Name of the entity	Net Assets, i.e., total assets minus total liabilities		Share in profit or (loss)		Share in other comprehensive income (OCI)		Share in total comprehensive income (TCI)	
		2017-18		2017-18		2017-18		2017-18	
		As % of consolidated net assets	₹ in Million	As % of consolidated profit or (loss)	₹ in Million	As % of consolidated OCI	₹ in Million	As % of consolidated TCI	₹ in Million
13	Sun Pharmaceuticals UK Limited	0.0	0.0	0.4	95.2	-	-	0.4	95.2
14	Sun Pharmaceutical Industries (Australia) Pty Limited	0.4	1,512.7	(5.6)	(1,220.1)	-	-	(4.6)	(1,220.1)
15	Aditya Acquisition Company Ltd.	0.0	12.0	0.0	5.6	-	-	0.0	5.6
16	Sun Pharmaceutical Industries (Europe) B.V.	(0.0)	(66.0)	0.3	62.0	-	-	0.2	62.0
17	Sun Pharmaceuticals Italia S.R.L.	0.0	46.1	(0.0)	(0.9)	-	-	(0.0)	(0.9)
18	Sun Pharmaceuticals Germany GmbH	(0.0)	(207.2)	0.1	15.0	-	-	0.1	15.0
19	Sun Pharmaceuticals France	(0.0)	(24.7)	(0.0)	(4.5)	-	-	(0.0)	(4.5)
20	Sun Pharma Global FZE (Consolidated with a Joint venture)	30.3	127,032.1	10.6	2,295.7*	22.6	1,073.1	12.8	3,368.8*
21	Sun Pharmaceuticals (SA) (Pty) Ltd.	(0.0)	(0.0)	0.0	0.1	-	-	0.0	0.1
22	Sun Global Canada Pty. Ltd.	(0.0)	(1.4)	(0.0)	(0.2)	-	-	(0.0)	(0.2)
23	Sun Pharma Philippines, Inc.	(0.1)	(441.5)	(0.2)	(38.4)	-	-	(0.1)	(38.4)
24	Sun Pharmaceuticals Korea Ltd.	0.0	4.4	0.0	0.0	-	-	0.0	0.0
25	Sun Global Development FZE	0.0	180.9	(0.0)	(0.7)	-	-	(0.0)	(0.7)
26	Sun Pharma Japan Ltd.	(0.4)	(1,480.3)	(4.4)	(950.6)	-	-	(3.6)	(950.6)
27	Sun Pharma HealthCare FZE	0.0	183.4	0.0	2.2	-	-	0.0	2.2
28	Sun Laboratories FZE	(0.1)	(265.1)	0.4	79.9	-	-	0.3	79.9
29	Taro Pharmaceutical Industries Ltd. (TARO) (Consolidated with its Subsidiaries)	34.8	146,191.6	76.6	16,551.7	45.0	2,140.0	70.9	18,691.7
30	Alkaloida Sweden AB	0.0	38.3	0.1	14.3	-	-	0.1	14.3
31	Sun Pharma Switzerland Ltd.	0.6	2,631.0	(0.0)	(4.7)	-	-	(0.0)	(4.7)
32	Sun Pharma Holdings	48.6	204,008.4	(0.1)	(29.5)	-	-	(0.1)	(29.5)
33	Sun Pharma East Africa Limited	(0.0)	(148.8)	(0.3)	(73.6)	-	-	(0.3)	(73.6)
34	Sun Pharma ANZ Pty Ltd (Formerly known as Ranbaxy Australia Pty Ltd)	(0.1)	(348.2)	0.4	80.2	-	-	0.3	80.2
35	Ranbaxy Farmaceutica Ltda.	(0.3)	(1,103.7)	(0.4)	(89.2)	-	-	(0.3)	(89.2)
36	Ranbaxy Pharmaceuticals Canada Inc.	0.1	278.2	(0.3)	(62.6)	-	-	(0.2)	(62.6)
37	Sun Pharma Egypt Limited LLC (Formerly known as Ranbaxy Egypt Ltd)	0.1	382.7	(0.1)	(22.0)	-	-	(0.1)	(22.0)
38	Rexcel Egypt LLC	(0.0)	(18.7)	(0.0)	(7.3)	-	-	(0.0)	(7.3)
39	Office Pharmaceutique Industriel Et Hospitalier	0.0	93.8	0.0	2.5	-	-	0.0	2.5

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

Disclosure of additional information pertaining to the Parent Company, subsidiaries, associates and joint ventures as per Schedule III of Companies Act, 2013:

ANNEXURE 'A'

S. No.	Name of the entity	Net Assets, i.e., total assets minus total liabilities		Share in profit or (loss)		Share in other comprehensive income (OCI)		Share in total comprehensive income (TCI)	
		2017-18		2017-18		2017-18		2017-18	
		As % of consolidated net assets	₹ in Million	As % of consolidated profit or (loss)	₹ in Million	As % of consolidated OCI	₹ in Million	As % of consolidated TCI	₹ in Million
40	Basics GmbH	0.2	1,024.6	0.3	54.1	-	-	0.2	54.1
41	Ranbaxy GmbH	0.0	2.0	-	-	-	-	-	-
42	Ranbaxy Ireland Limited	0.1	571.0	(0.1)	(14.7)	-	-	(0.1)	(14.7)
43	Ranbaxy Italia S.P.A.	0.0	0.7	(0.0)	(6.5)	-	-	(0.0)	(6.5)
44	Sun Pharmaceutical Industries S.A.C. (Formerly known as Ranbaxy - PRP (Peru) S.A.C.)	(0.0)	(125.0)	(0.1)	(29.6)	-	-	(0.1)	(29.6)
45	Ranbaxy (Poland) SP. Z O.O.	0.0	194.8	0.1	11.8	-	-	0.0	11.8
46	Terapia S.A.	3.4	14,079.7	10.1	2,174.2	-	-	8.2	2,174.2
47	AO Ranbaxy (Formerly Known ZAO Ranbaxy)	0.2	1,027.0	0.3	57.8	-	-	0.2	57.8
48	JSC Biosintez	0.2	994.4	(2.4)	(511.8)	-	-	(1.9)	(511.8)
49	Ranbaxy South Africa (Pty) Limited (Consolidated with its Subsidiary)	0.3	1,225.3	1.4	307.9	-	-	1.2	307.9
50	Ranbaxy Pharmaceuticals (Pty) Limited	(0.2)	(979.5)	0.8	183.1	-	-	0.7	183.1
51	Be- Tabs Investments (Pty) Limited	0.0	19.8	-	-	-	-	-	-
52	Laboratorios Ranbaxy, S.L.U.	0.1	355.3	0.3	62.9	-	-	0.2	62.9
53	Ranbaxy (U.K.) Limited	0.3	1,383.9	0.3	55.7	-	-	0.2	55.7
54	Ranbaxy Holdings (U.K.) Limited	0.7	2,832.7	-	-	-	-	-	-
55	Ranbaxy Europe Limited	0.0	0.0	(0.0)	(0.1)	-	-	(0.0)	(0.1)
56	Sun Pharma Holding USA Inc (Consolidated with its Subsidiaries, its associates and a Joint venture)	11.8	49,434.6	(25.3)	(5,466.9)#	-	-	(20.7)	(5,466.9)#
57	Ranbaxy (Thailand) Co., Ltd.	0.0	208.0	0.1	30.0	-	-	0.1	30.0
58	Sun Pharmaceuticals Morocco LLC (Formerly known as Ranbaxy Morocco LLC)	(0.0)	(72.9)	(0.1)	(31.2)	-	-	(0.1)	(31.2)
59	"Ranbaxy Pharmaceuticals Ukraine" LLC	0.0	158.6	0.2	48.0	-	-	0.2	48.0
	Non controlling interest in all subsidiaries	9.3	38,841.6	(20.7)	(4,468.0)	(10.0)	(477.7)	(18.8)	(4,945.7)
	Intercompany Elimination and Consolidation Adjustments	(153.6)	(643,919.3)	46.2	10,044.3	27.6	1,314.3	43.0	11,358.6
	Total	100.0	419,847.2	100.0	21,615.5	100.0	4,754.8	100.0	26,370.3

Includes share of profit/loss and share of TCI, from its associates and a joint venture of ₹ 262.0 Million

* Includes share of profit and share of TCI, from a joint venture of ₹ 7.6 Million

** With effect from July 27, 2017 Zenotech Laboratories Limited has ceased to be an associate and has become subsidiary of Sun Pharmaceutical Industries Limited.

Note: The above amounts / percentage of net assets and net profit or (loss) in respect of the Parent Company, its subsidiaries, associates and joint ventures are determined based on the amounts of the respective entities included in consolidated financial statements before inter-company eliminations / consolidation adjustments.

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

Disclosure of additional information pertaining to the Parent Company, subsidiaries, associates and joint ventures as per Schedule III of Companies Act, 2013:

ANNEXURE 'A'

S. No.	Name of the entity	Net Assets, i.e., total assets minus total liabilities		Share in profit or (loss)		Share in other comprehensive income (OCI)		Share in total comprehensive income (TCI)	
		2016-17		2016-17		2016-17		2016-17	
		As % of consolidated net assets	₹ in Million	As % of consolidated profit or (loss)	₹ in Million	As % of consolidated OCI	₹ in Million	As % of consolidated TCI	₹ in Million
	Parent Entity - Sun Pharmaceutical Industries Limited	52.0	210,124.7	(0.3)	(228.4)	4.8	(634.5)	(1.5)	(862.9)
Subsidiaries									
Indian									
1	Green Eco Development Centre Limited	0.0	1.6	(0.0)	(0.5)	-	-	(0.0)	(0.5)
2	Sun Pharma Laboratories Limited	48.9	197,557.8	10.9	7,584.3	0.8	(107.0)	13.3	7,477.3
3	Faststone Mercantile Company Private Limited	0.0	11.1	0.0	0.3	-	-	0.0	0.3
4	Neetnav Real Estate Private Limited	0.7	2,920.2	0.0	0.8	-	-	0.0	0.8
5	Realstone Multitrade Private Limited	0.0	11.1	0.0	0.4	-	-	0.0	0.4
6	Skisen Labs Private Limited	0.0	0.1	(0.0)	(0.0)	-	-	(0.0)	(0.0)
7	Softdeal Trading Company Private Limited	0.0	10.6	0.0	0.4	-	-	0.0	0.4
8	Universal Enterprises Private Limited	0.0	5.3	0.0	0.0	-	-	0.0	0.0
9	Sun Pharmaceutical Medicare Limited	(0.0)	(11.0)	(0.0)	(13.5)	-	-	(0.0)	(13.5)
Foreign									
1	Sun Pharmaceutical (Bangladesh) Limited	0.2	942.2	0.3	219.2	-	-	0.4	219.2
2	Sun Pharmaceutical Industries, Inc. (Consolidated with its Subsidiaries, its associates and a Joint venture)	3.1	12,430.7	(2.3)	(1,594.3)#	-	-	(2.8)	(1,594.3)#
3	Sun Farmaceutica Do Brasil Ltda.	(0.5)	(2,207.3)	0.3	185.1	-	-	0.3	185.1
4	Sun Pharma De Mexico S.A. DE C.V.	0.2	758.1	0.2	118.5	-	-	0.2	118.5
5	SPIL De Mexico S.A. DE C.V.	0.0	0.2	-	-	-	-	-	-
6	Sun Pharmaceutical Peru S.A.C.	(0.0)	(150.0)	(0.0)	(19.9)	-	-	(0.0)	(19.9)
7	OOO "Sun Pharmaceutical Industries" Limited	(0.0)	(182.6)	0.0	12.7	-	-	0.0	12.7
8	Sun Pharma De Venezuela, C.A.	(0.4)	(1,444.5)	(0.5)	(325.3)	-	-	(0.6)	(325.3)
9	Ranbaxy Pharmacie Generiques	(0.4)	(1,658.4)	(0.2)	(173.6)	-	-	(0.3)	(173.6)
10	Ranbaxy (Malaysia) SDN. BHD.	0.1	333.4	0.1	86.6	-	-	0.2	86.6
11	Ranbaxy Nigeria Limited	0.1	551.5	(0.2)	(114.2)	-	-	(0.2)	(114.2)

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

Disclosure of additional information pertaining to the Parent Company, subsidiaries, associates and joint ventures as per Schedule III of Companies Act, 2013:

ANNEXURE 'A'

S. No.	Name of the entity	Net Assets, i.e., total assets minus total liabilities		Share in profit or (loss)		Share in other comprehensive income (OCI)		Share in total comprehensive income (TCI)	
		2016-17		2016-17		2016-17		2016-17	
		As % of consolidated net assets	₹ in Million	As % of consolidated profit or (loss)	₹ in Million	As % of consolidated OCI	₹ in Million	As % of consolidated TCI	₹ in Million
12	Sun Pharma (Netherlands) B.V. (Formerly known as Ranbaxy (Netherlands) B.V.)	13.2	53,421.2	1.5	1,079.2	-	-	1.9	1,079.2
13	Alkaloida Chemical Company Zrt.	6.1	24,524.0	(1.9)	(1,356.0)	-	-	(2.4)	(1,356.0)
14	Sun Pharmaceuticals UK Limited	(0.0)	(91.4)	(0.0)	(0.8)	-	-	(0.0)	(0.8)
15	Sun Pharmaceutical Industries (Australia) Pty Limited	0.5	1,975.6	(0.5)	(360.9)	-	-	(0.6)	(360.9)
16	Aditya Acquisition Company Ltd.	0.0	6.0	0.0	5.6	-	-	0.0	5.6
17	Sun Pharmaceutical Industries (Europe) B.V.	(0.0)	(110.5)	0.0	26.9	-	-	0.0	26.9
18	Sun Pharmaceuticals Italia S.R.L.	0.0	40.5	(0.0)	(1.5)	-	-	(0.0)	(1.5)
19	Sun Pharmaceuticals Spain, S.L.U.	-	-	(0.0)	(5.2)	-	-	(0.0)	(5.2)
20	Sun Pharmaceuticals Germany GmbH	(0.0)	(186.0)	(0.0)	(2.4)	-	-	(0.0)	(2.4)
21	Sun Pharmaceuticals France	(0.0)	(17.1)	(0.0)	(4.3)	-	-	(0.0)	(4.3)
22	Sun Pharma Global FZE (Consolidated with a Joint venture)	30.5	123,500.6	21.0	14,620.6*	27.4	(3,657.4)	19.5	10,963.2*
23	Sun Pharmaceuticals SA (Pty) Ltd	(0.0)	(0.1)	(0.0)	(0.0)	-	-	(0.0)	(0.0)
24	Sun Global Canada Pty. Ltd.	(0.0)	(1.1)	(0.0)	(0.0)	-	-	(0.0)	(0.0)
25	Sun Pharma Philippines, Inc.	(0.1)	(419.5)	(0.2)	(152.5)	-	-	(0.3)	(152.5)
26	Sun Pharmaceuticals Korea Ltd.	0.0	4.2	(0.0)	(0.3)	-	-	(0.0)	(0.3)
27	Sun Global Development FZE	0.0	181.3	(0.0)	(0.7)	-	-	(0.0)	(0.7)
28	Sun Pharma Japan Ltd.	(0.1)	(443.6)	(0.2)	(117.8)	-	-	(0.2)	(117.8)
29	Sun Pharma HealthCare FZE	0.0	181.0	0.0	2.5	-	-	0.0	2.5
30	Sun Laboratories FZE	(0.1)	(344.7)	(0.2)	(114.3)	-	-	(0.2)	(114.3)
31	Taro Pharmaceutical Industries Ltd. (TARO) (Consolidated with its Subsidiaries)	33.2	134,415.9	44.0	30,612.8	12.6	(1,683.7)	51.4	28,929.1
32	Alkaloida Sweden AB	0.0	20.0	0.0	9.6	-	-	0.0	9.6
33	Sun Pharma Switzerland Ltd.	(0.0)	(21.8)	(0.0)	(27.8)	-	-	(0.0)	(27.8)
34	Ocular Technologies SARL	0.6	2,626.6	3.9	2,713.8	-	-	4.8	2,713.8
35	Sun Pharma Holdings	50.4	203,802.5	(0.0)	(9.7)	-	-	(0.0)	(9.7)

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

Disclosure of additional information pertaining to the Parent Company, subsidiaries, associates and joint ventures as per Schedule III of Companies Act, 2013:

ANNEXURE 'A'

S. No.	Name of the entity	Net Assets, i.e., total assets minus total liabilities		Share in profit or (loss)		Share in other comprehensive income (OCI)		Share in total comprehensive income (TCI)	
		2016-17		2016-17		2016-17		2016-17	
		As % of consolidated net assets	₹ in Million	As % of consolidated profit or (loss)	₹ in Million	As % of consolidated OCI	₹ in Million	As % of consolidated TCI	₹ in Million
36	Sun Pharma East Africa Limited	(0.0)	(71.5)	(0.0)	(32.2)	-	-	(0.1)	(32.2)
37	Sun Pharma ANZ Pty Ltd (Formerly known as Ranbaxy Australia Pty Ltd)	(0.1)	(429.7)	0.0	34.8	-	-	0.1	34.8
38	Ranbaxy Farmaceutica Ltda.	(0.3)	(1,070.3)	0.1	87.3	-	-	0.2	87.3
39	Ranbaxy Pharmaceuticals Canada Inc.	0.1	332.7	(0.1)	(64.1)	-	-	(0.1)	(64.1)
40	Sun Pharma Egypt Limited LLC (Formerly known as Ranbaxy Egypt Ltd)	0.1	265.7	(0.1)	(95.4)	-	-	(0.2)	(95.4)
41	Rexcel Egypt LLC	(0.0)	(10.9)	(0.0)	(11.8)	-	-	(0.0)	(11.8)
42	Office Pharmaceutique Industriel Et Hospitalier	0.0	78.6	0.0	14.5	-	-	0.0	14.5
43	Basics GmbH	0.2	842.2	0.1	41.2	-	-	0.1	41.2
44	Ranbaxy GmbH	0.0	1.7	-	-	-	-	-	-
45	Ranbaxy Ireland Limited	0.1	505.2	0.2	146.8	-	-	0.3	146.8
46	Ranbaxy Italia S.P.A.	0.0	19.8	(0.0)	(33.9)	0.0	(2.5)	(0.1)	(36.4)
47	Sun Pharmaceutical Industries S.A.C. (Formerly known as Ranbaxy - PRP (Peru) S.A.C.)	(0.0)	(94.5)	(0.0)	(22.2)	-	-	(0.0)	(22.2)
48	Ranbaxy (Poland) Sp. Z o.o.	0.0	156.9	0.0	11.0	-	-	0.0	11.0
49	Terapia S.A.	2.6	10,409.9	3.2	2,237.1	-	-	4.0	2,237.1
50	AO Ranbaxy (Formerly Known ZAO Ranbaxy)	0.2	987.2	0.2	143.0	-	-	0.3	143.0
51	JSC Biosintez	0.4	1,703.7	0.0	25.1	-	-	0.0	25.1
52	Ranbaxy South Africa Proprietary Limited (Consolidated with its Subsidiary)	0.2	852.4	0.4	308.1	-	-	0.5	308.1
53	Ranbaxy Pharmaceuticals (Pty) Limited	(0.3)	(1,035.4)	0.3	186.9	-	-	0.3	186.9
54	Be- Tabs Investments (Pty) Limited	0.0	17.3	0.0	0.1	-	-	0.0	0.1
55	Laboratorios Ranbaxy, S.L.U.	0.1	248.6	0.2	104.9	-	-	0.2	104.9
56	Ranbaxy (U.K.) Limited	0.3	1,164.6	0.1	63.2	-	-	0.1	63.2
57	Ranbaxy Holdings (U.K.) Limited	0.6	2,480.0	(0.0)	(1.0)	-	-	(0.0)	(1.0)
58	Ranbaxy Europe Limited	0.0	148.1	0.0	0.0	-	-	0.0	0.0
59	Ranbaxy Inc. (Consolidated with its Subsidiaries)	9.4	38,000.0	7.6	5,297.3	-	-	9.4	5,297.3
60	Sun Pharmaceuticals Holdings USA, INC	5.1	20,673.7	0.0	0.1	-	-	0.0	0.1
61	Ranbaxy (Thailand) Co., Ltd.	0.0	160.8	(0.1)	(91.1)	-	-	(0.2)	(91.1)

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

Disclosure of additional information pertaining to the Parent Company, subsidiaries, associates and joint ventures as per Schedule III of Companies Act, 2013:

ANNEXURE 'A'

S. No.	Name of the entity	Net Assets, i.e., total assets minus total liabilities		Share in profit or (loss)		Share in other comprehensive income (OCI)		Share in total comprehensive income (TCI)	
		2016-17		2016-17		2016-17		2016-17	
		As % of consolidated net assets	₹ in Million	As % of consolidated profit or (loss)	₹ in Million	As % of consolidated OCI	₹ in Million	As % of consolidated TCI	₹ in Million
62	Sun Pharmaceuticals Morocco LLC (Formerly known as Ranbaxy Morocco LLC)	(0.0)	(40.2)	0.1	81.7	-	-	0.1	81.7
63	"Ranbaxy Pharmaceuticals Ukraine" LLC	0.0	107.4	0.0	27.1	-	-	0.0	27.1
	Non controlling interest in all subsidiaries	9.4	37,908.6	(12.7)	(8,818.6)	(11.5)	1,534.3	(12.9)	(7,284.3)
	Foreign Joint Venture (Investment as per equity method)								
1	MSD - Sun LLC (Consolidated with its subsidiary)	0.0	0.7	-	-	-	-	-	-
	Intercompany Elimination and Consolidation Adjustments	(166.3)	(673,076.4)	24.8	17,348.4	65.9	(8,786.8)	15.1	8,561.6
	Total	100.0	404,305.3	100.0	69,643.7	100.0	(13,337.6)	100.0	56,306.1

Includes share of profit and share of TCI, from its associates and joint venture of ₹ 101.8 Million.

* Includes share of loss and share of TCI, from a joint venture of ₹ 2.5 Million.

Note: The above amounts / percentage of net assets and net profit or (loss) in respect of the Parent Company, its subsidiaries, associates and joint ventures are determined based on the amounts of the respective entities included in consolidated financial statements before inter-company eliminations / consolidation adjustments.

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

IND AS- 24 - " RELATED PARTY DISCLOSURES"

ANNEXURE 'B'

Names of related parties where there are transactions and description of relationships

a	Key Managerial Personnel (KMP)	
	Dilip S. Shanghvi	Managing Director
	Sudhir V. Valia	Executive Director
	Sailesh T. Desai	Executive Director
	Israel Makov	Chairman and Non- Executive Director
	Kalyansundaram Subramanian (w.e.f. February 14, 2017)	Executive Director
b	Non - Executive Directors	
	S. Mohanchand Dadha	
	Hasmukh S. Shah (resigned w.e.f. November 15, 2017)	
	Keki M. Mistry	
	Ashwin S. Dani	
	Rekha Sethi	
	Vivek c. Sehgal (w.e.f. November 14, 2017)	
c	Relatives of Key Managerial Personnel	
	Aalok Shanghvi	
	Vidhi Shanghvi	
d	Others (Entities in which the KMP and Relatives of KMP have control or significant influence)	
	Makov Associates Ltd	
	Shantilal Shanghvi Foundation	
	Sun Pharma Advanced Research Company Ltd	
	Sun Petrochemicals Pvt Ltd	
	Alfa Infraprop Pvt. Ltd.	
	Sidmak Laboratories India Private Limited	
	Ramdev Chemicals Private Limited	
	Sholapur Organics Private Limited	
	United Medisales Private Limited	
	Virtuous Finance Private Limited	
	Aditya Medisales Limited	
	United Medisales Private Limited	
e	Joint Venture	
	S & I Ophthalmic LLC	
	Artes Biotechnology GmbH	
f	Associates	
	Zenotech Laboratories Limited (Refer Note 39 t and 39 u of consolidated financial statements)	
	Daiichi Sankyo (Thailand) Ltd. (Refer Note 39 r of consolidated financial statements)	
	Medinstill LLC	
	scPharmaceuticals Inc.	
	Trumpcard Advisors and Finvest LLP	
	Generic Solar Power LLP	
	Vintage Power Generation LLP	
g	Unconsolidated subsidiary	
	Foundation for Disease Elimination and Control of India	

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

IND AS- 24 - " RELATED PARTY DISCLOSURES"

ANNEXURE 'B'

Details of related party transaction:

	Year ended March 31, 2018	Year ended March 31, 2017
	₹ in Million	
Purchase of goods	308.3	28.2
Associates	-	12.9
Others	308.3	15.3
Purchase of property, plant and equipment and other intangible assets	650.2	885.4
Others	650.2	885.4
Sale of goods	79,876.2	103.4
Associates	-	38.8
Others	79,876.2	64.6
Sale of property, plant and equipment and other intangible assets	0.5	-
Others	0.5	-
Receiving of service	1,209.4	1,296.6
Others	1,005.6	1,296.6
Joint venture	40.9	-
Associate	162.9	-
Reimbursement of expenses paid	68.4	17.7
Associates	5.7	2.8
Key managerial personnel ₹ Nil (March 31, 2017 : ₹ 45,815)	-	0.0
Others	62.2	14.9
Unconsolidated subsidiary	0.5	-
Rendering of service	178.3	147.8
Joint venture	0.1	11.6
Associates	-	-
Others	178.2	136.2
Reimbursement of expenses received	326.4	290.1
Others	326.1	289.8
Unconsolidated subsidiary	0.3	0.3
Loans / deposit given	6,300.0	-
Others	6,300.0	-
Loans received back	9,912.4	-
Others	9,912.4	-
Purchase of Investment in associates and joint venture and unconsolidated subsidiary	324.7	1,856.1
Associates	324.7	1,856.0
Joint venture	-	-
Unconsolidated subsidiary	-	0.1
Interest income	1,058.7	70.4
Associates	19.1	70.4
Others	1,039.6	-
Lease rental and hire charges	51.0	51.1
Others	51.0	51.1
Receipt on account of assets given under finance lease	-	46.8
Others	-	46.8
Rent expense	6.8	-
Others	6.8	-
Provision for doubtful loans and interest accrued and due on loans	-	63.4
Associates	-	63.4
Advance received back	2.5	-
Unconsolidated subsidiary	2.5	-
Advance given	2.5	-
Unconsolidated subsidiary	2.5	-
Remuneration / compensation	237.7	294.9
Key managerial personnel *	217.6	281.6
Relatives of Key managerial personnel	20.1	13.3
Donation	62.8	52.1
Unconsolidated subsidiary	42.8	-
Others	20.0	52.1

(*) Remuneration to key managerial personnel includes the refund received from key managerial personnel in respect of excess remuneration paid for financial year 2014-15, 2015-16 and 2016-17.

Notes to the Abridged Consolidated Financial Statements

for the year ended March 31, 2018

IND AS- 24 - " RELATED PARTY DISCLOSURES"**ANNEXURE 'B'****Balance outstanding as at the end of the year**

	₹ in Million	
	As at March 31, 2018	As at March 31, 2017
Receivables	12,287.2	1,130.4
Joint venture	-	-
Others	12,287.2	1,129.6
Unconsolidated subsidiary	-	0.8
Payables	917.6	833.8
Associates	-	137.7
Key managerial personnel	169.5	153.7
Relatives of key managerial personnel	0.8	0.6
Others	747.3	541.8
Capital advance	212.9	212.9
Associates	212.9	212.9
Deposit given	658.6	-
Others	0.5	-
Associates	658.1	-
Loan given	-	454.0
Associates *	-	454.0
Advance from customer	3.4	-
Others	3.4	-
Advance for supply of goods/services	0.1	-
Others	0.1	-

* Net of Provision for doubtful loans and interest accrued and due on loans thereof ₹ Nil [March 31, 2017 : ₹ 726.9 Million]

Key Managerial Personnel who are under the employment of the Company are entitled to post employment benefits and other long term employee benefits recognised as per Ind AS 19 - 'Employee Benefits' in the financial statements. As these employee benefits are lump sum amount provided on the basis of actuarial valuation, the same is not included above and there is no Share-based payments to key managerial personnel of the Company.

FORM AOC - 1

Pursuant to First Proviso to Sub-Section (3) of Section 129 of Companies Act, 2013 with the Rule 5 of Companies (Accounts) Rules, 2014 Statement Containing Salient Features of the Financial Statement of Subsidiaries / Associate Companies/ Joint Ventures

Sr No		Name of the subsidiary company	PART "A": Subsidiaries														₹ in Million
		Date since when subsidiary was acquired	Reporting Currency	Rate	Capital	Reserve	Total Assets	Total Liabilities	Investment Other than Investment in Subsidiary	Turnover	Profit / (Loss) before Taxation	Provision for Taxation	Profit / (Loss) after Taxation	Proposed Dividend	% of Shareholding		
1		Green Eco Development Centre Limited	12.11.2010	INR	1.00	7.0	(5.4)	1.6	0.0	-	-	(0.1)	-	(0.1)	-	100.00%	
2		Sun Pharmaceutical (Bangladesh) Limited	29.03.2001	BDT	0.77	46.3	1,038.5	1,506.0	421.2	-	1,308.7	306.0	118.8	187.2	-	72.50%	
3		Sun Pharmaceutical Industries, Inc.	14.06.2011	USD	64.93	13,872.9	2,382.6	81,682.8	65,427.3	7,297.4	35,759.0	(14,988.5)	(41.7)	(14,946.8)	-	100.00%	
4		Sun Farmaceutica do Brasil Ltda.	22.05.2009	BRL	19.52	108.8	(2,397.6)	576.8	2,865.6	-	1,076.4	(168.5)	28.0	(196.5)	-	100.00%	
5		Sun Pharma De Mexico S.A. DE C.V.	03.12.2002	MXN	3.52	3.6	669.8	988.9	315.5	-	1,267.0	263.0	88.3	174.7	-	75.00%	
6		SPIL De Mexico S.A. DE C.V.	13.02.2002	MXN	3.52	0.2	-	0.2	-	-	-	-	-	-	-	100.00%	
7		Sun Pharmaceutical Peru S.A.C.	27.06.2006	PEN	20.11	0.0	(157.1)	0.2	157.3	-	-	(1.0)	-	(1.0)	-	99.33%	
8		OOO "Sun Pharmaceutical Industries" Limited	12.11.2007	RUB	1.13	0.1	(169.1)	32.9	201.9	-	-	(1.3)	1.2	(2.5)	-	100.00%	
9		Sun Pharma De Venezuela, C.A.	06.11.2011	VEF	0.01	0.1	(2.6)	0.8	3.3	-	-	3.6	-	3.6	-	100.00%	
10		Chattem Chemicals Inc.	24.11.2008	USD	64.93	2,235.8	1,023.4	3,426.4	167.2	-	1,436.5	(464.3)	(49.9)	(414.4)	-	100.00%	
11		The Taro Development Corporation	20.09.2010	USD	64.93	0.0	(0.4)	1,289.2	1,289.6	-	-	-	-	-	-	100.00%	
12		Alkaloida Chemical Company Zrt.	05.08.2005	USD	64.93	5,795.7	18,655.2	37,265.1	12,814.2	-	1,395.2	(99.5)	2.0	(101.5)	-	99.99%	
13		Sun Pharmaceuticals UK Limited	20.06.2005	GBP	91.88	0.1	(0.1)	-	-	-	-	104.0	-	104.0	-	100.00%	
14		Sun Pharmaceutical Industries (Australia) Pty Ltd	11.03.2008	AUD	49.78	3,467.0	(1,954.2)	8,532.6	7,019.8	-	3,501.1	(1,216.6)	-	(1,216.6)	-	100.00%	
15		Aditya Acquisition Company Ltd.	22.04.2007	ILS	18.55	0.0	12.0	30.0	18.0	-	145.3	7.4	1.7	5.7	-	100.00%	
16		Sun Pharmaceutical Industries (Europe) B.V.	29.06.2007	EURO	80.47	1.4	(67.5)	1,557.7	1,623.8	-	1,386.6	62.2	-	62.2	-	100.00%	
17		Sun Pharmaceuticals Italia S.R.L.	14.04.2008	EURO	80.47	0.8	45.2	46.3	0.3	-	-	(0.9)	-	(0.9)	-	100.00%	
18		Sun Pharmaceuticals Germany GmbH	11.08.2008	EURO	80.47	2.0	(209.2)	1,356.3	1,563.5	-	745.9	13.9	5.1	8.8	-	100.00%	
19		Sun Pharmaceuticals France	10.02.2009	EURO	80.47	3.0	(27.7)	337.7	362.4	-	158.5	(4.8)	-	(4.8)	-	100.00%	
20		Sun Pharma Global FZE	25.11.2008	USD	64.93	267.8	126,764.2	137,227.5	10,195.5	6,093.2	24,039.7	2,302.4	-	2,302.4	-	100.00%	
21		Sun Pharmaceuticals (SA) (Pty) Ltd.	22.10.2008	ZAR	5.54	0.0	(0.1)	23.8	23.9	-	21.0	0.0	-	0.0	-	100.00%	
22		Sun Global Canada Pty. Ltd.	23.06.2009	USD	64.93	0.1	(1.4)	-	1.3	-	-	(0.2)	-	(0.2)	-	100.00%	
23		Sun Laboratories FZE	13.03.2011	USD	64.93	795.5	(1,060.6)	2,760.2	3,025.3	-	4,006.7	80.0	-	80.0	-	100.00%	
24		Sun Global Development FZE	13.04.2011	USD	64.93	185.6	(4.8)	200.4	19.6	-	-	(0.7)	-	(0.7)	-	100.00%	
25		Sun Pharma Japan Ltd.	01.03.2012	JPY	0.61	97.0	(1,574.8)	1,751.4	3,229.2	-	25.7	(1,008.6)	0.2	(1,008.8)	-	100.00%	
26		Sun Pharma Philippines, Inc.	08.12.2011	PHP	1.24	10.7	(452.5)	232.6	674.4	-	296.8	(32.9)	27.7	(60.6)	-	100.00%	
27		Sun Pharma Healthcare FZE	25.03.2012	USD	64.93	185.6	(2.2)	183.5	0.1	-	-	2.2	-	2.2	-	100.00%	
28		Sun Pharmaceuticals Korea Ltd.	20.09.2011	KRW	0.06	6.1	(1.6)	6.1	1.6	-	-	0.0	-	0.0	-	100.00%	
29		Caraco Pharmaceuticals Private Limited	12.01.2012	INR	1.00	0.1	(0.1)	0.0	0.0	-	-	(0.0)	-	(0.0)	-	100.00%	
30		Sun Pharma Laboratories Ltd	09.03.2012	INR	1.00	0.5	196,823.2	227,734.3	30,910.6	5,714.3	51,099.1	11,582.4	2,820.2	8,762.2	4,790.0	100.00%	
31		Morley & Company, Inc.	05.05.1983	USD	64.93	0.2	(0.1)	0.2	0.1	-	-	-	-	-	-	100.00%	
32		Taro Pharmaceutical Industries Ltd. (TARO)	20.09.2010	USD	64.93	44.2	143,136.8	147,281.9	4,100.9	20,731.6	16,014.2	14,710.9	1,001.0	13,709.9	-	74.82%	

₹ in Million

FORM AOC - 1

Pursuant to First Proviso to Sub-Section (3) of Section 129 of Companies Act, 2013 with the Rule 5 of Companies (Accounts) Rules, 2014
Statement Containing Salient Features of the Financial Statement of Subsidiaries / Associate Companies/ Joint Ventures

Sr No		Name of the subsidiary company	PART "A": Subsidiaries												₹ in Million
		Date since when subsidiary was acquired	Reporting Currency	Rate	Capital	Reserve	Total Assets	Total Liabilities	Investment Other than Investment in Subsidiary	Turnover	Profit / (Loss) before Taxation	Provision for Taxation	Profit / (Loss) after Taxation	Proposed Dividend	% of Shareholding
33	Taro Pharmaceuticals Inc.	20.09.2010	CAD	50.33	12,148.2	79,783.5	95,373.7	3,442.0	25,308.2	17,627.8	6,009.7	1,182.6	4,827.1	-	74.82%
34	Taro Pharmaceuticals U.S.A., Inc.	20.09.2010	USD	64.93	9.4	(1,730.1)	31,562.4	33,283.1	-	34,905.9	662.8	2,889.6	(2,226.8)	-	74.82%
35	Taro Pharmaceuticals North America, Inc.	20.09.2010	USD	64.93	0.0	32,776.4	32,776.4	-	4,310.8	-	12,035.2	-	12,035.2	-	74.82%
36	Taro Pharmaceuticals Europe BV.	20.09.2010	EURO	80.47	1.4	2.6	44.2	40.2	-	-	40.6	-	40.6	-	74.82%
37	Taro Pharmaceuticals Ireland Ltd	20.09.2010	EURO	80.47	40.3	(40.3)	-	-	-	-	(304.0)	-	(304.0)	-	74.82%
38	Taro International Ltd.	20.09.2010	USD	64.93	0.0	578.5	1,094.1	515.6	-	1,698.4	203.7	49.1	154.6	-	74.82%
39	Taro Pharmaceuticals (UK) Ltd.	20.09.2010	GBP	91.88	0.0	(0.0)	-	-	-	-	842.3	-	842.3	-	74.82%
40	Taro Pharmaceuticals Canada, Ltd.	20.09.2010	CAD	50.33	0.0	0.1	0.1	-	-	-	0.1	-	0.1	-	74.82%
41	Alkaloida Sweden AB	22.11.2012	SEK	7.83	55.8	(17.3)	143.0	104.5	-	696.0	17.0	-	17.0	-	100.00%
42	Dusa Pharmaceuticals, Inc.	19.12.2012	USD	64.93	0.6	8,105.4	10,527.3	2,421.3	-	6,090.7	1,674.8	(1,360.9)	3,035.7	-	100.00%
43	Mutual Pharmaceutical Company Inc.	05.02.2013	USD	64.93	0.0	9,127.2	9,211.3	84.1	-	4,380.5	1,611.0	1,676.4	(65.4)	-	100.00%
44	Faststone Mercantile Company Private Limited	01.04.2012	INR	1.00	0.1	11.4	11.5	0.0	-	-	0.5	0.1	0.4	-	100.00%
45	Neetnav Real Estate Private Limited	01.04.2012	INR	1.00	0.1	2,920.8	3,077.3	156.4	-	1.3	0.8	0.2	0.6	-	100.00%
46	Realstone Multitrade Private Limited	01.04.2012	INR	1.00	0.1	11.4	11.6	0.1	-	-	0.5	0.1	0.4	-	100.00%
47	Skisen Labs Private Limited	01.04.2012	INR	1.00	163.6	(163.6)	0.1	0.1	0.0	(0.0)	(0.0)	-	(0.0)	-	100.00%
48	Softdeal Trading Company Private Limited	01.04.2012	INR	1.00	0.1	10.9	11.0	0.0	-	-	0.5	0.1	0.4	-	100.00%
49	Universal Enterprises Private Limited	31.08.2012	INR	1.00	4.5	0.8	5.3	0.0	-	-	(0.0)	-	(0.0)	-	100.00%
50	Sun Pharma Switzerland Ltd.	10.06.2013	CHF	68.26	6.8	(5.4)	14.0	12.6	-	-	(2.1)	-	(2.1)	-	100.00%
51	Sun Pharma Holdings	06.08.2015	USD	64.93	222,115.3	(18,087.6)	204,784.9	757.2	-	-	(29.7)	-	(29.7)	-	100.00%
52	Pharmalucence, Inc.	15.07.2014	USD	64.93	0.0	5,469.1	7,217.9	1,748.8	-	2,423.7	353.9	(69.7)	423.6	-	100.00%
53	PI Real Estate Ventures LLC	15.07.2014	USD	64.93	584.5	321.9	1,993.0	1,086.6	-	214.3	135.1	28.4	106.7	-	100.00%
54	Sun Pharma East Africa Limited	13.06.2014	KES	0.64	0.1	(105.6)	358.6	464.1	-	363.3	(75.8)	(22.4)	(53.4)	-	100.00%
55	Basics GmbH	24.03.2015	EURO	80.47	392.3	372.6	5,320.2	4,555.3	-	3,164.3	89.5	35.3	54.2	-	100.00%
56	Ranbaxy GmbH	24.03.2015	EURO	80.47	2.0	-	5.2	3.2	-	65.2	-	-	-	-	100.00%
57	"Ranbaxy Pharmaceuticals Ukraine" LLC	24.03.2015	UAH	2.45	98.0	37.7	208.4	72.7	-	731.9	38.0	6.8	31.2	-	100.00%
58	Sun Pharmaceuticals Morocco LLC (Formerly known as Ranbaxy Morocco LLC)	24.03.2015	MAD	7.09	86.8	(159.5)	1,236.2	1,308.9	-	1,224.6	48.0	53.8	(5.8)	-	100.00%
59	Sun Pharmaceutical Industries S.A.C. (Formerly known as Ranbaxy - PRP (Peru) S.A.C.)	24.03.2015	PEN	20.11	87.3	(211.8)	229.7	354.2	-	301.3	(29.8)	-	(29.8)	-	100.00%
60	Ranbaxy Holdings (U.K.) Limited	24.03.2015	GBP	91.88	2,807.4	140.7	2,948.9	0.8	-	-	167.3	-	167.3	-	100.00%
61	Ranbaxy Pharmacie Genériques	24.03.2015	EURO	80.47	2,007.6	(4,206.7)	986.5	3,185.6	-	1,501.9	(273.6)	-	(273.6)	-	100.00%

FORM AOC - 1

Pursuant to First Proviso to Sub-Section (3) of Section 129 of Companies Act, 2013 with the Rule 5 of Companies (Accounts) Rules, 2014
Statement Containing Salient Features of the Financial Statement of Subsidiaries / Associate Companies/ Joint Ventures

Sr No		Name of the subsidiary company	Date since when subsidiary was acquired	Reporting Currency	Rate	Capital	Reserve	Total Assets	Total Liabilities	Investment Other than Investment in Subsidiary	Turnover	Profit / (Loss) before Taxation	Provision for Taxation	Profit / (Loss) after Taxation	Proposed Dividend	% of Shareholding
PART "A": Subsidiaries																
62		Office Pharmaceutique Industriel Et Hospitalier	24.03.2015	EURO	80.47	107.0	(13.2)	297.3	203.5	-	278.7	2.5	-	2.5	-	100.00%
63		Ranbaxy Italia S.P.A.	24.03.2015	EURO	80.47	4.0	0.1	2,222.8	2,218.7	-	1,734.7	(20.3)	1.6	(21.9)	-	100.00%
64		Ranbaxy Pharmaceuticals (Pty) Limited	24.03.2015	ZAR	5.54	1,108.4	(2,136.5)	6,406.5	7,434.6	-	6,836.0	195.2	-	195.2	-	100.00%
65		Sonke Pharmaceuticals Proprietary Limited	24.03.2015	ZAR	5.54	11.1	597.7	3,008.5	2,399.7	-	6,408.8	507.2	146.3	360.9	-	70.00%
66		Ranbaxy South Africa (Pty) Limited	24.03.2015	ZAR	5.54	97.0	688.0	2,544.6	1,759.6	-	1,617.1	1.9	(9.6)	11.5	-	100.00%
67		Sun Pharma Egypt Limited LLC (Formerly known as Ranbaxy Egypt Ltd)	24.03.2015	EGP	3.67	483.2	(96.0)	563.7	176.5	-	360.4	(14.1)	4.6	(18.7)	-	100.00%
68		Rexel Egypt Company LLC	24.03.2015	EGP	3.67	0.9	(19.6)	5.6	24.3	-	(2.6)	(7.4)	-	(7.4)	-	100.00%
69		Ranbaxy (U.K.) Limited	24.03.2015	GBP	91.88	1,998.3	(614.5)	2,605.7	1,221.9	-	1,898.9	76.9	17.1	59.8	-	100.00%
70		Ranbaxy (Poland) SP. Z O.O.	24.03.2015	PLN	19.11	82.0	112.8	244.9	50.1	-	552.9	17.4	4.8	12.6	-	100.00%
71		Ranbaxy Nigeria Limited	24.03.2015	NGN	0.21	8.2	200.4	2,123.1	1,914.5	-	1,024.0	(428.7)	5.1	(433.8)	-	85.31%
72		Ranbaxy (Thailand) Co., Ltd.	24.03.2015	THB	2.08	238.8	(30.9)	990.0	782.1	-	1,290.3	30.9	-	30.9	-	100.00%
73		Ohm Laboratories, Inc.	24.03.2015	USD	64.93	15.5	7,124.6	214,538.0	207,397.9	-	15,381.5	2,810.9	(1,253.3)	4,064.2	-	100.00%
74		Ranbaxy Laboratories, Inc.	24.03.2015	USD	64.93	-	80.8	80.8	-	-	3,587.0	(568.7)	-	(568.7)	-	100.00%
75		Ranbaxy Signature LLC	24.03.2015	USD	64.93	3.2	354.8	497.7	139.7	-	528.7	411.6	-	411.6	-	67.50%
76		Ranbaxy Pharmaceuticals, Inc.	24.03.2015	USD	64.93	0.0	4.8	4.8	-	-	4,065.3	(3,117.3)	-	(3,117.3)	-	100.00%
77		Ranbaxy Inc.	24.03.2015	USD	64.93	-	642.3	750.8	108.5	-	-	(364.8)	(148.1)	(216.7)	-	100.00%
78		Ranbaxy Ireland Limited	24.03.2015	EURO	80.47	572.2	(2.0)	572.9	2.7	-	6.1	(8.1)	7.6	(15.7)	-	100.00%
79		AO Ranbaxy (Formerly Known ZAO Ranbaxy)	24.03.2015	RUB	1.13	183.8	835.4	4,038.9	3,019.7	-	5,999.8	147.2	75.6	71.6	-	100.00%
80		Laboratorios Ranbaxy, S.L.U.	24.03.2015	EURO	80.47	80.5	281.2	1,597.2	1,235.5	-	1,695.2	75.3	8.6	66.7	-	100.00%
81		Ranbaxy (Malaysia) SDN. BHD.	24.03.2015	MYR	16.80	139.4	740.8	1,641.3	761.1	-	2,006.2	495.6	-	495.6	-	90.74%
82		Ranbaxy Farmaceutica Ltda.	24.03.2015	BRL	19.52	339.0	(1,437.9)	1,060.0	2,158.9	-	1,716.4	(25.5)	48.2	(73.7)	-	100.00%
83		Ranbaxy Europe Limited	24.03.2015	GBP	91.88	0.0	-	0.0	-	-	-	(0.0)	-	(0.0)	-	100.00%
84		Sun Pharma ANZ Pty Ltd (Formerly known as Ranbaxy Australia Pty Ltd)	24.03.2015	AUD	49.78	866.2	(1,214.8)	973.8	1,322.4	-	2,163.3	83.1	-	83.1	-	100.00%
85		Ranbaxy Pharmaceuticals Canada Inc.	24.03.2015	CAD	50.33	113.3	164.9	877.8	599.6	-	1,181.0	(66.6)	-	(66.6)	-	100.00%
86		Terapia S.A.	24.03.2015	RON	17.27	432.1	14,702.3	17,868.5	2,734.1	-	11,851.9	2,643.3	350.7	2,292.6	-	96.81%
87		Be- Tabs Investments (Pty) Limited	24.03.2015	ZAR	5.54	0.0	19.8	19.8	-	-	-	(0.0)	-	(0.0)	-	100.00%
88		Sun Pharma (Netherlands) BV (Formerly known as Ranbaxy (Netherlands) BV)	24.03.2015	USD	64.93	44,039.3	8,655.3	53,355.2	660.6	923.6	0.0	(485.6)	95.5	(581.1)	-	100.00%
89		Insite Vision Incorporated	02.11.2015	USD	64.93	0.0	(349.9)	1,264.3	1,614.2	-	-	224.4	1,192.6	(968.2)	-	100.00%
90		JSC Biosintez	19.12.2016	RUB	1.13	0.3	723.1	4,700.1	3,976.7	2.3	2,906.1	80.7	72.5	8.2	-	85.10%

₹ in Million

FORM AOC - 1

Pursuant to First Proviso to Sub-Section (3) of Section 129 of Companies Act, 2013 with the Rule 5 of Companies (Accounts) Rules, 2014
Statement Containing Salient Features of the Financial Statement of Subsidiaries / Associate Companies/ Joint Ventures

Sr No	Name of the subsidiary company	Date since when subsidiary was acquired	Reporting Currency	Rate	Capital	Reserve	Total Assets	PART "A": Subsidiaries					Profit / (Loss) after Taxation	Proposed Dividend	% of Shareholding
								Total Liabilities	Investment Other than Investment in Subsidiary	Turnover	Profit / (Loss) before Taxation	Provision for Taxation			
91	Sun Pharmaceuticals Holdings USA, Inc	18.11.2016	USD	64.93	0.0	20,697.6	20,697.6	-	-	-	-	-	-	-	100.00%
92	Foundation for Disease Elimination and Control of India	21.09.2016	INR	1.00	0.1	3.9	4.8	0.8	-	42.8	5.1	-	5.1	-	100.00%
93	Zenotech Laboratories Ltd	27.07.2017	INR	1.00	610.3	(190.1)	817.4	397.2	-	111.4	(118.5)	-	(118.5)	-	57.56%
94	Sun Pharmaceutical Medicare Limited	16.01.2017	INR	1.00	2.5	(86.4)	3,077.1	3,161.0	-	1,199.2	(61.4)	-	(61.4)	-	100.00%

Note:

- 0.0' represents amount less than 0.05 million and rounded off
- In respect of entities at Sr. Nos. 4 to 8, 57, 79, 89 and 90 the reporting date is as of December 31, 2017 and different from the reporting date of the Parent Company. Adjustments have been made for significant transactions of these subsidiaries for the periods from January 01, 2017 to March 31, 2017 and January 01, 2018 to March 31, 2018, on the basis of their management accounts for the said periods.
- Entities at Sr. No. 93 have been incorporated / acquired during the year ended March 31, 2018.
- Foundation for Disease Elimination and Control of India (FDEC), a wholly owned subsidiary incorporated in India on September 21, 2016 by the Company as part of its Corporate Social Responsibility (CSR) initiative. FDEC has entered into an MOU with Indian Council of Medical Research (ICMR) and Madhya Pradesh State Government to undertake the Malaria Elimination Demonstration Project with a goal to eliminate Malaria in the state. FDEC is a Section 8 company not considered for consolidation since it can apply its income for charitable purposes only and can raise funds/contribution independently.
- Taro Pharmaceutical India Private Limited has been liquidated on April 04, 2017.
- With effect from December 21, 2017 S & I Ophthalmic LLC has been dissolved.
- With effect from April 01, 2017 vide certificate dated August 09, 2017 Ocular Technologies SARRL has been merged with Sun Pharma Switzerland Limited.
- With effect from July 27, 2017 Zenotech Laboratories Limited has ceased to be an associate and has become subsidiary of Sun Pharmaceutical Industries Limited.
- Books of accounts and other related records/documents of the overseas subsidiaries of the Zenotech Laboratories Limited were missing and due to non-availability of those records/information, Zenotech Laboratories Limited is unable to prepare consolidated accounts.
- With effect from August 01, 2017, Ranbaxy Pharmaceuticals, Inc. and Ranbaxy Laboratories, Inc. has been merged with Sun Pharmaceutical Industries Inc.
- With effect from May 20, 2018 Sun Pharmaceuticals UK Limited has been dissolved.
- Taro Pharmaceuticals Ireland Limited is under Liquidation.
- Taro Pharmaceuticals (UK) Limited is under Liquidation.
- Ranbaxy Europe Limited is under Liquidation.
- 3 Skyline LLC and One Commerce drive LLC are being consolidated with Taro Pharmaceuticals U.S.A., Inc.
- With effect from April 25, 2017 Insite Vision Ltd. has been dissolved.
- With effect from June 19, 2017 MSD - Sun LLC is liquidated.
- Fraizer Healthcare VII, L.P. and Versant Venture Capital V, L.P. were treated as associates till March 31, 2017 and are now being classified and measured as investments at fair value through profit or loss.
- The above does not include Taro Pharmaceutical Laboratories Inc., 2 Independence Way LLC, URL PharmaPro LLC and Dungan Mutual Associates LLC as they have no operation and does not have any Assets, Liabilities or Equity as on the close of their Financial Year.

FORM AOC - 1

Pursuant to First Proviso to Sub-Section (3) of Section 129 of Companies Act, 2013 with the Rule 5 of Companies (Accounts) Rules, 2014

Statement Containing Salient Features of the Financial Statement of Subsidiaries / Associate Companies/ Joint Ventures

₹ in Million

Part "B": Associate Companies and Joint Ventures						
Sr. No	Name of Associates/Joint Ventures	Jointly Controlled Entity		Associates		
		Artes Biotechnology GmbH	S & I Ophthalmic LLC	sc Pharmaceuticals Inc.	Generic Solar Power LLP	Trumpcard Advisors and Finvest LLP
1	Latest audited Balance Sheet Date	31-Dec-17	31-Dec-17	31-Dec-17	31-Mar-18	31-Mar-18
	Date of acquisition	13.02.2014	28.10.2013	29.12.2016	09.10.2015	31.03.2017
2	Shares of Associate/Joint Ventures held by the company on the year end					
	No.	15,853	NA	13,000,000	28,760	NA
	Amount of Investment in Associates/ Joint Venture	252.8	-	867.6	0.0	444.6
	Extend of Holding %	45.00%	50.00%	11.69%	28.76%	40.61%
3	Description of how there is significant influence	NA	NA	NA	NA	NA
4	Reason why the associate/joint venture is not consolidated	NA	NA	NA	NA	NA
5	Networth attributable to Shareholding as per latest audited Balance Sheet	55.7	-	1,003.5	0.0	0.2
6	Profit / Loss for the year					
	i. Considered in Consolidation	7.6	(15.4)	(250.1)	(0.0)	132.1
	ii. Not Considered in Consolidation	9.3	(15.4)	(1,889.1)	0.0	193.2

For and on behalf of the Board of Directors of
Sun Pharmaceutical Industries Limited

DILIP S. SHANGHVI
Managing Director

SUDHIR V. VALIA
Wholtime Director

SAILESH T. DESAI
Wholtime Director
Mumbai, May 25, 2018

C. S. MURALIDHARAN
Chief Financial Officer

SUNIL R. AJMERA
Company Secretary



Sun Pharmaceutical Industries Ltd.

Registered Office: SPARC Tandalja, Vadodara - 390 012, Gujarat, India **Tel Nos:** 0265-6615500/600/700 **Fax No:** 0265-2354897
Corporate Office: Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon - East, Mumbai - 400 063, Maharashtra, India.
CIN: L24230GJ1993PLC019050 **Website:** www.sunpharma.com **Email:** secretarial@sunpharma.com

NOTICE OF ANNUAL GENERAL MEETING

NOTICE is hereby given that the **Twenty-Sixth Annual General Meeting** of the members of **Sun Pharmaceutical Industries Limited** will be held on **Wednesday, September 26, 2018 at 02:45 p.m. at Crystal Hall, Grand Mercure Vadodara Surya Palace, Opposite Parsi Agyari, Sayajigunj, Vadodara - 390 020, Gujarat, India** to transact the following business:

ORDINARY BUSINESS:

1. a. To receive, consider and adopt the audited standalone financial statements of the Company for the financial year ended March 31, 2018 and the reports of the Board of Directors and Auditors thereon.
- b. To receive, consider and adopt the audited consolidated financial statements of the Company for the financial year ended March 31, 2018 and the report of the Auditors thereon.
2. To consider declaration of dividend on equity shares for the financial year ended March 31, 2018.*
3. To appoint a Director in place of Mr. Dilip S. Shanghvi (DIN: 00005588), who retires by rotation and being eligible, offers himself for re-appointment.
4. To appoint a Director in place of Mr. Sudhir V. Valia (DIN: 00005561), who retires by rotation and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:

5. **To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution:**

"RESOLVED THAT pursuant to the provisions of Section 149, 152 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with Schedule IV of the Act and the Companies (Appointment and Qualification of Directors) Rules, 2014 and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), Mr. Vivek Chaand Sehgal (DIN: 00291126), who was appointed as an Additional Independent Director with effect from November 14, 2017, by the Board of Directors of the Company and who holds office up to the date of this Annual General Meeting, be and is hereby appointed as an Independent Director of the Company, who shall not be liable to retire by rotation, for a term of 5 (Five) years commencing from November 14, 2017 upto November 13, 2022."

6. **To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution:**

"RESOLVED THAT pursuant to the provisions of Section 149, 152 and other applicable provisions, if any, of the Companies

Act, 2013 ('the Act') read with Schedule IV of the Act and the Companies (Appointment and Qualification of Directors) Rules, 2014 and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), Mr. Gautam Doshi (DIN: 00004612), who was appointed as an Additional Independent Director with effect from May 25, 2018, by the Board of Directors of the Company and who holds office up to the date of this Annual General Meeting, be and is hereby appointed as an Independent Director of the Company, who shall not be liable to retire by rotation, for a term of 5 (Five) years commencing from May 25, 2018 upto May 24, 2023."

7. **To consider and, if thought fit, to pass the following resolution as a Special Resolution:**

"RESOLVED THAT in accordance with the provisions of Sections 196, 197, 198, 203 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with Schedule V of the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force); relevant provisions of Articles of Association of the Company and subject to such approval(s) as may be necessary under law, Mr. Sudhir V. Valia (DIN: 00005561) be and is hereby re-appointed as the Whole-time Director of the Company upon the expiry of his present term of office on March 31, 2019, for a further period of 5 (Five) years commencing from April 01, 2019 to March 31, 2024 and the consent of the members of the Company, be and is hereby accorded for maximum remuneration to be paid to Mr. Sudhir V. Valia for a period of 3 (Three) years commencing from April 01, 2019 to March 31, 2022, on such terms and conditions including the said remuneration to be paid to him as minimum remuneration in the event of loss or inadequacy of profits in any financial year during the aforesaid period, as stated below and as set out in the draft Agreement as placed before the meeting duly initialled by the Chairman of this meeting for the purpose of identification, and the said draft Agreement be and is hereby specifically approved with liberty to the Board of Directors to alter, vary and modify the terms and conditions of the said appointment and/or remuneration and/or the said draft Agreement, in such manner as may be agreed to, between the Board of Directors and Mr. Sudhir V. Valia, within and in accordance with Act or such other applicable provisions or any statutory modification(s) or re-enactment(s) thereof and, if necessary, subject to the approval of Central Government as may be necessary and agreed to between the Board of Directors and as may be acceptable to Mr. Sudhir V. Valia:

- a) Salary (including bonus and perquisites) up to ₹6,00,00,000/- (Rupees Six Crores only) per annum.

Perquisites: He will be entitled to furnished/nonfurnished accommodation or house rent allowance, gas, electricity, medical reimbursement, leave travel concession for self and family, club fees, personal accident insurance, company maintained car, telephone and such other perquisites in accordance with the Company's rule, the monetary value of such perquisites to be determined in accordance with the Income-Tax Rules, 1962 being restricted to ₹75,00,000/- (Rupees Seventy Five Lakhs only) per annum.

- b) Company's contribution to provident fund and superannuation fund or annuity fund, gratuity payment as per Company's rules and encashment of leave at the end of his tenure, though payable, shall not be included in the computation of ceiling on remuneration and perquisites as aforesaid.
- c) **Minimum Remuneration:** In the event of loss or inadequacy of profits in any financial year, Mr. Sudhir V. Valia shall be entitled to receive a total remuneration including perquisites, etc. not exceeding the ceiling limits as approved by the Board of Directors and the members hereinabove, as minimum remuneration subject to receipt of such approvals as may be required, if any.
- d) **Other terms and conditions:** Subject to the control and supervision of the Board of Directors and subject to the provisions of the Act, Mr. Sudhir V. Valia shall have the powers of general conduct and management of the affairs of the Company and he shall be entitled to exercise all such powers and to do all such acts and things the Company is authorised to exercise and all such powers, acts or things which are directed or required by the Act or any other Law or by the Articles of Association of the Company except such powers/acts/things which can be exercised or done by the Company in General Meeting or by the Board of Directors at their Meeting only. Mr. Sudhir V. Valia to perform such duties and exercise such powers as are additionally entrusted to him by the Board and/or the Chairman and that he is further authorised to do all such acts, deeds, things and matters as he may be required to do, as a Whole-time Director. The appointment would be subject to the provisions of Section 152 (6) of the Act i.e. Mr. Sudhir V. Valia shall be liable to retire by rotation. The re-appointment will be for a period of five years which may be terminated by either party giving to the other thirty days' notice in writing or upon Mr. Sudhir V. Valia's ceasing to be a Director of the Company.

RESOLVED FURTHER THAT in the event of any statutory amendments, modifications or relaxation by the Central Government to Schedule V of the Act, the Board of Directors be and is hereby authorised to vary or increase the remuneration (including the minimum remuneration), i.e. the salary, perquisites, allowances, etc. within such prescribed limit or ceiling and the aforesaid draft Agreement between the Company and Mr. Sudhir V. Valia be suitably amended to give effect to such modification, relaxation or variation, subject to such approvals as may be required under law.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to take such steps as they may deem fit, expedient or desirable to give effect to this resolution."

8. To consider and, if thought fit, to pass the following resolution as a Special Resolution:

"RESOLVED THAT in accordance with the provisions of Sections 196, 197, 198, 203 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with Schedule V of the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force); relevant provisions of Articles of Association of the Company and subject to such approval(s) as may be necessary under law, Mr. Sailesh T. Desai (DIN: 00005443) be and is hereby re-appointed as the Whole-time Director of the Company upon the expiry of his present term of office on March 31, 2019, for a further period of 5 (Five) years commencing from April 01, 2019 to March 31, 2024 and the consent of the members of the Company, be and is hereby accorded for maximum remuneration to be paid to Mr. Sailesh T. Desai for a period of 3 (Three) years commencing from April 01, 2019 to March 31, 2022, on such terms and conditions including the said remuneration to be paid to him as minimum remuneration in the event of loss or inadequacy of profits in any financial year during the aforesaid period, as stated below and as set out in the draft Agreement as placed before the meeting duly initialled by the Chairman of this meeting for the purpose of identification, and the said draft Agreement be and is hereby specifically approved with liberty to the Board of Directors to alter, vary and modify the terms and conditions of the said appointment and/or remuneration and/or the said draft Agreement, in such manner as may be agreed to, between the Board of Directors and Mr. Sailesh T. Desai, within and in accordance with Act or such other applicable provisions or any statutory modification(s) or re-enactment(s) thereof and, if necessary, subject to the approval of Central Government as may be necessary and agreed to between the Board of Directors and as may be acceptable to Mr. Sailesh T. Desai:

- a) Salary (including bonus and perquisites) up to ₹1,80,00,000/- (Rupees One Crore Eighty Lakhs only) per annum.

Perquisites: He will be entitled to furnished/nonfurnished accommodation or house rent allowance, gas, electricity, medical reimbursement, leave travel concession for self and family, club fees, personal accident insurance, company maintained car, telephone and such other perquisites in accordance with the Company's rule, the monetary value of such perquisites to be determined in accordance with the Income-Tax Rules, 1962 being restricted to ₹25,00,000/- (Rupees Twenty Five Lakhs only) per annum.

- b) Company's contribution to provident fund and superannuation fund or annuity fund, gratuity payment as per Company's rules and encashment of leave at the end of his tenure, though payable, shall not be included in the

computation of ceiling on remuneration and perquisites as aforesaid.

- c) **Minimum Remuneration:** In the event of loss or inadequacy of profits in any financial year, Mr. Sailesh T. Desai shall be entitled to receive a total remuneration including perquisites, etc. not exceeding the ceiling limits as approved by the Board of Directors and the members hereinabove, as minimum remuneration subject to receipt of such approvals as may be required, if any.
- d) **Other terms and conditions:** Subject to the control and supervision of the Board of Directors and subject to the provisions of the Act, Mr. Sailesh T. Desai shall have the powers of general conduct and management of the affairs of the Company and he shall be entitled to exercise all such powers and to do all such acts and things the Company is authorised to exercise and all such powers, acts or things which are directed or required by the Law or any other Act or by the Articles of Association of the Company except such powers/acts/things which can be exercised or done by the Company in General Meeting or by the Board of Directors at their Meeting only. Mr. Sailesh T. Desai to perform such duties and exercise such powers as are additionally entrusted to him by the Board and/or the Chairman and that he is further authorised to do all such acts, deeds, things and matters as he may be required to do, as a Whole-time Director. The appointment would be subject to the provisions of Section 152 (6) of the Act i.e. Mr. Sailesh T. Desai shall be liable to retire by rotation. The re-appointment will be for a period of five years which may be terminated by either party giving to the other thirty days' notice in writing or upon Mr. Sailesh T. Desai's ceasing to be a Director of the Company.

RESOLVED FURTHER THAT in the event of any statutory amendments, modifications or relaxation by the Central Government to Schedule V of the Act, the Board of Directors be and is hereby authorised to vary or increase the remuneration (including the minimum remuneration), i.e. the salary, perquisites, allowances, etc. within such prescribed limit or ceiling and the aforesaid draft Agreement between the Company and Mr. Sailesh T. Desai be suitably amended to give effect to such modification, relaxation or variation, subject to such approvals as may be required under law.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to take such steps as they may deem fit, expedient or desirable to give effect to this resolution."

9. **To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution:**

"RESOLVED THAT in accordance with the provisions of Sections 196, 203 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with Schedule V of the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force); relevant provisions of Articles of Association of

the Company and subject to such approval(s) as may be necessary under law, Mr. Kalyanasundaram Subramanian (DIN: 00179072) ("Mr. Kal") be and is hereby re-appointed as the Whole-time Director of the Company upon the expiry of his present term of office on February 13, 2019, for a further period of 2 (Two) years commencing from February 14, 2019 to February 13, 2021, without any remuneration, on such terms and conditions as stated below and as set out in the draft Agreement as placed before this meeting duly initialled by the Chairman of this meeting for the purpose of identification, and the said draft Agreement be and is hereby specifically approved with liberty to the Board of Directors to alter, vary and modify the terms and conditions of the said appointment and/or the said draft Agreement, in such manner as may be agreed to, between the Board of Directors and Mr. Kal, within and in accordance with Act or such other applicable provisions or any statutory modification(s) or re-enactment(s) thereof and, if necessary, subject to the approval of Central Government as may be necessary and agreed to between the Board of Directors and as may be acceptable to Mr. Kal:

- I) Subject to the supervision and control of the Board of Directors and subject to the provisions of the Act, Mr. Kal, the Whole-time Director will carry out such duties and exercise such powers as may be entrusted to him by the Board of Directors and the Managing Director.

He will report to Mr. Dilip S. Shanghvi, the Managing Director of the Company. He is further authorised to do all such acts, deeds, things and matter as may be required to do, as the Whole-time Director. The Appointee shall perform such duties and exercise such powers as are additionally entrusted to him by the Board.

- II) **Remuneration:**
No remuneration shall be payable to Mr. Kal for his reappointment as Whole-time Director of the Company. His re-appointment would be without any remuneration, however, he will be entitled for reimbursement of expenses incurred while discharging his duties as the Whole-time Director of the Company.

- III) **Other Terms and Conditions:**
The re-appointment of Mr. Kal as the Whole time Director of the Company would be subject to the provisions of Section 152 (6) of the Act, i.e. Mr. Kal would be liable to retire by rotation. The re-appointment as Whole-time Director will be terminated by either party giving to other thirty day's notice in writing or upon Mr. Kal ceasing to be a Director of the Company.

RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to take such steps as they may deem fit, expedient or desirable to give effect to this resolution."

10. **To consider and, if thought fit, to pass the following resolution as a Special Resolution:**

"RESOLVED THAT pursuant to Regulation 17(1A) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to be effective from April 01,

2019 (including any statutory modification(s) or re-enactment(s) thereof for the time being in force), the approval of the members be and is hereby accorded for continuation of Directorship of Mr. Israel Makov (DIN:05299764), Non-executive Director and Chairman of the Company."

11. To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution:

"**RESOLVED THAT** pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the members be and hereby ratify the remuneration as set out in the Explanatory Statement annexed to this Notice payable to M/s. Kailash Sankhlecha & Associates, Cost Accountants, Firm's Registration No. 100221, appointed as the Cost Auditors of the Company to conduct the audit of cost records maintained by the Company for the financial year 2018-19.

RESOLVED FURTHER THAT the Board of Directors of the Company or any Committee thereof, be and is hereby authorized to do all such acts, deeds and things, to execute all such documents, instruments and writings as may be required to give effect to this resolution."

By order of the Board of Directors
For Sun Pharmaceutical Industries Ltd.

Sunil R. Ajmera
Company Secretary

Mumbai
May 25, 2018

Registered Office:
SPARC, Tandalja, Vadodara - 390 012.

* The actual equity dividend to be declared by the members at the 26th Annual General meeting will be for only equity shares other than the equity shares in respect of which the equity shareholder(s) has/have waived/forgone his/her/their right to receive the dividend for the financial year ended March 31, 2018 in accordance with the rules framed by the Board as per Note no. 14 hereinafter appearing.

NOTES:

1. The Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013 ('the Act') relating to the Special Business to be transacted at the 26th Annual General Meeting of the Company (the "Meeting" or "AGM") under Item Nos. 5 to 11.

The relevant details as required under Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and Clause 1.2.5 of Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India (SS-2), in respect of the persons seeking appointment / re-appointment as Director is given under the heading "Profile of Directors" forming part of this Notice.

2. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF/HERSELF AND SUCH PROXY NEED NOT BE A MEMBER OF THE COMPANY.
3. The Proxy form duly completed must reach the Registered Office of the Company not later than forty-eight hours before the scheduled time of the commencement of the Meeting.
4. Pursuant to the provisions of Section 105 of the Act read with the Companies (Management and Administration) Rules, 2014, a person can act as a proxy on behalf of not more than fifty members and holding in aggregate not more than ten percent of the total share capital of the Company. Members holding more than ten percent of the total share capital of the Company may appoint a single person as proxy, who shall not act as a proxy for any other person or member. Proxies submitted on behalf of limited companies, societies, etc., must be supported by an appropriate resolution / authority, as applicable.
5. Corporate members intending to send their authorized representative(s) to attend and vote on their behalf at the Meeting are requested to submit to the Company a certified true copy of the resolution of the Board of Directors or other governing body of the body corporate authorizing their representative(s) to attend and vote along with specimen signature of authorized representative(s) before commencement of the Meeting.
6. Member(s)/ proxy(ies)/ Authorised Representative(s) should bring their attendance slips duly filled in for attending the Meeting.
7. The Proxy should carry his/her identity proof i.e. a Pan Card / Aadhaar Card / Passport / Driving License / Voter ID Card or such other proof(s) to prove his/her identity at the venue of the Meeting.
8. In case of joint holders attending the Meeting, the member whose name appears as the first holder in the order of names as per Register of Members will be entitled to vote.
9. Members of the Company had approved the appointment of S R B C & Co LLP, Chartered Accountants, as the Statutory Auditor of the Company at the 25th Annual General Meeting of the Company for a period of five years upto the conclusion of 30th Annual General Meeting of the Company. This appointment was required to be ratified by members at every Annual General Meeting in accordance with the Act, however, in accordance with the Companies Amendment Act, 2017, enforced on May 07, 2018 by Ministry of Corporate Affairs, the appointment of Statutory Auditors is now not required to be ratified by the members at every Annual General Meeting.
10. The Register of Members and Share Transfer Books of the Company will be closed from Wednesday, September 19, 2018 to the date of the 26th AGM of the Company be held on Wednesday, September 26, 2018 (both days inclusive) for the

purpose of the 26th AGM of the Company and for the payment of Dividend.

11. This Notice of this AGM along with the Annual Report 2017-18 is being sent by electronic mode to those members whose e-mail address are registered with the Company's Registrar & Share Transfer Agents, Link Intime India Pvt. Ltd. / Depositories. Physical copies of the Notice of 26th AGM along with Abridged Annual Report are being sent, by the permitted mode, to those members whose email addresses are not registered and the members who have specifically requested for the physical copy in addition to e-mail. However, in case a member wishes to receive a physical copy of the full Annual Report 2017-18, he/she is requested to write to Link Intime India Pvt. Ltd., C 101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai 400 083 or email at rnt.helpdesk@linkintime.co.in from their registered e-mail ID, duly quoting his/her DP ID and Client ID or the Folio number, as the case may be. A copy of the Notice of the Meeting along with the Annual Report 2017-18 is also available for download on the website of the Company www.sunpharma.com. To support the 'Green Initiative', members who have not registered their e-mail addresses are requested to register the same with our Registrar & Share Transfer Agents, Link Intime India Pvt. Ltd. / Depositories.
12. Relevant documents / agreements referred to in the accompanying Notice and the Explanatory Statement are open for inspection by the members at the Registered Office and the Corporate Office of the Company on all working days, except Saturdays and Sundays, between 11:00 a.m. IST and 1:00 p.m. IST upto the date of the Meeting and at the venue of the Meeting during Meeting hours.
13. The Board of Directors at its Meeting held on May 25, 2018, recommended a Dividend of ₹2/- (Rupees Two only) per equity share of ₹1/- each of the Company for the year ended March 31, 2018 and the same if declared at the Meeting will be paid on or before October 01, 2018 to the Company's members whose names stand in the Register of Members as beneficial owners at the close of business hours on Tuesday, September 18, 2018 as per the list provided by National Securities Depository Limited ("NSDL") and Central Depository Services (India) Limited ("CDSL") in respect of shares held in electronic form and as members in the Register of Members of the Company after giving effect to valid transfers in physical form lodged with the Company on or before Tuesday, September 18, 2018.
14. At the Extra Ordinary General Meeting of the members of the Company held on Monday, September 1, 2003, the members had approved, by way of a Special Resolution, certain amendments whereby few Articles were inserted in the Articles of Association of the Company relating to enabling the Company to implement any instruction from member(s) of the Company to waive/forgo his/their right to receive the dividend (interim or final) from the Company for any financial year. The above referred amendments as approved at the aforesaid Extra Ordinary General Meeting have been retained and are inter alia forming part of new set of Articles of Association adopted

at the 24th Annual General Meeting of the Company held on Saturday, September 17, 2016. Thus, the members of the Company can waive/forgo, if he/they so desire(s), his/their right to receive the dividend (interim or final) for any financial year effective from the dividend recommended by the Board of Directors of the Company for the year ended March 31, 2004 on a year to year basis, as per the rules framed by the Board of Directors of the Company from time to time for this purpose. The member, if so wishes to waive/forgo the right to receive Dividend for the year ended March 31, 2018, shall fill up the form and send it to the Company's Registrars on or before Tuesday, September 18, 2018. The form prescribed by the Board of Directors of the Company for waiving/forgoing the right to receive Dividend for any year shall be available for download on the Company's website www.sunpharma.com under section "Investor - Shareholder's Information- Statutory Communication" or can also be obtained from the Company's Registrar and Share Transfer Agents, Link Intime India Pvt. Ltd.

The Board of Directors of the Company at its meeting held on September 1, 2003 have framed the following rules under old Article 190A (corresponding Article no. 142 as per the new set of Articles of Association) of the Articles of Association of the Company for members who want to waive/forgo the right to receive dividend in respect of financial year 2002-2003 or for any year thereafter:

- I. A Shareholder can waive/forgo the right to receive the dividend (either final and/or interim) to which he is entitled, on some or all the Equity Shares held by him in the Company as on the Record Date/ Book-closure Date fixed for determining the names of Members entitled for such dividend. However, the Shareholder cannot waive/forgo the right to receive the dividend (either final and/or interim) for a part of percentage of dividend on a share(s).
- II. The Equity Shareholder(s) who wish to waive/forgo the right to receive the dividend for any year shall inform the Company in the form prescribed by the Board of Directors of the Company only.
- III. In case of joint holders holding the Equity Shares of the Company, all the joint holders are required to intimate to the Company in the prescribed form their decision of waiving/forgoing their right to receive the dividend from the Company.
- IV. The Shareholder, who wishes to waive/forgo the right to receive the dividend for any year shall send his irrevocable instruction waiving/ forgoing dividend so as to reach the Company before the Record Date /Book Closure Date fixed for the payment of such dividend. Under no circumstances, any instruction received for waiver/ forgoing of the right to receive the dividend for any year after the Record Date / Book Closure Date fixed for the payment of such dividend for that year shall be given effect to.
- V. The instruction once given by a Shareholder intimating his waiver/forgoing of the right to receive the dividend

for any year for interim, final or both shall be irrevocable and can not be withdrawn for that particular year for such waived/forgone the right to receive the dividend. But in case, the relevant Shares are sold by the same Shareholder before the Record Date/Book Closure Date fixed for the payment of such dividend, the instruction once exercised by such earlier Shareholder intimating his waiver/forgoing the right to receive dividend will be invalid for the next succeeding Shareholder(s) unless such next succeeding Shareholder(s) intimates separately in the prescribed form, about his waiving/ forgoing of the right to receive the dividend for the particular year.

- VI. The Equity Shareholders who wish to waive/forgo their right to receive the dividend for any year can inform the Company in the prescribed form only after the beginning of the relevant financial year for which the right to receive the dividend is being waived/forgone by him.
- VII. The instruction by a Shareholders to the Company for waiving/ forgoing the right to receive dividend for any year is purely voluntary on the part of the Shareholder(s). There is a no interference with a Shareholder's Right to receive the dividend, if he does not wish to waive/forgo his right to receive the dividend. No action is required on the part of Shareholder who wishes to receive dividends as usual. Such Shareholder will automatically receive dividend as and when declared.
- VIII. The decision of the Board of Directors of the Company or such person(s) as may be authorized by Board of Directors of the Company shall be final and binding on

the concerned Shareholders on issues arising out of the interpretation and/or implementation of these Rules.

- IX. These Rules can be amended by the Board of Directors of the Company from time to time as may be required.

15. The members of erstwhile Tamilnadu Dadha Pharmaceuticals Limited; erstwhile Gujarat Lyka Organics Limited; erstwhile Phlox Pharmaceuticals Limited and erstwhile Ranbaxy Laboratories Limited; who have not yet sent their share certificates of erstwhile Tamilnadu Dadha Pharmaceuticals Limited; erstwhile Gujarat Lyka Organics Limited; erstwhile Phlox Pharmaceuticals Limited and erstwhile Ranbaxy Laboratories Limited, respectively for exchange with the share certificates of Sun Pharmaceutical Industries Limited, are requested to do so at the earliest, since share certificates of the erstwhile Tamilnadu Dadha Pharmaceuticals Limited; erstwhile Gujarat Lyka Organics Limited; erstwhile Phlox Pharmaceuticals Limited and erstwhile Ranbaxy Laboratories Limited are no longer tradable/ valid.

16. The members may be aware that the equity shares of the Company had been subdivided from 1 (One) equity share of ₹5/- (Rupees Five Only) each to 5 (Five) equity shares of ₹1/- each on November 29, 2010 based on the Record Date of November 26, 2010. The members who have yet not sent their share certificates of ₹5/- (Rupees Five Only) each of the Company for exchange with new equity shares of ₹1/- each are requested to send the same to the Company's Registrar and Share Transfer Agents, Link Intime India Pvt. Ltd. since the old share certificates of ₹5/- (Rupees Five Only) each are no longer tradable.

17. Pursuant to Section 124 of the Act, the amount of dividend remaining unclaimed for a period of seven years shall be transferred to the Investor Education and Protection Fund ("IEPF"). The Company will be transferring the unclaimed dividends during the financial years ending March 31, 2019 to March 31, 2025 as given below:

Dividend for Financial Year	Date of Declaration of Dividend entitled	Rate of Dividend	Last date for claiming unpaid Dividend	Due Date for transfer to IEPF
2010-2011	16.09.2011	₹3.50 per share of ₹1/- each	15.09.2018	14.10.2018
2011-2012	10.08.2012	₹4.25 per share of ₹1/- each	09.08.2019	07.09.2019
2012-2013	30.09.2013	₹2.50 per share of ₹1/- each	26.09.2020	25.10.2020
2013-2014	27.09.2014	₹1.50 per share of ₹1/- each	27.09.2021	26.10.2021
2014-2015	31.10.2015	₹3.00 per share of ₹1/- each	30.10.2022	29.11.2022
2015-2016	17.09.2016	₹1.00 per share of ₹1/- each	16.09.2023	15.10.2023
2016-2017	26.09.2017	₹3.50 per share of ₹1/- each	26.09.2024	25.10.2024

Members who have not encashed their dividend warrants, for the financial year ended March 31, 2011 and onwards are requested to approach the Company's Registrar & Share Transfer Agents, Link Intime India Pvt. Ltd. at C-101, 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai - 400083, Maharashtra, India, to claim their unpaid Dividend. The Dividend declared for the financial year ended March 31, 2011 and remaining unpaid and unclaimed, will be transferred to the Investor Education and Protection Fund ("IEPF") by October 14, 2018. Pursuant to the provisions of Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016,

the Company has uploaded the details of unpaid and unclaimed amounts lying with the Company as on September 26, 2017 (date of the last Annual General Meeting of the Company) on the website of the Company viz., www.sunpharma.com under head "Investor" sub-head "Shareholder Information" as well as on the website of the Ministry of Corporate Affairs viz., www.iepf.gov.in.

18. The members may note that pursuant to Section 124(6) of the Act read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 as

amended from time to time ("the Rules"), the shares in respect of which dividend has not been paid or claimed by the members for seven consecutive years or more shall be transferred to the demat account created by the IEPF Authority.

Consequently, the Company has transferred the shares to the IEPF Authority in respect of which dividend has remained unpaid or unclaimed from the financial year 2009-10 for 7 (seven) consecutive years, the details of which are available on website of the Company www.sunpharma.com under head "Investor" sub-head "Shareholder Information".

The details of shares liable to be transferred to the IEPF Authority are also available on website of the Company www.sunpharma.com under head "Investor" sub-head "Shareholder Information". These shares will be transferred to the IEPF Authority as per the requirements of Rules.

The procedure to claim shares from IEPF Authority is provided on the website of the Company and can be accessed from: www.sunpharma.com under head "Investor" sub-head "Shareholder Information".

19. The amendment to Regulation 40 of Listing Regulations vide Gazette notification dated June 08, 2018 has mandated that transfer of securities would be carried out in dematerialized form only. Accordingly, with effect from December 05, 2018, shares which are lodged for transfer shall be in dematerialized form only. The concerned are hence requested to get their physical shares dematerialized urgently as with effect from December 05, 2018, except in case of transmission or transposition of securities, requests for effecting transfer of securities shall not be processed unless the securities are held in the dematerialized form.
20. Route map along with prominent landmark to the Venue of the Meeting is provided at the end of this Notice.
21. Remote e-voting and electronic voting system:

Voting through electronic means:

- (a) In accordance with the applicable provisions of the Listing Regulations and the Act, read with Companies (Management and Administration) Rules, 2014 including any amendments thereto, the Company is pleased to provide facility to its members, to cast their vote electronically for all the resolutions proposed at the 26th Annual General Meeting. The Company has appointed CDSL to provide e-voting facilities to its members.
- (b) The voting right of members shall be in proportion to one vote per fully paid equity share of the Company held by them as on the cut-off date Tuesday, September 18, 2018.
- (c) The remote e-voting period begins on Sunday, September 23, 2018 at 09:00 a.m. and ends on Tuesday, September 25, 2018 at 05:00 p.m. During this period, members of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date i.e. Tuesday,

September 18, 2018, may cast their vote electronically. The remote e-voting module shall be disabled by CDSL for voting thereafter.

- (d) The facility for voting through electronic means shall also be made available at the Meeting and members of the Company as of cut-off date, attending the Meeting who have not already cast their vote by remote e-voting shall be able to exercise their right to vote at the Meeting. The members who have cast their vote by remote e-voting prior to the Meeting may attend the Meeting but shall not be entitled to cast their vote again.
- (e) Mr. Chintan Goswami, Partner of KJB & Co LLP and failing him Mr. Alpeshkumar Panchal, Partner of KJB & Co LLP Practicing Company Secretaries, Mumbai, has been appointed by the Board of Directors of the Company, as the Scrutinizer to scrutinize the e-voting process (remote e-voting and electronic voting at the venue) in a fair and transparent manner and they have communicated their willingness to be appointed as such and that they are available for the said purpose.
- (f) The procedure and instructions for members voting by remote e-voting are as under:
 - (i) The voting period begins on Sunday, September 23, 2018, at 09:00 a.m. and ends on Tuesday, September 25, 2018 at 05:00 p.m. During this period, members of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date of Tuesday, September 18, 2018, may cast their vote electronically. The remote e-voting module shall be disabled by CDSL for voting thereafter.
 - (ii) The members should log on to the e-voting website www.evotingindia.com.
 - (iii) Click on Shareholders / Members tab.
 - (iv) Now Enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Members holding shares in Physical Form should enter Folio Number registered with the Company.
 - (v) Next enter the Image Verification as displayed and Click on Login.
 - (vi) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier voting of any company, then your existing password is to be used.

- (vii) If you are a first time user, follow the steps given below:

	For Members holding shares in Demat Form and Physical Form
PAN	Enter your 10 digit alpha-numeric PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) <ul style="list-style-type: none"> Members who have not updated their PAN with the Company/Depository Participant are requested to use the e-voting code which is printed on address label on the envelope for the Abridged Annual Report sent in Physical, in the PAN field. For those having email IDs the e-voting code is sent by email.
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. <ul style="list-style-type: none"> If both the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (iv).

Any person who becomes a member of the Company after dispatch of the Notice and holds shares of the Company as on the cut-off date ie. Tuesday, September 18, 2018 and whose PAN is not registered with the Company may obtain the e-voting code detail by writing to the Company at rnt.helpdesk@linkintime.co.in or secretarial@sunpharma.com or contact Mr. Ashok Bhuta, Compliance Officer.

- (viii) After entering these details appropriately, click on "SUBMIT" tab.
- (ix) Members holding shares in physical form will then directly reach the Company selection screen. However, members holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (x) For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (xi) Click on the EVSN for Sun Pharmaceutical Industries Limited to vote.
- (xii) On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same option "YES/NO"

for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.

- (xiii) Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
- (xiv) After selecting the resolution you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
- (xv) Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.
- (xvi) You can also take out print of the voting done by you by clicking on "Click here to print" option on the Voting page.
- (xvii) If Demat account holder has forgotten the changed password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xviii) Shareholders can also cast their vote using CDSL's mobile app m-Voting available for android based mobiles. The m-Voting app can be downloaded from Google Play Store. Apple and Windows phone users can download the app from the App Store and the Windows Phone Store respectively. Please follow the instructions as prompted by the mobile app while voting on your mobile.
- (xix) Note for Non – Individual Shareholders and Custodians
- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodian are required to log on to www.evotingindia.com and register themselves as Corporates
 - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
 - After receiving the login details a compliance user should be created using the admin login and password. The Compliance user would be able to link the account(s) for which they wish to vote on.
 - The list of accounts should be mailed to helpdeskevoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
 - A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same and send the scan copy of the Board resolution/ POA to scrutinizer@sunpharma.com.

- (xx) In case you have any queries or issues regarding remote e-voting, you may refer the Frequently Asked Questions ("FAQs") and remote e-voting manual available at www.evotingindia.com, under help section or write an email to helpdesk.evoting@cdslindia.com.

Any person having any grievances in connection with remote e-voting may write to:

Name	: Mr. Rakesh Dalvi
Designation	: Deputy Manager
Address	: CDSL, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mills Compounds, N M Joshi Marg, Lower Parel (East), Mumbai – 400 013, Maharashtra, India.
Email ID	: helpdesk.evoting@cdslindia.com
Toll Free Number	: 1800225533

- g) The Scrutinizer will, immediately after the conclusion of electronic voting system at the venue of the Meeting, start scrutinizing the votes cast at the Meeting by electronic voting alongwith remote e-voting and prepare a consolidated Scrutinizer's Report and submit thereafter to the Chairman of the Meeting or any person authorised by him in writing. The result declared along with the consolidated Scrutinizer's Report will be placed on the Company's website at www.sunpharma.com and on the website of CDSL at www.evotingindia.com within 48 hours of the conclusion of the Meeting. The Company will simultaneously forward the results to BSE Limited and National Stock Exchange of India Limited, where the shares of the Company are listed.

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

As required under Section 102 of the Companies Act, 2013, the following Explanatory Statement sets out material facts relating to the Special Business as set out at Item Nos. 5 to 11 of the accompanying Notice dated May 25, 2018.

Item No. 5 and 6

Mr. Vivek Chaand Sehgal (DIN: 00291126) ("Mr. Sehgal"), was appointed as an Additional Independent Director on November 14, 2017, in terms of Section 161(1) of the Companies Act, 2013 ("Act"), by the Board of Directors of the Company on the recommendation of Nomination and Remuneration Committee. Pursuant to the provisions of the aforesaid Section of the Act, Mr. Sehgal holds office upto to the conclusion of this 26th Annual General Meeting.

Mr. Gautam Doshi (DIN: 00004612), was appointed as an Additional Independent Director on May 25, 2018, in terms of Section 161(1) of the Act, by the Board of Directors of the Company on the recommendation of Nomination and Remuneration Committee. Pursuant to the provisions of the aforesaid Section of the Act, Mr. Gautam Doshi holds office upto to the conclusion of this 26th Annual General Meeting.

Further pursuant to Sections 149, 152 and Schedule IV of the Act read with Companies (Appointment and Qualification of

Directors) Rules, 2014, the approval of members is being sought for appointment of Mr. Sehgal and Mr. Gautam Doshi as Independent Directors, for a term of 5 years i.e from November 14, 2017 upto November 13, 2022 and from May 25, 2018 upto May 24, 2023, respectively and during their tenure of appointment they shall not be liable to retire by rotation.

The Company has received declaration from Mr. Sehgal and Mr. Gautam Doshi, stating that they meet the criteria of Independence as prescribed under sub-section (6) of Section 149 of the Act. In the opinion of the Board, they fulfil the conditions specified in the said Act and the rules made thereunder for appointment as Independent Directors of the Company and that they are independent of the management.

The Company has also received notice pursuant to Section 160 of the Act from members proposing the candidature for appointment of Mr. Sehgal and Mr. Gautam Doshi as Independent Directors of the Company.

Profile and other particulars of Mr. Sehgal and Mr. Gautam Doshi, as required under the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India, are provided under heading "Profile of Directors" forming part of this Notice.

The Board of Directors recommend the resolutions as set out in item no. 5 and 6 of this Notice for approval of the members as Ordinary Resolutions.

None of the Directors or Key Managerial Personnel of the Company and their relatives, other than Mr. Sehgal and Mr. Gautam Doshi and their relatives, for their respective resolutions relating to their appointment, are in any way concerned or interested in the resolutions as set out at Item no. 5 and 6 of this Notice.

Item No. 7 and 8

Mr. Sudhir V. Valia and Mr. Sailesh T. Desai were re-appointed as the Whole-time Directors of the Company by way of Special Resolutions passed by the members at the 21st Annual General Meeting of the Company held on September 30, 2013, for a period of 5(five) years effective from April 01, 2014 and their present term of re-appointment is upto March 31, 2019.

Mr. Sudhir V. Valia and Mr. Sailesh T. Desai have been re-appointed as the Whole-time Directors of the Company by the Board of Directors on recommendation of the Nomination and Remuneration Committee of the Company, at their respective meetings held on May 25, 2018, subject to approval of members, for a further term of 5 (five) years i.e. from April 01, 2019 upto March 31, 2024 and also approved and recommended the maximum remuneration payable to them, for a period of 3 (three) years with effect from April 01, 2019 upto March 31, 2022. The remuneration was approved for the period of three years due to loss/inadequacy of profit, pursuant to requirements of Schedule V of Companies Act, 2013 ("Act").

The members' approval is being sought for re-appointment of Mr. Sudhir V. Valia and Mr. Sailesh T. Desai, as the Whole-time

Directors of the Company for a further term of 5 (five) years from April 01, 2019 upto March 31, 2024 and for approval of their remuneration for a period of 3 (three) years from April 01, 2019 upto March 31, 2022 as provided in the resolutions set out at Item Nos. 7 and 8 of this Notice.

The brief terms of re-appointment including remuneration of Mr. Sudhir V. Valia and Mr. Sailesh T. Desai, as recommended by Nomination and Remuneration Committee and approved by the Board of Directors are provided in the resolutions set out at Item No. 7 and 8 of this Notice.

Mr. Sudhir V. Valia and Mr. Sailesh T. Desai, fulfil all the conditions given under Section 196(3) and Schedule V of the Act for being eligible for their re-appointment. They are not disqualified in terms of Section 164 of the Act from being appointed as Director.

The draft agreement to be entered into with Mr. Sudhir V. Valia and Mr. Sailesh T. Desai, are available for inspection by any member of the Company at the Registered Office of the Company on all working days except Saturdays and Sundays between 11:00 a.m. IST and 1:00 p.m. IST up to the date of this 26th Annual General Meeting and at the venue of this Annual General Meeting during Meeting hours.

Profile and other particulars, as required under provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India of Mr. Sudhir V. Valia and Mr. Sailesh T. Desai, are provided under heading "Profile of Directors" forming part of this Notice.

The Board recommends the resolutions as set out at Item no. 7 and 8 of this Notice for approval of the members as Special Resolutions.

None of the Directors or Key Managerial Personnel of the Company and their relatives, other than Mr. Sudhir V. Valia and his relatives to whom resolution no. 7 relates and Mr. Dilip S. Shanghvi, being brother-in-law of Mr. Sudhir V. Valia, are in any way concerned or interested in the resolution as set out at Item no. 7 of this Notice.

None of the Directors or Key Managerial Personnel of the Company and their relatives, other than Mr. Sailesh T. Desai and his relatives to whom resolution no. 8 relates, are in any way concerned or interested in the resolution as set out at Item no. 8 of this Notice.

STATEMENT OF INFORMATION FOR THE MEMBERS PURSUANT TO SECTION II OF PART II OF SCHEDULE V OF THE COMPANIES ACT, 2013.

I. GENERAL INFORMATION

1. Nature of industry:

The Company is engaged into development, manufacture, sale, trading, marketing and export of various pharmaceutical products.

2. Date of commencement of commercial production:

The Company is carrying on pharmaceutical business since its incorporation.

3. Financial performance based on given indicators: Standalone Financial Results:

(₹ in millions except EPS)		
Particulars	2017-18	2016-17*
Profit (Loss) after tax	(4,945.9)	(228.4)
Net Worth	197,701.0	210,124.7
Revenue from operations	79,476.0	77,932.0
Earnings Per Share	₹(2.1)	₹(0.1)

*The Standalone Financial Results figures for 2016-17 have been restated to give effect to the merger of Sun Pharma Medisales Private Limited, Ranbaxy Drugs Limited, Gufic Pharma Limited and Vidyut Investments Limited into the Company with Appointed date of April 01, 2017.

Consolidated Financial Results:

(₹ in millions except EPS)		
Particulars	2017-18	2016-17*
Profit after tax and non-controlling interest	21,615.5	69,643.7
Net Worth	381,005.6	366,396.7
Revenue from operations	264,894.6	315,784.4
Earnings Per Share	₹9.0	₹29.0

4. Foreign investments or collaboration, if any:

For details of investment made by the Company, please refer the schedule nos. 5, 6, 7 and 14 of the Standalone Balance sheet forming part of the Annual Report for 2017-18.

As on March 31, 2018, the Shareholding of Foreign Investors, in the Company is detailed as under:

Particulars	No. of Shares	%
Foreign Portfolio Investors	387782873	16.16
Foreign Institutional Investor	3806500	0.16
Foreign Nationals	21040	0.00
Non Resident Indians (Repat)	4877089	0.20
Non Resident Indians (Non Repat)	2565549	0.11
Foreign Companies	671865	0.03
Overseas Bodies Corporate	46000	0.00
Foreign Bank	25422	0.00
Total	399796338	16.66

The Company has not entered into any material foreign collaboration.

II. INFORMATION ABOUT THE APPOINTEE

1. Background details:

The background details and profile of Mr. Sudhir V. Valia and Mr. Sailesh T. Desai are stated in "Profile of Directors" to this Notice.

2. Past remuneration:

The details of remuneration that Mr. Sudhir V. Valia and Mr. Sailesh T. Desai, Whole-time Directors are entitled, the remuneration actually paid to them for the last financial year 2017-18 subject to approval of the Central Government and maximum limit of remuneration as approved by the members are detailed below:

Name of the Director	Amount of remuneration entitled (including contribution to PF) for the year 2017-18, as approved by the Board within the limit as approved by the members (excluding Perquisites such as reimbursement of electricity charges, motor vehicle charges, etc. which shall be taken at actuals)	Actual Amount paid out of the amount entitled for the year 2017-18, (including contribution to PF and Perquisites such as reimbursement of electricity charges, motor vehicle charges, etc. at actuals)	Amount of Remuneration paid for 2017-18, after excluding Contribution to PF which is excluded for calculation of limit as per Schedule V of the Companies Act, 2013	(₹ in crores)
				Maximum Remuneration p.a. as approved by Board and by Members at the 24th AGM, subject to approval of the Central Government, for the current tenure of appointment*
Mr. Sudhir V. Valia	3.93	3.36	3.02	5.64
Mr. Sailesh T. Desai	1.38	1.43	1.31	1.54

* Company's contribution to provident fund and superannuation fund or annuity fund, gratuity payment as per Company's rules and encashment of leave at the end of his tenure, are not included in the computation of, ceiling on remuneration and perquisites as aforesaid.

The Company has made application to Central Government for approval of remuneration to Mr. Sudhir Valia for 2017-18 as per his entitlement as provided above, the approval of which is awaited. The amount of remuneration paid to Mr. Sudhir Valia for 2017-18, is subject to approval of Central Government.

3. Recognition or awards:

Mr. Sudhir V. Valia, Whole-time Director is recipient of following awards:

Year	Awards
2011	1 Best CFO in Pharma and Healthcare CNBC TV 18 CFO Awards
2012	2 Best CFO in Pharma and Healthcare CNBC TV 18 CFO Awards
2009	3 Best CFO in Pharma and Healthcare CNBC TV 18 CFO Award
	4 The Adivasi Sevak Puraskar (2008-09) by the Government of Maharashtra for his Contribution towards the welfare of tribals in the field of education

4. Job Profile and suitability:

Mr. Sudhir V. Valia, Whole-time Director of the Company is having rich experience in taxation & finance and has successfully contributed towards the growth of the Company.

Mr. Sailesh T. Desai, Whole-time Director of the Company is highly experienced and provided significant contribution in some of the marketing areas for the products of the Company.

7. Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any:

Apart from the remuneration and perquisites paid to Mr. Sudhir V. Valia and Mr. Sailesh T. Desai and their shareholding held directly or indirectly in the Company and Mr. Sudhir V. Valia being the brother in law of Mr. Dilip S. Shanghvi, Managing Director of the Company, they do not have any pecuniary relationship directly or indirectly with the Company and its managerial personnel.

5. Remuneration Proposed:

Details of remuneration proposed for approval of the members at this 26th Annual General Meeting of the Company are as provided in the resolutions as set out at Item No. 7 and 8 of this Notice.

6. Comparative remuneration profile with respect to industry, size of the Company, profile of the position and person:

The current remuneration being paid to the Whole-time Directors (looking at the profile of the position and person) are lower than the remuneration being paid by the companies of reasonably comparable size in the industry in which the Company operates.

III. OTHER INFORMATION

1. Reasons of loss or inadequate profits and steps taken or proposed to be taken for improvement:

The Company has reported a net loss on standalone basis mainly due to the exceptional item of ₹9,505 million in respect of the anti-trust litigation for Modafinil in the US. But for this exceptional item, the Company would have reported a profit at the net level. During the current year, the Company continued its efforts of implementing various initiatives including optimisation and cost control programs.

Some of the Company's subsidiaries in India & overseas are engaged in substantial business activities. However, the Company continues to earn profit on consolidated basis and hence there are no specific steps required to take and proposed to be taken for improvement other than working towards cost optimization.

2. Expected increase in productivity and profits in measurable terms:

The Company has earned profit of ₹1,762 million on standalone basis for the quarter ended March 31, 2018 and the Company is taking appropriate measures to increase productivity and improve profitability.

IV. Disclosures:

The disclosures as required on all elements of remuneration package such as salary, benefits, bonuses, pensions, details of fixed components and performance linked incentives along with performance criteria, service contract details, notice period, severance fees, etc. have been made under the heading Corporate Governance forming part of the Annual Report for 2017-18.

Item No. 9

Mr. Kalyanasundaram Subramanian ("Mr. Kal") was appointed as the Whole-time Director of the Company by way of an Ordinary Resolution passed by the members at the 25th Annual General Meeting of the Company for a period of 2 (two) years effective from February 14, 2017 and their present term of appointment is upto February 13, 2019 without any remuneration.

Mr. Kal has been re-appointed as the Whole-time Director of the Company by the Board of Directors on recommendation of the Nomination and Remuneration Committee of the Company, at their respective meetings held on May 25, 2018, subject to approval of members, for a further term of 2 (two) years i.e. from February 14, 2019 upto February 13, 2021 without any remuneration.

Mr. Kal fulfils all the conditions given under Section 196(3) and Schedule V of the Companies Act, 2013 ("Act") for being eligible for his re-appointment. He is not disqualified in terms of Section 164 of the Act, from being appointed as Director.

The brief terms of appointment of Mr. Kal as recommended by Nomination and Remuneration Committee and approved by the Board of Directors are provided in the Resolution set out at Item No. 9 of this Notice.

The draft agreement to be entered into with Mr. Kal is available for inspection by any member of the Company at the Registered Office of the Company on all working days except Saturdays and Sundays between 11:00 a.m. IST and 1:00 p.m. IST up to the date of this Annual General Meeting and at the venue of this Annual General Meeting during Meeting hours.

Profile and other particulars of Mr. Kal, as required under the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India, are provided under heading "Profile of Directors" forming part of this Notice.

Mr. Kal, is having rich experience in the pharmaceutical industry and has successfully contributed towards the growth of the Company.

The members' approval is being sought for re-appointment of Mr. Kal as a Whole-time Director of the Company for a period of 2 (two) years effective from February 14, 2019 to February 13, 2021 without any remuneration, in terms of applicable provisions of the Act and rules made thereunder.

Further the members may note that, Mr. Kal is also CEO and Whole-time Director of Sun Pharma Laboratories Limited (SPLL), a wholly owned subsidiary of the Company and SPLL at its Board meeting held on May 24, 2018 have re-appointed and approved the maximum remuneration of Mr. Kal as the CEO & Whole-time Director of SPLL for a period of two (2) years i.e. from February 13, 2019 to February 12, 2021, subject to approval of the members of SPLL at the ensuing annual general meeting of SPLL.

The Board recommends the resolution set out at Item no. 9 of this Notice for approval of the members as an Ordinary Resolution.

None of the Directors, Key Managerial Personnel or their relatives, except Mr. Kal and his relatives to whom this resolution relates, are in any way concerned or interested in the above resolution as set out at Item no. 9 of this Notice.

Item No. 10:

In terms of the recently notified Regulation 17(1A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to be effective from April 01, 2019, the consent of the members by way of Special Resolution is required for continuation of a Non-Executive Director of a company beyond the age of seventy five years.

Mr. Israel Makov, Non-executive Director and Chairman of the Company, is currently of 79 years.

Mr. Israel Makov, is highly experienced in Pharmaceutical Industry as per detailed disclosure under heading "Profile of Directors" forming part of this Notice and has successfully contributed towards the growth of the Company.

Mr. Israel Makov, having attained the age, beyond the age specified in the aforesaid Regulation, the approval of members is being sought by way of Special Resolution at the ensuing 26th Annual General Meeting of the Company for continuation of his Directorship in the Company.

Profile and other particulars of Mr. Israel Makov, as required under the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India, are provided under heading "Profile of Directors" forming part of this Notice.

The Board recommends the resolution set out at Item no. 10 of this Notice for approval of the members as a Special Resolution.

None of the Directors, Key Managerial Personnel or their relatives, except Mr. Israel Makov and his relatives to whom this resolution relates, are in anyway concerned or interested in the above resolution as set out at Item No. 10 of this Notice.

Item No. 11:

M/s. Kailash Sankhlecha & Associates, Cost Accountants, have been appointed as the Cost Auditors by the Board of Directors of the Company on recommendation of the Audit Committee for

conducting audit of cost records pertaining to the formulations and bulk drugs activities of the Company for the financial year ending March 31, 2019 at a remuneration of ₹20,75,000/- (Rupees Twenty Lakhs Seventy Five Thousand Only) excluding reimbursement of out of pocket expenses and applicable taxes.

In terms of provisions of Section 148(3) of the Companies Act, 2013 read with Companies (Audit and Auditors) Rules, 2014, members ratification is required for remuneration payable to the Cost Auditors.

Therefore, consent of the members of the Company is being sought for ratification of the remuneration payable to the Cost Auditors for the financial year ending March 31, 2019.

The Board recommends the resolution as set out at item no. 11 of the Notice for approval of the members as an Ordinary Resolution.

None of the Directors or Key Managerial Personnel or their relatives are in anyway concerned or interested in the above resolution as set out at Item no. 11 of this Notice.

PROFILE OF DIRECTORS

(Details of Directors proposed to be appointed/ re-appointed)

As required under Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and as required under Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India (SS - 2), the particulars of Directors who are proposed to be appointed / reappointed and/or whose remuneration is proposed to be approved at this 26th Annual General Meeting, are given below.

The details of Board and Committee Meetings attended by these Directors during the year 2017-18 are stated in the Corporate Governance Report which forms part of 26th Annual Report.

The details of remuneration, wherever applicable, are provided in the respective resolution(s).


Particulars	Mr. Dilip S. Shanghvi	Mr. Sudhir V. Valia	Mr. Gautam Doshi
Age	62 Years	61 Years	65
Brief resume of the Director including nature of expertise in specific functional areas	<p>Mr. Dilip S. Shanghvi is a graduate in commerce from the University of Calcutta. He is the Managing Director of the Company and Chairman & Managing Director of Sun Pharma Advanced Research Company Limited. He is the founding partner of Sun Pharmaceutical Industries Limited (SPIL) in 1993. Under his leadership SPIL has recorded an all-round growth in business. He has extensive experience in the pharmaceutical industry. As the promoter of SPIL, he has been actively involved in international pharmaceutical markets, business strategy, business development and research and development functions in the Company.</p> <p>Mr. Shanghvi is a recipient of several awards as listed below:</p> <ol style="list-style-type: none"> 1. Lifetime Outstanding Achievement Award - IMA - 2018 2. Entrepreneur of the Year Award - AIMA - 2017 3. Padma Shri - 2016 (Fourth Highest Civilian Award - Government of India) 4. NDTV Business Leadership Award - Pharmaceutical - 2016 5. JRD Tata Corporate Leadership Award AIMA (All India Management Association) 2014 6. Economic Times Business Leader of the Year Award 2014 7. CNBC-TV18, Outstanding Business Leader of the Year 2014 8. Forbes Entrepreneur of the Year 2014 9. World Entrepreneur of the Year - Ernst and Young 2011 10. Indian of the Year (Business) CNN IBN 2011 11. Businessman of the Year - Business India 2011 12. Entrepreneur of the Year - Ernst and Young 2010 13. Entrepreneur of the Year - Economic Times 2008 14. First of the Year Business Standard 2008 15. First of the Year Business Standard 2007 16. Entrepreneur of the Year - Ernst and Young 2007 17. Pharmaceutical Company (MNC) Juran Quality Medal 2007 <p>Entrepreneur of the Year (Healthcare and Life Sciences) Ernst and Young 2005</p>	<p>Mr. Sudhir V. Valia holds a Bachelor's degree in Commerce from University of Mumbai and is also a qualified Chartered Accountant with more than three decades of taxation and finance experience. He has been the Director of Sun Pharmaceutical Industries Limited since 1994 and is also on the Board of Taro Pharmaceutical Industries Ltd. Mr. Valia has won several awards including CNBC TV 18's CFO of the Year in the Pharmaceutical and Healthcare Sectors for two consecutive years - 2011 and 2012, as well as in the year 2009. He is actively involved in the field of social activities and he was awarded the Advaiti Sevak Puraskar (2008-2009) by the Government of Maharashtra for his contribution towards the welfare of tribals, particularly in the field of education in his capacity as visionary and Director of Shantilal Shanghvi Foundation. He is also a Director of Krishna Vrundavan Pratishthan.</p>	<p>Mr. Gautam Doshi, a Chartered Accountant and Masters in Commerce, has been in professional practice for over 40 years. He advises various industrial groups and families and also serves as director on boards of public listed and unlisted companies.</p> <p>Mr. Doshi has more than 40 years of experience in wide range of areas covering Mergers and Acquisitions, Direct, Indirect and International Taxation, Transfer Pricing, Accounting and Corporate and Commercial Laws. He has been actively involved in conceptualizing and implementing a number of mergers and restructuring transactions both domestic and cross border, involving many of the top 20 listed companies on BSE as also those forming part of FTSE 100.</p> <p>A prolific speaker, Mr. Doshi has addressed several seminars and conferences within and outside of India and courses organized by the Institute of Chartered Accountants of India, International Fiscal Association, Other professional bodies and Chambers of Commerce.</p> <p>He has served on the Councils of Western Region as also All India level of the Institute of Chartered Accountants of India which has the task of development and regulation of profession of accountancy in India. During his tenure on the Council, he served on several committees and contributed significantly to the work of Board of Studies which is responsible for education and system of training of students. He also served as Chairman of Committees on direct and indirect taxation.</p>
Date of First appointment on the Board	March 01, 1993	January 31, 1994	May 25, 2018
Directorship held in other companies (excluding foreign companies & Section 8 companies)	<ol style="list-style-type: none"> 1. Sun Pharma Advanced Research Company Limited 2. Sun Petrochemicals Private Limited 3. Alfa Inraprop Private Limited 4. Aadiya Clean Power Ventures Private Limited 	<ol style="list-style-type: none"> 1. Sun Pharma Advanced Research Company Limited 2. Aadiya Clean Power Ventures Private Limited 3. Sun Petrochemicals Private Limited 4. Suraksha Asset Reconstruction Private Limited 5. Suraksha Thermal Energy Private Limited 6. Fasttrack Housing Finance Limited 7. Alfa Inraprop Private Limited 8. Universal Enterprises Private Limited 9. ITI Mutual Fund Trustee Private Limited 10. ITI Reinsurance Limited 11. Sun Pharma Advanced Research Company Limited 12. Reliance Communications Infrastructure Limited 13. Reliance MediaWorks Limited 14. Connect Capital Private Limited 15. Reliance Anil Dhirubhai Ambani Group Limited 16. Reliance Telecom Limited 17. Pramal Phytocare Limited 18. Reliance Home Finance Limited 19. Banda Real Estate Private Limited 20. Kudal Real Estate Private Limited 21. Aashni Ecommerce Private Limited 22. Capricorn Realty Limited 23. Reliance Nippon Life Insurance Company Limited 	<ol style="list-style-type: none"> 1. Reliance Communications Infrastructure Limited 2. Reliance MediaWorks Limited 3. Connect Capital Private Limited 4. Reliance Anil Dhirubhai Ambani Group Limited 5. Reliance Telecom Limited 6. Pramal Phytocare Limited 7. Reliance Home Finance Limited 8. Banda Real Estate Private Limited 9. Kudal Real Estate Private Limited 10. Aashni Ecommerce Private Limited 11. Capricorn Realty Limited 12. Reliance Nippon Life Insurance Company Limited 13. Reliance Communications Infrastructure Limited 14. Member of Nomination & Remuneration Committee 15. Reliance Home Finance Limited 16. Member of Nomination & Remuneration Committee 17. Member of Stakeholders Relationship Committee 18. Member of Corporate Social Responsibility (CSR) Committee 19. Member of Risk Management Committee 20. Member of Willful Defaulter's Review Committee 21. Reliance MediaWorks Limited 22. Corporate Investment Committee 23. Member of Audit Committee 24. Reliance Telecom Limited 25. Member of Corporate Social Responsibility Committee 26. Pramal Phytocare Limited 27. Chairman of Audit Committee 28. Member of Nomination & Remuneration Committee 29. Reliance Nippon Life Insurance Company Limited 30. Member of Board Audit & Compliance Committee 31. Member of Board Risk Management Committee 32. Member of Board Policyholders' Protection Committee 33. Member of Board Investment Committee 34. Member of Board Shareholder Grievance Committee 35. Member of Board Asset Liability Management Committee 36. Member of Board Nomination & Remuneration Committee
Membership / Chairmanships of Committees of other public Companies	<ul style="list-style-type: none"> • Sun Pharma Advanced Research Company Limited: • Member of Corporate Social Responsibility Committee • Member of Fund Management Committee • Member of Securities Allotment Committee 	<ol style="list-style-type: none"> 1. Sun Pharma Advanced Research Company Limited: • Chairman of Corporate Social Responsibility Committee • Member of Stakeholders Relationship Committee • Member of Audit Committee • Member of Securities Allotment Committee 2. Sun Pharma Laboratories Limited: • Chairman of Corporate Social Responsibility Committee • Member of Audit Committee 	<ul style="list-style-type: none"> • Member of Audit Committee • Member of Nomination & Remuneration Committee • Reliance Home Finance Limited • Member of Nomination & Remuneration Committee • Member of Stakeholders Relationship Committee • Member of Corporate Social Responsibility (CSR) Committee • Member of Risk Management Committee • Member of Willful Defaulter's Review Committee • Reliance MediaWorks Limited • Corporate Investment Committee • Member of Audit Committee • Reliance Telecom Limited • Member of Corporate Social Responsibility Committee • Pramal Phytocare Limited • Chairman of Audit Committee • Member of Nomination & Remuneration Committee • Reliance Nippon Life Insurance Company Limited • Member of Board Audit & Compliance Committee • Member of Board Risk Management Committee • Member of Board Policyholders' Protection Committee • Member of Board Investment Committee • Member of Board Shareholder Grievance Committee • Member of Board Asset Liability Management Committee • Member of Board Nomination & Remuneration Committee
Inter-se Relationship between Directors	Mr. Dilip S. Shanghvi is Brother-in-law of Mr. Sudhir V. Valia, Whole-time Director of the Company	Mr. Sudhir V. Valia is Brother-in-law of Mr. Dilip S. Shanghvi, Managing Director of the Company	None
No. of Shares held in the Company (singly or jointly as first holder) as on March 31, 2018	230285690 Equity Shares	14345019 Equity Shares	8000 Equity Shares

Particulars	Mr. Vivek Chaand Sehgal	Mr. Sailesh T. Desai	Mr. Kalyanasundaram Subramanian ("Mr. Kal")	Mr. Israel Makov
Age	61	63 Years	64 Years	79 Years
Brief resume of the Director including nature of expertise in specific functional areas	<p>Mr. Vivek Chaand Sehgal is the Chairman of Samvardhana Motherhood Group (SMG). In 1977 he entered the field of manufacturing with a cable and wire manufacturing unit. SMG is present in 37 countries with over 230 facilities across the globe. Motherhood Sumi Systems Limited (MSSL), the flagship company of SMG, is now one of the largest auto ancillary companies in India.</p> <p>The Group has a diversified product range covering wiring harnesses, rear view mirrors, integrated plastic modules, lighting systems and a wide range of modules and components. SMG today is one of the leading suppliers of rearview mirrors globally & the leading supplier of polymer modules in Europe along with market leadership positions in most of the other product verticals in India. Under the leadership of Mr. Sehgal, SMG has evolved as a leading full system solutions provider to the global automotive industry.</p> <p>He is a visionary who has the ability of sighting opportunities for the benefit of the Group whether it be in the form of joint ventures or acquisitions.</p> <p>Among the many accolades he has received, Mr. Sehgal was adjudged Man of the Year 2010 by Auto Car Professional Magazine. He received Ernst & Young Entrepreneur of the Year Award for manufacturing in 2012. He has been adjudged the Best CEO, 2013 for Auto Ancillaries by Business Today Magazine in India. He was adjudged as the 'CEO of the Year 2015' by Business Standard. He also received the Best CEO award in 2016 in all Asia Executive Team Rankings for autos and auto parts sector by Institutional Investor Magazine. Recently Mr. Sehgal has been declared EY Entrepreneur of the Year 2016.</p>	<p>Mr. Sailesh T. Desai is a science graduate from Kolkata University and is a successful entrepreneur with more than three decades of wide industrial experience including more than two decades in the pharmaceutical industry.</p>	<p>Mr. Kal joined Sun Pharmaceutical Industries Limited (SPIL) in January 2010 after 22 years with GSK in various parts of the world.</p> <p>Mr. Kal is a Chemistry graduate and a Chartered Accountant from India with 37 years of experience of which some 30 years in the pharmaceutical industry.</p> <p>Mr. Kal's career in Pharma industry began when he joined Burroughs Wellcome, in New Zealand as Commercial Advisor in 1988. His long and varied career with Burroughs Wellcome in New Zealand which was acquired by Glaxo to become GlaxoWellcome and finally GlaxoSmithKline, includes assignments as Vice President, head of Classic Brands business of Emerging Markets; Area Director South Asia & Managing Director, GSK India; Managing Director - GlaxoWellcome, Singapore (Singapore, Indochina & Myanmar). Commercial Director - Burroughs Wellcome, New Zealand.</p> <p>In 2010, Mr. Kal joined SPIL as the Chief Executive Officer to manage India and Emerging Markets (EM) and was a board member of the Company. Mr. Kalyanasundaram Subramanian spearheaded opening of SPIL operations in few important markets such as Japan, MENA.</p> <p>In 2012, Mr. Kal moved to USA to assume responsibility for Taro operations in North America.</p> <p>In Jan 2017, Mr. Kal moved back to India to manage India and EM regions of SPIL.</p> <p>He is CEO of Sun Pharma Laboratories Limited.</p>	<p>Mr. Israel Makov is a Non-executive Chairman of the Company since May 29, 2012. He is also the former President and CEO of Teva Pharmaceutical Industries Ltd. He joined Teva in 1995 and led the company's global expansion, managing over 12 acquisitions, two of which were the largest MSA deals in the Israeli history at the time. Under Mr. Makov's leadership, Teva became the undisputed global leader in the generic pharmaceutical industry and a global leader in the treatment of Multiple sclerosis.</p> <p>Mr. Israel Makov is Chairman of Biolight - an emerging global ophthalmic company focused on the discovery, development and commercialization of products for ophthalmic conditions and Chairman of Micromedic Technologies Ltd. - a cluster of companies engaged in cancer diagnostics.</p> <p>Mr. Makov is the former Chairman of Given Imaging - the developer and world's leading provider of capsule endoscopy and Netafim - the pioneer and global leader in smart irrigation solutions.</p> <p>Mr. Israel Makov holds a B.Sc. in Agriculture and M.Sc. in Economics from the Hebrew University, Jerusalem.</p>
Date of First appointment on the Board	November 14, 2017	March 25, 1999	February 14, 2017	May 29, 2012
Directorship held in other companies (excluding foreign companies & section 8 companies)	<ol style="list-style-type: none"> 1. Motherhood Sumi Systems Limited 2. Motherhood Techno Tools Limited 3. Samvardhana Motherhood International Limited 4. Motherhood Sumi Infotech & Designs Limited 5. Kyungshin Industrial Motherhood Pvt. Ltd. 6. Fritzmeier Motherhood Cabin Engineering Pvt. Ltd. 7. Calsonic Kansei Motherhood Auto Products Pvt. Ltd. 8. Magneti Marelli Motherhood Auto System Pvt. Ltd. 9. Anest Iwata Motherhood Private Limited 10. Motherhood Bergstrom HVAC Solutions Pvt. Ltd. 11. A Basic Concepts Designs Pty. Ltd. 12. Motherhood Auto Limited 13. Renu Farms Limited 	<ol style="list-style-type: none"> 1. Sun Pharma Laboratories Limited 2. Sun Pharmaceutical Medicare Limited 3. Universal Enterprises Private Limited 	Sun Pharma Laboratories Limited	Nil
Membership / Chairmanships of Committees of other public Companies	<ol style="list-style-type: none"> 1. Motherhood Sumi Systems Limited 2. Motherhood Auto Limited 	<p>Sun Pharma Laboratories Limited</p> <ul style="list-style-type: none"> ● Member of Nomination and Remuneration Committee 	<p>Sun Pharma Laboratories Limited</p> <ul style="list-style-type: none"> ● Member of Corporate Social Responsibility Committee 	Nil
Inter-se Relationship between Directors	None	None	None	None
No. of Shares held in the Company (singly or jointly as first holder) as on March 31, 2018	Nil	3740747 Equity Shares	Nil	Nil

Route Map to 26th AGM Venue

Crystal Hall, Grand Mercure Vadodara Surya Palace, Vadodara

Prominent Landmark: Opposite Parsi Agyari, Sayajigunj



Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,
Western Express Highway,
Goregaon (East), Mumbai – 400063 India
Tel. : (91-22) 43244324 / 1234
Fax.: (91-22) 43244343
CIN: L24230GJ1993PLC019050, www.sunpharma.com



To,
Shareholders (holding shares in Physical Form)

Date: August 20, 2018

Subject: - Second reminder letter for Updating the KYC details and intimation to dematerialise physical securities.

Dear Sir/Madam,

We refer to the first request letter dated July 12, 2018 sent by Link Intime India Pvt. Ltd., for updation of necessary KYC details, to those shareholders of Sun Pharmaceutical Industries Ltd., who are holding shares in physical form and have not yet submitted their KYC documents. The SEBI Circular No. SEBI/HO/MIRSD/DOP1/CIR/P/2018/73 dated 20th April 2018 has directed all the listed companies to record the PAN of all the shareholders and Bank Account details of registered shareholder. We request you to submit the relevant documents in the KYC FORM provided overleaf, by ticking in the appropriate checkboxes on the basis of requirement shown under the above referred letter, and send the KYC FORM duly filled alongwith relevant documents, to our RTA- Link Intime India Pvt. Ltd., **within 21 days from the receipt of this letter.**

Kindly refer the list of supporting documents to be submitted for updating your KYC details.

Sr.No	REQUEST TO BE UPDATED	SUPPORTING DOCUMENTS
A	PAN	<ul style="list-style-type: none"> Self- attested legible copy of PAN card (exempted for Sikkim Shareholders) (Shareholders from Sikkim can provide self-attested copy of Aadhaar Card/Voters Card/Driving License/Passport or any other identity proof as issued by Govt.)
B	BANK ACCOUNT DETAILS	<ul style="list-style-type: none"> Self- attested legible copy of address proof. Any 1 from, a. Utility bill (not older than 3 months) b. Aadhaar Card c. Passport. Original cancelled cheque leaf of registered shareholder Legible copy of Bank Statement/Passbook with details of registered shareholder viz. name, address, account number etc. duly attested by Bank Manager or equivalent (If shareholders' name is not printed on cheque leaf)
C	SPECIMEN SIGNATURE	<ul style="list-style-type: none"> Affidavit for change of signature shares/bonds, duly notarised on non-judicial stamp paper of Rs. 100/- * Format for signature verification * Original cancelled cheque leaf Legible copy of Bank Statement/Passbook with details of shareholder viz. name, address, account number etc. duly attested by Bank Manager or equivalent (If shareholders' name is not printed on cheque leaf)
D	EMAIL ID	<ul style="list-style-type: none"> To be mentioned in KYC form printed overleaf
E	MOBILE NO.	<ul style="list-style-type: none"> To be mentioned in KYC form printed overleaf
F	NOMINATION	<ul style="list-style-type: none"> Nomination Registration form *

Note: - 1. * The relevant formats are available on the website of our RTA- www.linkintime.co.in → Resources → Downloads → General.
2. Single copy of document is sufficient for updating multiple requests.

Further as per SEBI circular SEBI/LAD-NRO/GN/2018/24 dated 08th June 2018, BSE circular no. LIST/COMP/15/2018-19 dated 05th July, 2018 and NSE Ref. No NSE/CML/2018/26 dated 09th July, 2018 shareholders, are advised to **dematerialise their physical securities** since requests for effecting transfer of physical securities (except in case of transmission or transposition of securities) shall not be permitted from 05th December 2018.

Kindly note that, as per SEBI directive, enhanced due diligence procedure will be applicable if KYC requirements are not fulfilled.

Yours faithfully,
For Sun Pharmaceutical Industries Ltd.
Sd/-
Ashok I. Bhuta
Compliance Officer

If you have already submitted the documents for updating KYC or have dematerialised your physical securities then please do not submit the documents again.

This Form is required to be submitted by those shareholders who are holding shares in physical form and have not yet submitted their KYC documents as per the SEBI Circular No SEBI/HO/MIRSD/DOP1/CIR/P/2018/73

KYC FORM

To
Linkintime India Private Limited
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai - 400083.
Unit: Sun Pharmaceutical Industries Limited

Date: __/__/____

Folio No: _____

No of Shares: _____

Dear Sir Madam,

We are forwarding herewith the required supporting documents by ticking in the appropriate checkbox below for all the fields where the status is shown as 'Required' in your first request letter dated July 12, 2018 for updation of necessary KYC details.

A) For registering PAN of registered shareholder and joint shareholders

☐ Registered shareholder ☐ Joint holder 1 ☐ Joint holder 2

B) For registering Bank details of registered shareholder only

☐ Aadhaar/Passport/utility bill ☐ Original cancelled cheque leaf ☐ Bank Passbook/Bank Statement

C) For registering the Specimen Signature of registered shareholder and joint shareholders

☐ Affidavit ☐ Format for signature verification ☐ Original cancelled cheque leaf ☐ Bank Passbook/Bank Statement

D) For Updating the email id of registered shareholder only: _____

E) For updating Mobile No. of registered shareholder only:

--	--	--	--	--	--	--	--	--	--

F) For registering the nominee details by the registered shareholder only: ☐ Nomination Registration form

Note: - 1. Shareholders from Sikkim can provide self-attested copy of Aadhaar Card/Voters Card/Driving License/Passport or any other identity proof as issued by Govt.

I /We hereby state that the above mentioned details are true and correct and we consent towards updating the particulars based on the self-attested copies of the documents enclosed with this letter by affixing my/our signature(s) to it

Sign: _____
Registered holder

Sign: _____
Joint holder 1

Sign: _____
Joint holder 2

Mr/Ms/Mrs _____ (registered holder)

Address: _____

City _____ PIN _____

NB: The above details will not be updated if the supporting documents are not attached and are not duly self attested and if the Form is not signed by all the joint shareholders.



Sun Pharmaceutical Industries Ltd.

Registered Office: SPARC Tandalja, Vadodara - 390 012, Gujarat, India **Tel Nos:** 0265-6615500 / 600/700 **Fax No:** 0265-2354897
Corporate Office: Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon -East, Mumbai - 400 063, India.
CIN: L24230GJ1993PLC019050 **Website:** www.sunpharma.com **Email:** secretarial@sunpharma.com

ATTENDANCE SLIP

TWENTY SIXTH ANNUAL GENERAL MEETING ON WEDNESDAY, SEPTEMBER 26, 2018 AT 02:45 P.M.

I /We hereby record my presence at the **Twenty Sixth Annual General Meeting of the Company at Crystal Hall, Grand Mercure Vadodara Surya Palace, Opposite Parsi Agyari, Sayajigunj , Vadodara - 390 020, Gujarat, India on Wednesday, September 26, 2018 at 02:45 P.M. IST**

Registered Folio/DP ID & Client ID : No. of shares.....

Name and address of the Member :

Joint Holder 1 :

Joint Holder 2 :

Signature of the Attending Member: Signature of Proxy:

NOTES:

- (1) Member/ Proxy holder wishing to attend the meeting must bring the Attendance Slip to the meeting and hand it over at the entrance duly signed.
- (2) Member/ Proxy holder desiring to attend the meeting should bring his/her copy of the Notice and Annual Report for reference at the meeting.

ELECTRONIC VOTING PARTICULARS

EVS (Electronic Voting Sequence Number)	User ID	* PAN
180730031	Use your DP ID/ Client ID/ Folio No.	Use your PAN. *Members who have not updated their PAN with the Company/ Depository Participant shall use e-voting code printed on the address label on the envelope in the PAN field. For those having email IDs the e-voting code is sent by email.

----- Cut here -----



Sun Pharmaceutical Industries Ltd.

Registered Office: SPARC Tandalja, Vadodara - 390 012, Gujarat, India **Tel Nos:** 0265-6615500 / 600/700 **Fax No:** 0265-2354897
Corporate Office: Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon -East, Mumbai - 400 063, India.
CIN: L24230GJ1993PLC019050 **Website:** www.sunpharma.com **Email:** secretarial@sunpharma.com

PROXY FORM

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]
[Form MGT-11]

Name of the member :

Registered address :

No. of Shares held :Folio No./ DP Id & Client Id :

Joint Holder(s) :

E-mail Id :

I/We, being the member(s), holding shares of Sun Pharmaceutical Industries Limited, hereby appoint:

1. Name: Address:
E-mail Id: Signature: or failing him / her;
2. Name: Address:
E-mail Id: Signature: or failing him / her;
3. Name: Address:
E-mail Id: Signature: or failing him / her;

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the **Twenty Sixth Annual General Meeting** of the Company, to be held on **Wednesday, September 26, 2018 at 02:45 P.M. at Crystal Hall, Grand Mercure Vadodara Surya Palace, Opposite Parsi Agyari, Sayajigunj, Vadodara - 390 020, Gujarat, India** and at any adjournment thereof in respect of such resolutions as are indicated overleaf:

Resolution No.	Resolution
	ORDINARY BUSINESS:
1.	a. Adoption of audited standalone financial statements of the Company for the financial year ended March 31, 2018 and the reports of the Board of Directors and Auditors thereon b. Adoption of audited consolidated financial statements of the Company for the financial year ended March 31, 2018 and the report of the Auditors thereon
2.	Declaration of dividend on equity shares for the financial year ended March 31, 2018
3.	Re-appointment of Mr. Dilip S. Shanghvi (DIN: 00005588), who retires by rotation and being eligible offers himself for re-appointment
4.	Re-appointment of Mr. Sudhir V. Valia (DIN: 00005561), who retires by rotation and being eligible offers himself for re-appointment
	SPECIAL BUSINESS:
5.	Appointment of Mr. Vivek Chaand Sehgal (DIN: 00291126) as Independent Director of the Company
6.	Appointment of Mr. Gautam Doshi (DIN: 00004612) as an Independent Director of the Company
7.	Special Resolution for re-appointment and remuneration of Mr. Sudhir V. Valia (DIN: 00005561) as Whole-time Director
8.	Special Resolution for re-appointment and remuneration of Mr. Saitesh T. Desai (DIN: 00005443) as Whole-time Director
9.	Re-appointment of Mr. Kalyanasundaram Subramanian (DIN: 00179072) as Whole-time Director without any remuneration
10.	Special Resolution for continuation of Directorship of Mr. Israel Makov (DIN:05299764)
11.	Ratification of Remuneration of Cost Auditors of the Company for the financial year 2018-19

Signature of Shareholder: Signed this day of 2018

Signature of Proxy holder(s):

Affix
Revenue
Stamp of
₹1/-

Note:

- The form of Proxy must be deposited at the Registered Office of the Company at SPARC, Tandalja, Vadodara – 390 012, Gujarat, India, at least 48 (Forty Eight) hours before the scheduled time of the commencement of the said Meeting.
- All alterations made in the form of proxy should be initialed.
- Please affix appropriate revenue stamp before putting signatures.
- In case of multiple proxies, the proxy later in time shall be accepted.

Notes

Notes

Notes

[illegible]

Corporate Information

Board of Directors

Israel Makov
Chairman

Dilip S. Shanghvi
Managing Director

Sudhir V. Valia
Whole-time Director

Sailesh T. Desai
Whole-time Director

Kalyanasundaram Subramanian
Whole-time Director

S. Mohanchand Dadha
Director

Hasmukh S. Shah
Director (upto November 15, 2017)

Keki M. Mistry
Director

Ashwin Dani
Director

Rekha Sethi
Director

Vivek Chaand Sehgal
Director (w.e.f. November 14, 2017)

Gautam Doshi
Director (w.e.f. May 25, 2018)

Chief Financial Officer
C. S. Muralidharan (w.e.f. June 19, 2017)

Uday V. Baldota (upto June 19, 2017)

Company Secretary
Sunil R. Ajmera

Auditors
S R B C & CO LLP
Chartered Accountants

Registrars & Share Transfer Agents
Link Intime India Pvt. Ltd.
C 101, 247 Park,
L B S Marg, Vikhroli (West),
Mumbai - 400 083
Tel: (022)-49186000
Fax: (022)-49186060
E-mail: sunpharma@linkintime.co.in
rnt.helpdesk@linkintime.co.in

Operational manufacturing plants

- 1 Dewas, Madhya Pradesh, India
- 2 Karkhadi, Gujarat, India
- 3 Baddi, Himachal Pradesh, India
- 4 Dadra, Dadra & Nagar Haveli, India
- 5 Ponda, Goa, India
- 6 Halol, Gujarat, India
- 7 Mohali, Punjab, India
- 8 Paonta Sahib, Himachal Pradesh, India
- 9 Silvassa, Dadra & Nagar Haveli, India
- 10 Ahmednagar, Maharashtra, India
- 11 Ankleshwar, Gujarat, India
- 12 Dahej, Gujarat, India
- 13 Maduranthakam, Tamilnadu, India
- 14 Malanpur, Madhya Pradesh, India
- 15 Panoli, Gujarat, India
- 16 Toansa, Punjab, India
- 17 Sun Pharma Laboratories Ltd.
Guwahati, Assam, India.
- 18 Sun Pharma Laboratories Ltd.
Jammu, Jammu & Kashmir, India
- 19 Sun Pharma Laboratories Ltd.
Ranipool, Sikkim, India
- 20 Sun Pharma Laboratories Ltd.
Setipool, Sikkim, India
- 21 Sun Pharmaceutical Medicare Ltd.
Baska, Gujrat, India
- 22 Sun Pharmaceutical Industries (Australia)
Pty Ltd., Latrobe, Australia
- 23 Sun Pharmaceutical Industries (Australia)
Pty Ltd., Port Fairy, Australia
- 24 Sun Pharmaceutical (Bangladesh) Ltd.
Joydevpur, Gazipur, Bangladesh
- 25 Taro Pharmaceuticals Inc.
Brampton, Ontario, Canada
- 26 Ranbaxy Egypt (L.L.C.)
October City, Giza, Egypt
- 27 Alkaloida Chemical Company Zrt,
Tiszavasvari, Kabay, Hungary
- 28 Taro Pharmaceutical Industries Ltd.
Haifa Bay, Israel
- 29 Ranbaxy Malaysia Sdn. Bhd.
Kuala Lumpur, Malaysia
- 30 Ranbaxy Nigeria Limited
Lagos (Magboro) Nigeria
- 31 S.C Terapia S. A.
Cluj, Romania
- 32 JSC Biosintez
Penza, Russia
- 33 Ranbaxy Pharmaceuticals (Pty) Ltd.
Roodepoort, Johannesburg, South Africa
- 34 Chattem Chemicals, Inc.
Chattanooga, USA

- 35 Dusa Pharmaceuticals Inc.
Wilmington, Massachusetts, USA
- 36 Ohm Laboratories, Inc.
Brunswick, New Jersey, USA
- 37 Pharmeducence Inc.
Billerica, Massachusetts, USA
- 38 Sun Pharmaceutical Industries Inc.
Cranbury, New Jersey, USA

Offices

Registered office

Sun Pharma Advanced Research Centre
(SPARC), Tandalja,
Vadodara - 390 020, Gujarat.

Corporate Office

Sun House, CTS No. 201 B/1,
Western Express Highway,
Goregaon (E), Mumbai 400063,
Maharashtra.
CIN: L24230GJ1993PLC019050
Tel: (022)-4324 4324
Fax: (022)-4324 4343
email: secretarial@sunpharma.com

Major R&D centres

India

1. Sun Pharma Advanced Research Centre,
F.P.27, Part Survey No. 27, C.S. No. 1050,
TPS No. 24, Village Tandalja, District,
Vadodara - 390 020, Gujarat.
2. 17-B, Mahal Industrial Estate, Mahakali
Caves Road, Andheri (East), Mumbai -
400 093, Maharashtra.
3. Village Sarhaul, Sector-18 , Gurgaon -
122015 (Haryana)

Israel


Chemistry and Discovery Research Israel,
14 Hakitor Street, P.O. Box 10347 Haifa Bay
2624761, Israel.

Canada

Taro Pharmaceuticals Inc., 130 East Drive,
Brampton, Ontario L6T 1C1, Canada.

US

Ohm Laboratories Inc., Terminal Road, New
Brunswick, New Jersey 08901 USA.





SUN HOUSE

CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, Maharashtra, India.

Tel : (+91 22) 4324 4324, Fax : (+91 22) 4324 4343

CIN: L24230GJ1993PLC019050

www.sunpharma.com